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Abstract
Mitochondria are metabolic hubs, with many diseases found to have altered metabolism and
mitochondrial dysfunction, such as ischaemia-reperfusion injury. A detailed understanding of
the metabolic changes in different cellular pools would aid diagnosis and treatment. However,
the current methods of mitochondrial isolation are too slow to provide a snapshot of purely
mitochondrial metabolism, meaning that current metabolic data is only from whole cell.
This project has developed and used a novel technique to rapidly isolate mitochondria from
tissue by density centrifugation through silicone oil, with a view to assess the mitochondrial
metabolic changes during ischaemia-reperfusion injury. This method has minimal cytosolic
contamination and is completed in under 5 minutes, and mass spectroscopy analysis has
shown enrichment of mitochondrial metabolites. Seahorse and Oroboros analysis have shown
that the mitochondria are functional and capable of coupled respiration. Data is presented on
how the method optimisation was analysed and developed. This largely reduced time frame
gives the advantage over other methods to enable the study of metabolism in mitochondria.
viii
All abbreviations, unless listed, are as described in the “Instructions to Authors” of the
Biochemical Journal (http://www.biochemj.org).
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Chapter 1
Introduction
1.1 General Introduction
Mitochondria are endosymbiotic organelles present inside most eukaryotic cells which
perform the vital role of ATP production by oxidative phosphorylation (OXPHOS), as
well as many other important functions. Mitochondria are thought to have evolved over 2
billion years ago when oxygen-utilising α-proteobacteria were engulfed by early eukaryotic
cells, forming a symbiotic relationship (Gray, 2012; Lane, Martin, 2010; Margulis, 1981).
Gradually, many of the genes from this engulfed cell were transferred to the host genome,
forming a relationship in which the oxygen-metabolising cell became a sub-cellular organelle
that provided an energy source to the host cell. The organelle maintained some of its own
genes and therefore the ability to use gene expression to modify certain factors independently,
such as the proton motive force (∆p). The basis of the endosymbiotic theory is that this
relationship enabled the host cell to increase in complexity and size, allowing the evolution
of modern eukaryotic cells (Lane, Martin, 2010). Mitochondria have become so embedded in
the function of eukaryotic cells that survival is dependent on fully functioning mitochondria
that are able to respond and adapt quickly to changes in the external environment so that a
steady energy supply can be maintained.
The division of labour in animals is achieved by specialised organs which perform specific
functions. Organs are composed of multiple cell types, which contain multiple organelles,
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which can be further compartmentalised by their spatial location within the cell. Organelles
perform different metabolic functions, and this generates discrete metabolite pools across the
cell, which are regulated by numerous, highly conserved metabolite transporters. This com-
partmentation has allowed the development of complexity in animals, with many metabolic
reactions able to occur simultaneously across different locations (Zecchin et al., 2015). Some
pathways require both intra- and extra-mitochondrial enzymes, such as the urea cycle. Mito-
chondrial subcellular localisation has been found to be important for cancer metastasis, with
mitochondria at the leading front of migrating epithelial cancer cells (Desai 2013), suggest-
ing the ATP required for actin remodelling during migration is supplied by mitochondria.
Metabolism can also be compartmentalised temporally, for example glycolysis activity peaks
during the S phase of the cell cycle (Zecchin et al., 2015).
The study of the compartmentalisation of metabolism is still an emerging field, partly due
to a lack of techniques to study metabolic pathways in real time and also due to caveats
to methods of visualising metabolic compartments. One such method is Förster resonance
energy transfer (FRET) (Hou et al., 2011). Limitations to the use of this method are that
the cells must be genetically modified and there are currently only a few reporter molecules.
At present, the most comprehensive method for studying cellular metabolism is metabolic
profiling by LC-MS or GC-MS methods.
Subcellular compartmentalisation delivers many advantages for metabolism. The unique
subcellular microenvironments allow specific enzymes to function at their optimal capacity.
For example, the enzymes of the lysosome, such as cathepsins, function optimally at an
acidic pH (Voet, Voet, 2011). Furthermore, substrates and cofactors required for the activity
of certain enzymes can be accumulated to the required concentrations in these smaller
subcompartments, compared to the larger space of the cytosol. These reactions would
otherwise be diffusion-limited due to substrate availability. Conversely, compartmentalisation
also generates compartments that are distinct from the cytosol. For example, the high
NADPH/NADP+ ratio in the cytosol allows fatty acid synthesis to take place. Similarly, a
membrane-bound compartment prevents the diffusion of metabolic intermediates, maximising
efficiency. Some metabolic reactions produce toxic by-products, which can be sequestered
away from the rest of the cell and disposed of. For example, hydrogen peroxide is contained
and disposed of inside peroxisomes. Compartmentalisation also prevents futile cycling of
metabolites by physically separating opposite reactions.
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Mitochondria are able to respond to short-term energy demands of the cell by increasing
or decreasing ATP production by OXPHOS, regulated by the magnitude of the ∆p (Brown,
1992; Chance, Williams, 1956; Mitchell, 1961; Murphy, Brand, 1987). Mitochondrial ATP
production is also regulated by the supply of electrons to the mitochondrial respiratory
complexes, which themselves generate the ∆p, as well as by the quantity of mitochondria in
the cell. Responding to cellular energy demands requires effective communication between
the mitochondria and other sub-cellular organelles. For example, an important signal that
the cell must respond to is oxygen. Cells have evolved multiple mechanisms to cope
with decreased oxygen levels, which include physiological responses such as vasodilation,
angiogenesis and erythropoiesis, as well as metabolic responses, such as the activation
of hypoxia-inducible transcription factors (HIFs) which promote glycolysis and allow the
continued production of ATP in the absence of oxygen. This is an important example of
communication between the mitochondria and the rest of the cell, as the HIF pathway can be
activated by mitochondrial succinate exported to the cytosol (Tannahill et al., 2013). The
release of succinate from mitochondria is also involved in downstream activation of the
immune response (Mills et al., 2017).
The release of two other important nutrients, glucose and fatty acids, from their respective
storage tissues liver and adipose tissue, is controlled by hormones. Once these are taken
up by the cell there are many processes in the cytosol that facilitate the uptake of these
nutrients or their downstream metabolites to the mitochondria, where they are substrates
for the tricarboxylic acid (TCA) cycle and fatty acid oxidation, which both occur in the
mitochondria and provide electrons to the respiratory complexes. A further example is the
export of mitochondrial citrate to the cytosol to engage in lipid synthesis. Also, mitochondrial
biogenesis (the growth and division of mitochondria) requires the synchronised transcription
of mitochondrial genes encoded by both the mitochondrial and nuclear genomes (Lane,
Martin, 2010).
A recently emerging form of communication between mitochondria and the cell is redox
signalling, in the form of reactive oxygen species (ROS). Mitochondria are major producers
of ROS, which in excess can overwhelm antioxidant responses, leading to oxidative damage
and cell death (Smith et al., 2012). However, there is growing consensus that the release
of ROS from mitochondria in controlled amounts can act as an important signal, informing
the rest of the cell of mitochondrial redox status. In particular, ROS generated by reverse
electron transport (RET) is potentially a signal involved in metabolic adaptation, and is
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tightly regulated and responsive to mitochondrial redox status (Chouchani et al., 2014, 2016;
Mills et al., 2016).
A key attribute of communication between mitochondria and the rest of the cell is energy
sensing. AMP-activated protein kinase (AMPK) is an energy-sensing enzyme and a master
regulator of energy metabolism (Jornayvaz, Shulman, 2010). It senses energy demand
through an increase in AMP and ADP relative to ATP, triggering activation of ATP-producing
mechanisms and inhibition of ATP-requiring mechanisms to limit energy demand (Carling
et al., 2011; Garcia, Shaw, 2017; Hardie et al., 2012).
Despite numerous adaptive mechanisms, mitochondrial dysfunction occurs in certain con-
ditions and plays a key role in many pathologies. Ischaemia-reperfusion injury (IRI) is
caused by the blockage and subsequent return of blood flow to an organ. It is a disease
whose pathology is dictated, in part, by mitochondrial dysfunction. There have been many
studies looking at how cell and mitochondrial metabolism is altered in IRI (Chouchani et al.,
2014; Ferrari, 1995; Heather et al., 2013; Martin et al., 2019) but these have all looked at
metabolism at the whole cell level. This could mask any changes at the mitochondrial level.
This project aimed to identify the metabolic changes in mitochondria during IRI and identify
the key differences to the response of the rest of the cell.
In order to study the mitochondrial metabolic response, in either normal conditions or during
IRI, the mitochondria must be isolated from the rest of the cell. The challenge here is that
metabolites are interchanged and distributed throughout the cell by the action of enzymes
and transporters. Therefore, to look at the level of a metabolite at any one time the isolation
method must be performed quickly and coolly enough to limit the action of these enzymes
and transporters. Unfortunately, no method met these fundamental criteria sufficiently at the
start of this project.
The first aim of this project was to develop a method of isolating mitochondria from tissue
that would enable me to obtain a true reading of the status of mitochondrial and cytosolic
metabolites during normoxia, IRI and other conditions. The second aim was to implement
the method in control tissue samples and analyse the metabolite levels by LC-MS. The third
aim was to measure the metabolic response of mitochondria and the whole cell in ischaemic
tissue. In the next sections, I give an overview of mitochondrial energy metabolism and
transport before focusing on existing methods of mitochondrial isolation.
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1.2 Structure and functions of mitochondria
1.2.1 Mitochondrial architecture, biogenesis and dynamics
According to the widely accepted endosymbiont theory, mitochondria originated from α-
proteobacteria which were enveloped by a primordial eukaryotic cell, leading to an en-
dosymbiotic relationship (Gray, 2012; Lane, Martin, 2010; Margulis, 1981). Mitochondria
have retained some of the original structure and functions that they performed early on in
the endosymbiosis, namely central metabolism and ATP generation for the rest of the cell,
but they have also acquired new functions such as apoptotic signalling (Rasola, Bernardi,
2011) and innate immune responses (Mills et al., 2017). In this way they have become fully
integrated into the metabolic and signalling pathways of the cell.
A few decades ago mitochondria were generally depicted as static rods, based on transmission
electron microscopy (TEM) studies (see Figure 1.1A and B), but due to work with electron
tomography and confocal microscopy they are now known to be far more dynamic, and that it
is more accurate to consider mitochondria as part of a fused, elongated and dynamic network
(Lee, Yoon, 2016) (Figure 1.1C and D). These networks can undergo fission and fusion,
depending on their function and the metabolic demands of the cell (Civitarese et al., 2007).
Mitochondria consist of two membranes and two aqueous spaces. The mitochondrial outer
membrane (MOM) is the outer barrier and separates the intermembrane space (IMS) from
the cytosol. The mitochondrial inner membrane (MIM) separates the IMS from the matrix.
The MOM is the primary barrier between the cytosol and the mitochondrion. It contains
thousands of copies of the pore-forming protein porin or voltage-dependent anion channel
(VDAC). This is a 31-kDa protein which forms a β -barrel structure with a central pore
of ∼3.5 nm (Mannella, 1992). The pore allows the passage of metabolites across the
MOM. Besides acting as a permeability barrier to proteins, the MOM has functions in cell
death, mitochondrial fission and fusion, mitophagy and inflammation (Arnoult et al., 2011;
Friedman, Nunnari, 2014). The IMS contains cytochrome c (Cyt c), a protein which is
involved in electron transfer on the MIM and is released into the cytoplasm during apoptosis
(Section 1.3.7). The IMS also contains other proteins such as Cu/Zn superoxide dismutase
(SOD), which detoxifies superoxide (O.−2 ), a potentially harmful by-product of oxygen
metabolism, discussed in more detail later. The MIM is a protein-rich membrane which is
highly folded into cristae. These sub-structures provide a large surface area to house the
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Fig. 1.1 Mitochondrial morphology. A) Cartoon model of mitochondrion (from Lodish et al. (2007)).
B) Electron micrograph of a mitochondrion. C) Computer model generated from segmented 3D tomo-
grams of a mitochondrion showing their 3D structure. D) Extended and interconnected mitochondrial
network in an african green monkey fibroblast (COS-7 cell). Pictures A-C taken from Frey, Mannella
(2000); D from Westermann (2002).
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electron transfer chain (ETC) and ATP synthase, maximising the area available for oxidative
phosphorylation and generating a high local concentration of H+, which is discussed later.
The matrix is a viscous, protein-rich compartment containing membrane-bound projections
of some respiratory complexes and the FoF1-ATP synthase as well as soluble enzymes (e.g.
those involved in the TCA cycle, amino acid, fatty acid and ROS metabolism), nucleotide
cofactors and many copies of the mitochondrial DNA (mtDNA) genome. The matrix also
contains replication, transcription and translation machinery for expression and maintenance
of mtDNA.
The human mitochondrial genome is a circular, double-stranded 16,569 bp molecule (Gustafs-
son et al., 2016). In mammals it encodes 37 genes: 22 transfer RNAs, 2 ribosomal RNAs and
13 polypeptides. All 13 polypeptides are components of respiratory chain complexes (I, III
and IV) or the FoF1-ATP synthase, with their remaining subunits encoded by nuclear DNA.
Complex II is entirely encoded by nuclear DNA. Despite having their own genome, 99 %
of the ∼1,000 mitochondrial proteins are encoded by nuclear genes (Schmidt et al., 2010).
This necessitates protein import systems (Figure 1.2). Many, but not all, nucleus-encoded
mitochondrial proteins have an N-terminal targeting signal to direct them to the correct
destination. The majority of mitochondrial proteins cross the MOM through the translocase
of the outer membrane (TOM) complex. Once in the IMS, proteins destined for the matrix are
imported by the presequence translocase of the inner membrane (TIM23) complex and the
presequence translocase-associated motor (PAM). This presequence import is driven by the
∆p. Mitochondrial processing peptidase (MPP) removes the presequence. IMS proteins are
imported and folded by the mitochondrial intermembrane space assembly (MIA) machinery.
Inner membrane proteins, such as metabolite carriers like the ADP/ATP carrier (AAC),
contain transmembrane segments that are hydrophobic. They are imported through the TOM
complex but then require the action of the chaperones in the IMS and the carrier translocase,
the TIM22 complex (Schmidt et al., 2010; Wiedemann, Pfanner, 2017).
The current structure of mitochondria contains vestiges of their past as α-proteobacteria.
The MOM and MIM have different lipid compositions. The MOM is more similar to the
endoplasmic reticulum (ER) membranes of the host eukaryotes and the MIM is more similar
to bacterial cell membranes, as it contains cardiolipin but no cholesterol (Cavalier-Smith,
2006). Much of the mitochondrial DNA replication machinery and ribosomes are similar to
bacteria (Gustafsson et al., 2016).
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Fig. 1.2 Mitochondrial protein import systems. The majority of mitochondrial proteins are im-
ported through the translocase of the outer membrane (TOM) complex. Once inside the IMS, targeting
signals direct the precursor proteins to different sorting machineries. Matrix proteins are imported
from the IMS to the matrix by the presequence translocase of the inner membrane (TIM23 complex)
and the presequence translocase-associated motor (PAM). Once in the matrix the presequences are
removed by mitochondrial processing peptidase (MPP). IMS proteins are imported and folded by
the mitochondrial intermembrane space assembly (MIA) machinery. Inner membrane proteins such
as carrier proteins are inserted into the inner membrane by the carrier pathway, with the action of
chaperones and the carrier translocase TIM22. From (Schmidt et al., 2010).
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As mitochondria are essential to the cell, there are many mitochondrial quality control mech-
anisms that help prevent mitochondrial dysfunction. One such mechanism is fission and
fusion of the mitochondrial network (Lee, Yoon, 2016). Fusion of mitochondria generates
continuous reticulated networks, which are hypothesised to maximise OXPHOS efficiency,
but the details of this remain obscure. Fusion and fission are both driven by membrane-
remodelling enzymes which are part of the dynamin family of large GTPases, including:
Dynamin-related/-like protein 1 (Drp1); mitofusin (Mfn) and optic atrophy 1 (OPA1) (Lee,
Yoon, 2016). Fusion is ∆p-dependent and so only polarised mitochondria can fuse together,
meaning that dysfunctional mitochondria with low ∆p are excluded and prevented from
damaging healthy networks of mitochondria (Twig et al., 2008). Whilst fusion is inhibited in
these depolarised mitochondria, increased fission occurs, resulting in a mixture of damaged
and healthy daughter organelles. This quality control mechanism means that damaged mito-
chondria are physically sequestered away from healthy mitochondria, before the damaged
daughter organelles are targeted for removal by mitophagy (Gottlieb, Gustafsson, 2011). The
healthy, polarised mitochondria are then able to recommence fusion and fission cycling.
Mitochondrial biogenesis is a complex process that involves the coordination of many path-
ways, such as nuclear-mitochondrial communication, mitochondrial protein expression and
import, mtDNA gene expression, assembly of multi-subunit enzyme complexes, mitochon-
drial turnover, and regulation of mitochondrial fission and fusion (Diaz, Moraes, 2008). The
expression of nuclear-encoded mitochondrial proteins is regulated by transcription factors
and transcriptional coactivators. For example, peroxisome proliferator-activated receptor
γ-coactivator-1α (PGC-1α) is an important transcriptional coactivator that coordinates mi-
tochondrial biogenesis through the activation of different transcription factors (Scarpulla,
2002). Two important transcription factors are the nuclear respiratory factors 1 and 2 (NRF-1
and NRF-2) (Virbasius et al., 1993a,b) which activate the nuclear transcription of mitochon-
drial genes (Diaz, Moraes, 2008). NRF-1 and -2 also activate mitochondrial transcription
factor A (Tfam), which further drives transcription and replication of mitochondrial DNA.
The PGC-1 family regulates a number of metabolic pathways involved in mitochondrial
biogenesis, including cellular respiration, thermogenesis and hepatic glucose metabolism.
Mitochondrial biogenesis is often upregulated in mitochondrial disorders, which are the
result of either nuclear or mtDNA mutations (Diaz, Moraes, 2008). These disorders often
exhibit abnormal mitochondrial proliferation in an attempt to compensate for deficiencies,
such as dysfunctional OXPHOS. As a result, these disorders often affect tissues with high
energy demands, such as brain, heart and skeletal muscle (Diaz, Moraes, 2008).
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Mitochondrial turnover must be carefully balanced with mitochondrial biogenesis to maintain
cellular homeostasis. In older literature, figures for mitochondrial turnover of 9.3, 17.5 and
24.4 days for mitochondria in liver, heart and brain respectively can be found (Menzies, Gold,
1971). However, these data are hard to interpret as mitochondrial turnover includes turnover
of whole mitochondria and individual proteins. The main way defective mitochondria are
removed is by a specialised form of autophagy termed mitophagy, whereby mitochondria are
selectively targeted for lysosomal degradation (Kim et al., 2007; Lee et al., 2012).
1.2.2 Oxidative phosphorylation
A major function of mitochondria is oxidative phosphorylation (OXPHOS), which is the
energy transducing process by which FoF1-ATP synthase phosphorylates ADP to generate
ATP (Chance, Williams, 1956). The energy used to drive this process comes from an
electrochemical proton potential gradient across the MIM called the proton motive force
(∆p). The ∆p comprises two components: a pH gradient (∆pH) (more basic in the matrix)
and the membrane potential (∆Ψ) (more negative in the matrix) and was first described
by Peter Mitchell in his chemiosmotic hypothesis (Mitchell, 1961). Metabolic substrates
such as glucose, fatty acids or amino acids are oxidised by passing their electrons to the
electron carriers NADH or FADH2 (Wilson, 2017). These factors then pass their electrons to
a series of respiratory complexes in the electron transport chain (ETC), which are arranged
in order of increasing reduction potential (Eh) (Nicholls, Ferguson, 2013; Sazanov, 2015).
The electron carriers ubiquinone (Q) in the MIM and Cyt c in the IMS are also involved in
transferring electrons down the ETC. At the end of the ETC, complex IV reacts with the
terminal electron acceptor O2, which is reduced to H2O. Electron transport is exergonic,
and the energy released enables complexes I, III and IV to pump protons across the MIM
from the matrix to the IMS against the growing proton electrochemical gradient, thereby
generating the ∆p. The ∆p drives the flow of protons back through FoF1-ATP synthase, down
the proton electrochemical gradient, and the energy of this is used to phosphorylate ADP
to ATP (Watt et al., 2010). Thus, substrate oxidation is coupled to ATP synthesis, via the
∆p and electron transfer to O2. This process is depicted in Figure 1.3 and outlined in more
detail below.
Electrons from NADH enter the ETC via complex I (NADH:Q oxidoreductase) (Brandt,
2006). NADH binds to complex I on the matrix side of the MIM at a flavin mononucleotide
(FMN), which accepts 2 electrons (e−) from NADH to generate FMNH2. The e− are then
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Fig. 1.3 The electron transport chain and oxidative phosphorylation. Electrons are donated to
Complex I or Complex II by the electron carriers NADH and FADH2 respectively. Electrons are
passed along the respiratory chain, which is composed of complexes arranged in order of increasing
reduction potential (Eh) (i.e more oxidising). The electron carriers ubiquinone (Q) and cytochrome
c (Cyt c) move the electrons down the chain. Finally, electrons reach Complex IV and are passed
onto the terminal electron acceptor O2, which is reduced to H2O. Electron transport is exergonic,
providing energy to complexes I, III and IV to pump protons across the MIM from the matrix to the
IMS, generating the ∆p. The ∆p drives H+ back down its gradient through the FoF1-ATP synthase,
which harnesses the energy of this movement to phosphorylate ADP to ATP. Adapted from Chouchani
et al. (2016).
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passed along a chain of 7 Fe-S clusters with increasing Eh within the hydrophilic arm of
complex I to Q forming ubiquinol (QH2). During this electron transfer process, complex I
pumps 4H+ from the matrix to the IMS.
Complex II (succinate:Q oxidoreductase) also donates electrons to Q. Complex II oxidises
succinate to fumarate and the e− are passed on to the cofactor FAD, generating FADH2. This
is re-oxidised by passing its electrons along a series of Fe-S clusters within the complex to Q
(Iverson, 2013). Unlike the other respiratory chain complexes, complex II does not pump
protons across the MIM.
Besides the NADH/complex I- and succinate/complex II-mediated pathways, there are at
least 3 other enzymes in mammalian mitochondria that donate electrons to the Q pool:
electron-transferring flavoprotein (ETF)-ubiquinone oxidoreductase; s,n-glycerophosphate
dehydrogenase (discussed further in Section 1.5.4.6) and dihydroorotate dehydrogenase.
Although they do not have the "complex" nomenclature of the other respiratory chain
enzymes, both ETF-ubiquinone oxidoreductase and s,n-glycerophosphate dehydrogenase
are connected to the respiratory chain. Electron-transferring flavoprotein (ETF) is located
in the mitochondrial matrix. It has 1 FAD cofactor and can accept electrons from a range
of flavin-containing dehydrogenases, such as enzymes involved in fatty acid oxidation. The
resulting FADH2 on ETF is oxidised by ETF-ubiquinone oxidoreductase, which houses
an FAD, an Fe-S and a Q binding site. ETF-ubiquinone oxidoreductase then passes its
electrons directly to Q (Watmough, Frerman, 2010). FADH2 is also produced during fatty
acid oxidation and is an intermediate of the TCA cycle from oxidation of acetyl CoA, and
can therefore transfer electrons directly to Q. The enzymes dihydroorotate dehydrogenase
(involved in pyrimidine biosynthesis) and s,n-glycerophosphate dehydrogenase are thought
to contain an FAD and donate electrons from FADH2 to Q (Nicholls, Ferguson, 2013).
QH2, from complex I, complex II, or the other enzymes mentioned above, binds to complex
III (cytochrome bc1 complex) at its Qo site near the cytosolic side of the MIM (Crofts, 2004).
One e− from the bound QH2 is passed to the 1 e− carrier protein Cyt c via an Fe-S cluster
and a cytochrome c1 centre, with 1H+ released into the IMS. The other e− is passed through
2 b-type cytochromes. The oxidised Q then binds to the Qi site (near the matrix) and the
electron on the b-type cytochrome is returned, generating the radical QH.. Another QH2
molecule binds to the Qo site and passes one electron to another Cyt c, and the second to the
radical, fully reducing it to QH2. This is known as the Q cycle and its net result is 1 reduced
QH2 and 1 oxidised Q which can return to complex I to pick up more electrons (Nicholls,
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Ferguson, 2013). 4H+ are pumped from the matrix to the IMS per QH2 oxidised. Cyt c then
transfers electrons to complex IV (cytochrome c oxidase).
The final step in the electron transfer chain of mitochondria is the passage of 4 electrons from
Cyt c and 4 protons from the matrix to molecular oxygen (O2) in complex IV to generate 2
H2O (Hosler et al., 2006). As the protons required for this are in the mitochondrial matrix
(the N-side of the membrane) and the electrons come from the IMS (the P-side), this results
in the transfer of 4 positive charges from the N-side to the P-side per O2 reduced. In addition,
complex IV is a proton pump and translocates 2 additional protons per 2 electrons from the
N- to the P-phase (Kaila et al., 2010; Nicholls, Ferguson, 2013).
Complex V (FoF1-ATP synthase) then harnesses this proton electrochemical potential gra-
dient to generate ATP. FoF1-ATP synthase is a proton translocating complex made from 2
substructures: Fo and F1 (Walker, 2013). Fo is an insoluble transmembrane (TM) protein
with a proton-translocation channel and F1 is a soluble peripheral membrane protein that
protrudes into the matrix. Fo and F1 are joined by a 50 Å central stalk and a smaller peripheral
stalk. ADP and Pi bind to the β -subunit on one of three αβ -protomers in the F1 component.
These protomers can exist in one of 3 conformational states that favour: binding of ADP
and Pi, phosphorylation of ADP or release of ATP (Watt et al., 2010). In a process called
the binding change mechanism, the protomers cycle through each of these conformational
states. This is driven by the rotation of the c-ring (which has 8 subunits in mammals) in the
Fo component relative to the central stalk. This rotation is itself driven by the return of H+
from the IMS into the matrix through FoF1-ATP synthase. 2.7 protons are required to make 1
ATP molecule in the matrix (Watt et al., 2010).
The ATP is transported to the cytosol for use in energy requiring processes via the AAC,
in a 1:1 exchange for ADP. This is an electrogenic process because ATP is exported as
ATP4− and ADP is imported as ADP3−. The ∆ψ drives this electrogenic exchange. The
AAC only translocates ADP for ATP and is not able to change the total adenine pool size.
Therefore, the action of the ATP-Mg/Pi carrier (APC) is also required to change total pool
sizes, by catalysing the electroneutral exchange of ATP.Mg2− for HPO42− (Klingenberg,
2008). Pi for phosphorylation of ADP is imported into the matrix via the phosphate carrier
(PiC). This transport is electroneutral, with most evidence favouring an H2PO4−:H+ symport
mechanism driven by the ∆pH (Nicholls, Ferguson, 2013). The relationship of these carriers
is depicted in Figure 1.4. Continuous ATP synthesis requires the coordinated activity of
the ATP synthase, the AAC, and the PiC. The PiC and the AAC result in the import of one
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Fig. 1.4 Adenine nucleotide and phosphate transport in mitochondria. Phosphate (H2PO−4 )
required for phosphorylation of ADP is imported into the mitochondria by the phosphate carrier
(PiC) in an electroneutral symport mechanism with H+. The ADP is imported into the mitochondria
in an electrogenic exchange with ATP catalysed by the ADP/ATP carrier (AAC). ATP synthase
phosphorylates ADP to ATP, concomitantly importing a proton into the matrix. As the AAC is a strict
1:1 exchanger it does not provide a mechanism for changing the total adenine nucleotide pool size.
This is fulfilled by the ATP-Mg/Pi carrier (APC), which catalyses the import of ATP.Mg2+ via an
electroneutral exchange with HPO2−4 .
additional proton to compensate for the charge imbalance of the AAC, so the H+/ATP is
3.7. The P/O ratio is the ratio of the number of moles of ADP phosphorylated to ATP per 2
electrons in a defined segment of the electron transfer chain.
1.3 The role of mitochondria in cellular metabolism
Aerobic respiration in mitochondria requires several interconnecting pathways that converge
to donate electrons to the ETC. Below, I outline the major metabolic pathways of cellular
metabolism, with a particular emphasis on those that are either partly, or completely, housed
within mitochondria and which feed products to mitochondria.
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1.3.1 Glycolysis
Glycolysis is a cytosolic pathway but its intermediates, such as pyruvate and (indirectly)
NADH, can be shuttled into mitochondria for use in energy transduction and biosynthesis
(Bar-Even et al., 2012). The pathway generates ATP without using oxygen and is used in
both aerobic and anaerobic conditions (Chandel, 2015). It is comprised of 10 enzymatic
reactions that can be broadly split into ATP-requiring and ATP-generating reactions (Figure
1.5). Glycolysis begins with the phosphorylation of glucose and its end product is pyruvate,
with many of its intermediates able to enter other biosynthetic pathways. Each molecule of
glucose generates 2 molecules of pyruvate, with a net generation of 2 x ATP (4 generated and
2 invested) and 2 x NADH (Rich, Maréchal, 2010). In the presence of oxygen, both pyruvate
and NADH are shuttled into the mitochondria. As NADH cannot cross the MIM and does not
have a transporter, it enters the mitochondria indirectly through various mechanisms, such
as the malate-aspartate shuttle (MAS). Once inside the mitochondria, NADH is oxidised by
complex I of the ETC and pyruvate is decarboxylated by pyruvate dehydrogenase (PDH).
This generates 1 x acetyl CoA (AcCoA) and 1 x NADH per pyruvate molecule. In the
absence of oxygen, pyruvate cannot enter the ETC as the terminal electron acceptor, O2,
is not present. Instead, pyruvate is reduced to lactate by lactate dehydrogenase (LDH),
coupled to NADH oxidation. Anaerobic glycolysis to lactate regenerates NAD+ pools so that
glycolysis, and thus ATP synthesis, can occur in the absence of O2. In aerobic conditions,
pyruvate is converted to malate before entry into the mitochondria via the MAS, which
consists of several steps.
1.3.2 Gluconeogenesis
Glucose is stored in the body as glycogen in the liver, but the storage capacity of the liver is
not sufficient to meet the glucose demands of the body, particularly under fasting conditions.
Therefore, a further source of glucose is required: gluconeogenesis, which synthesises
glucose from non-carbohydrate metabolites (Chandel, 2015). These include glycolytic
lactate and pyruvate, TCA cycle intermediates and many amino acid carbon skeletons. The
entry point for these precursors is oxaloacetate (OAA) (Figure 1.5). Fatty acids are not
able to enter gluconeogenesis because their complete breakdown yields AcCoA, and there
is no pathway for AcCoA conversion to oxaloacetate in mammals. Gluconeogenesis is
also a way of regenerating glycolytic intermediates for the synthesis of other molecules,
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Fig. 1.5 Glycolysis and gluconeogenesis. The 10 steps of glycolysis are shown are shown alongside
the steps of gluconeogenesis. Enzymes exclusive to glycolysis are shown in blue, with blue arrows
depicting their reactions, and enzymes exclusive to gluconeogenesis are shown in red, with red arrows
depicting their reactions. Enzymes and the reactions which are common to both glycolysis and
gluconeogenesis are depicted in black. ATP and GTP molecules invested are shown in red circles
and ATP and NADH molecules generated are shown in green circles. PEPCK: phosphoenolpyruvate
carboxykinase.
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such as lipids. The primary site of gluconeogenesis is the liver, and its reactions occur
in both the mitochondrial matrix and the cytosol (Zhang et al., 2019). The majority of
gluconeogenesis uses glycolytic enzymes, but three of the steps are catalysed by different
enzymes (depicted in red in Figure 1.5) as these must overcome large negative free energy
changes in the direction of glycolysis. The first reaction catalysed by a separate enzyme is
catalysed by pyruvate carboxylase and phosphoenolpyruvate carboxykinase (PEPCK), which
generates PEP from pyruvate. The second is catalysed by fructose 1,6-bisphosphatase, which
converts fructose 1,6-bisphosphate to fructose-6-phosphate. The final reaction is catalysed by
glucose-6-phosphatase, and generates glucose from glucose-6-phosphate. The biosynthetic
gluconeogenesis and degradative pathway glycolysis differ in 3 reactions, which allows both
directions to be simultaneously thermodynamically favourable under the same conditions
(Chandel, 2015).
1.3.3 The tricarboxylic acid cycle
Pyruvate from glycolysis can enter the mitochondria and there be converted to AcCoA by
PDH, which joins a larger pool of AcCoA from the oxidation of amino acids and fatty acids,
and enters the TCA cycle. This is a central metabolic pathway of 8 enzymatic reactions that
occurs in the mitochondrial matrix (Figure 1.6). The cycle generates the energy equivalents
ATP or GTP and the reducing equivalents NADH and FADH2, which ultimately generate
ATP via OXPHOS (Akram, 2014). The cycle begins with AcCoA which is oxidised in a
stepwise manner during the 8 reactions to yield 3 x NADH, 1 x FADH2, 1 x GTP and 2
x CO2. Glycolysis generates 2 x ATP (net) from 1 molecule of glucose, whereas aerobic
respiration can theoretically generate an additional ∼36 x ATP from 1 molecule of glucose:
2 x ATP from TCA cycle and ∼34 x ATP from OXPHOS (10 x NADH and 4 x FADH2).
Thus it can be seen that aerobic respiration of glucose is more energy efficient in terms of
ATP production than glycolysis alone (Rich, Maréchal, 2010).
The TCA cycle is positioned at the core of cellular metabolism and acts as a biosynthetic
hub. It forms a bridge between metabolism and oxidative phosphorylation because one
of its enzymes, SDH, is an enzyme of the TCA cycle and also a respiratory complex of
the ETC. Furthermore, TCA cycle intermediates can feed into other metabolic pathways,
acting as precursors for many other biomolecules such as haem, from succinyl-CoA, and
lipids, from AcCoA (Akram, 2014; Chandel, 2015). The intermediates that are removed
must be replenished, so that the cycle can continue. This is referred to as anaplerosis and
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Fig. 1.6 The citric acid cycle. The cycle begins when acetyl CoA (AcCoA) is reduced to citrate.
The cycle generates 3 x NADH, 1 x FADH2, 1 x GTP and 2 x CO2. Reducing equivalents (NADH
and FADH2) and energy equivalents (GTP) generated during the cycle are shown in green circles.
Enzymes are written in blue. PDH: pyruvate dehydrogenase; CoA: Coenzyme A.
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can occur because many different substrates can be broken down to enter the TCA cycle at
various points, including fatty acids, amino acids and pyruvate. One important anaplerotic
process is the conversion of pyruvate to OAA by pyruvate carboxylase. Another major
input is glutaminolysis. This is the conversion of glutamine to glutamate and finally to
α-ketoglutarate, which can enter the TCA cycle. Glutaminolysis is an important mechanism
during lipid synthesis, as citrate is exported from the mitochondria to participate in the
lipid synthesis. The removal of citrate limits the formation of downstream α-ketoglutarate
(Chandel, 2015). The TCA cycle allows mitochondria to monitor and respond to the needs
of cellular metabolism, and synthesise the biomolecules they need to carry out their own
functions and for export for cellular functions.
1.3.4 Amino acid metabolism
There are 20 amino acids, nine of which are “essential” in humans and must be obtained
from the diet, whilst the rest can be synthesised from glycolytic and TCA cycle intermediates.
Amino acids are important for protein synthesis but also have roles in the generation of
glucose, ATP and fatty acids and are precursors for haem groups and signalling molecules
such as neurotransmitters (Chandel, 2015). Amino acid metabolism occurs in both the cytosol
and the mitochondrial matrix.
In the heart, amino acids are metabolised under normal and pathological conditions. They
have an anaplerotic role and can be metabolised to TCA cycle intermediates to generate
energy (Drake et al., 2012). For example, glutamate can be transaminated to α-ketoglutarate,
which can either enter the TCA cycle to generate NADH and GTP or be further metabolised
to alanine, aspartate and arginine. Asparagine can be used as a mechanism to remove excess
nitrogen from the cell, or be converted to aspartate. Aspartate can then be transaminated
to oxaloacetate and enter the TCA cycle. This transamination reaction is reversible, al-
lowing aspartate and asparagine to act as sinks for excess oxaloacetate. Alanine can be
transaminated to pyruvate, whose oxidation yields NADH and GTP. The branched-chain
amino acids (BCAAs) can be metabolised to AcCoA, pyruvate and succinyl-CoA, which
has been suggested to be cardioprotective during ischaemia. Other amino acids can also
be catabolised by the heart, with varying energy recovery yields. It should be noted that
under normal conditions amino acid metabolism contributes only a small amount to cardiac
ATP production. However, in certain conditions, such as when oxygen levels fall during
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ischaemia, the heart relies on a broader range of fuel sources, including amino acids (Drake
et al., 2012).
Besides energy generation, amino acid metabolism has important biosynthetic roles in the
cell. For example, the mitochondrial enzyme aminolevulinate synthase (ALAS) is the rate-
limiting enzyme in haem synthesis (Dwyer et al., 2009). Furthermore, mitochondrial glycine
is a precursor in haem synthesis. Glycine and glutamate serve as neurotransmitters, with
glutamate also generating the neurotransmitter γ-aminobutyric acid (GABA). Glutamate,
glycine and cysteine generate the antioxidant glutathione. The metabolism of arginine by
nitric oxide synthase (NOS) generates nitric oxide (NO), an important signaling molecule in
the heart. Methionine provides the methyl group necessary for DNA and histone methyltrans-
ferases which regulate epigenetics. Glutamate is important for the interconversion of many
different amino acids because it can act as both a nitrogen donor and acceptor (Chandel,
2015).
1.3.5 The urea cycle
Free amino acids cannot be stored and are deaminated, generating a carbon skeleton and
ammonium (NH+4 ). Ammonium at high levels is toxic and must be removed. It is converted to
urea by the urea cycle and excreted via the kidneys in mammals. The urea cycle consists of 5
enzymatic reactions and is mostly found in the liver, in both the mitochondria and the cytosol
(Figure 1.16). The first two steps occur in the mitochondrial matrix: carbamoyl phosphate
synthetase I generates carbamoyl phosphate from NH+4 and HCO
−
3 , using 2 ATP molecules
and sequestering the first nitrogen atom. Ornithine transcarbamoylase combines ornithine
and carbamoyl phosphate to form citrulline. Citrulline is exported from the mitochondrial
matrix to the cytosol in exchange for ornithine by the ornithine carrier (ORC). Citrulline and
aspartate are converted to argininosuccinate in the cytosol by argininosuccinate synthetase,
using another ATP molecule and incorporating the second nitrogen atom. Argininosuccinase
metabolises argininosuccinate to arginine and fumarate. Finally, arginine is converted
to ornithine by arginase, generating urea (Chandel, 2015; Morris, 2002). The fumarate
produced in the cytosol is converted to malate by cytosolic fumarase. Malate can then
enter the mitochondria and its conversion to oxaloacetate generates NADH, which is able to
generate ATP through OXPHOS.
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1.3.6 Fatty acid oxidation
Fatty acids are important structural and metabolic components of the cell. They are incorpo-
rated into many different types of lipids, such as the energy storing triacylglycerols (TAGs)
(glycerol attached to saturated and unsaturated fatty acids) and the membrane components
phospholipids (a glycerol molecule with two fatty acid tails attached to a polar molecule, such
as choline, via a phosphate bond) (Chandel, 2015). Lipids also have metabolic roles in the
cell. For example, the fatty acid arachidonic acid is a precursor of prostaglandins, These are
a subclass of eicosanoids with hormone-like effects in mammals, and can be inflammatory
and act as vasodilators (Kuehl, Egan, 1980).
Mitochondria have a role in both fatty acid synthesis and breakdown (termed β -oxidation).
Although fatty acid synthesis occurs in the cytosol, where the high NADPH/NADP+ ratio
drives the reactions, mitochondrial citrate is required to provide the building blocks. Citrate
is exported from the mitochondria to the cytosol, where it is metabolised to AcCoA by ATP
citrate lyase (ACL)(Kastaniotis et al., 2017). AcCoA is then carboxylated to malonyl-CoA
by AcCoA carboxylase (ACC), which is an irreversible reaction. The synthesis pathway then
enters the elongation phase, whereby malonyl-acyl carrier protein (ACP) is formed from
malonyl-CoA and acetyl-ACP is formed from AcCoA, catalysed by malonyl transacylase
and acetyl transacylase respectively. Malonyl-ACP and acetyl-ACP then react in a series of 7
enzymatic reactions to form palmitate, catalysed by fatty acid synthase. In mammals these
enzymes are collectively termed type II fatty acid synthase (FAS-II). Palmitate can then be
further modified to other fatty acids.
A key difference between fatty acid synthesis and β -oxidation is the electron donor. β -
oxidation uses FAD, whereas synthesis utilises NADPH. The metabolism of citrate by ACL
yields oxaloacetate and AcCoA, which is directly involved in fatty acid synthesis. Malate
dehydrogenase reduces this oxaloacetate to malate, which can be oxidised to pyruvate
in the cytosol. This generates cytosolic NADPH which drives many of the reactions of
fatty acid synthesis. The pentose phosphate pathway (PPP), 1-carbon metabolism and
isocitrate dehydrogenase 1 (IDH1) also generate NADPH needed for fatty acid synthesis.
Besides citrate, AcCoA can also be generated in the mitochondria from pyruvate (either from
glycolysis or amino acid metabolism).
Stored TAGs can be broken down to generate fatty acids and glycerol. The glycerol backbone
enters glycolysis through dihydroxyacetone phosphate. The fatty acids enter the mitochondria
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which house the enzymes required for β -oxidation, which is an ATP-generating process.
For β -oxidation to occur, the fatty acids must be transported into the mitochondrial matrix
from the cytosol, via the carnitine transport cycle (Figure 1.7)(Kerner, Hoppel, 2000). This
requires the fatty acid to first be converted to a fatty acyl-CoA by the action of fatty acyl-CoA
synthetase in the cytosol. Carnitine acyl transferase (CPT1) can then replace CoA with a
carnitine molecule, forming a fatty acyl carnitine molecule. This is translocated into the
mitochondrial matrix by carnitine-acylcarnitine translocase in the MIM via an exchange
mechanism with carnitine. Once in the matrix carnitine acyltransferase II removes the
carnitine from the fatty acylcarnitine, generating fatty acyl-CoA. The carnitine is shuttled
back across the membrane to act as a tag for another fatty acyl-CoA (Kerner, Hoppel, 2000).
The fatty acyl-CoA in the matrix can then enter the β -oxidation pathway. The long chains of
fatty acyl-CoAs are degraded by the sequential removal of 2-carbon acetyl-CoA, concomi-
tantly generating NADH and FADH2 (Adeva-Andany et al., 2019; Houten et al., 2016). After
each removal, the subsequent 2-carbon shorter acyl-CoA becomes the substrate for another
round of β -oxidation. As each acetyl-CoA generates 3 NADH, 1 FADH2 and 1 GTP, for
the 16-carbon fatty acid palmitate, its complete β -oxidation generates 31 NADH (24 from
acetyl-CoA + 7 from 7 x rounds of β -oxidation), 15 FADH2 (8 from acetyl-CoA + 7 from 7
x rounds of β -oxidation) and 8 GTP. NADH and FADH2 can enter OXPHOS to generate
ATP, and GTP can be converted to ATP by nucleoside diphosphate (NDP) kinase. As each
NADH generates 2.5 ATP, FADH2 generates 1.5 ATP, and 1 GTP can be converted to 1 ATP,
108 molecules of ATP are generated from palmitate oxidation. Subtracting the 2 ATP used
for the activation step gives a net ATP yield of 106 ATP molecules from palmitate oxidation.
Some tissues, such as the heart, rely on β -oxidation all the time, whereas other tissues switch
to β -oxidation when cellular glucose levels are low, and glycolysis cannot generate acetyl-
CoA (Houten et al., 2016). Fatty acid oxidation then steps in to generate the acetyl-CoA
needed to maintain the TCA cycle. The heart is described as a "metabolic omnivore" and
switches rapidly between fuel sources according to supply (Grynberg, Demaison, 1996). The
heart uses fatty acid as its main fuel source because storage of fatty acids as TAGs in the body
as an energy store is more efficient than glucose storage. This is because the energy density
of fatty acids is much higher compared to glucose, stored as glycogen. The oxidation of these
energy-rich molecules yields around twice as much energy as glucose (39 kJ/g for palmitate
compared to 15 kJ/g for glucose). This is because fatty acid oxidation (or β -oxidation) occurs
by the stepwise release of AcCoA from the acyl-CoA, generating 1 x NADH and 1 x FADH2.
Each AcCoA then yields 3 x NADH, 1 x FADH2 and 1 x GTP in the TCA cycle. This means
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Fig. 1.7 The carnitine shuttle imports fatty acids into the mitochondria. Fatty acids in the cytosol
are converted to a fatty acyl-CoA by fatty acyl-CoA synthetase. The fatty acyl-CoA can then be
tagged with a carnitine by carnitine acyltransferase I (CPT1) in the MOM, generating a fatty acyl
carnitine. The carnitine/acylcarnitine carrier (CAC) in the MIM catalyses the exchange of the fatty
acyl carnitine for matrix carnitine. Once in the matrix, the fatty acyl carnitine is converted to to fatty
acyl-CoA by carnitine acyltransferase II (CPTII). This releases carnitine, which is shuttled back to the
cytosol to tag another fatty acyl-CoA for transport.
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the oxidation of the 16-carbon fatty acid palmitate yields ∼106 x ATP (Röhrig, Schulze,
2016).
1.3.7 Other functions of mitochondria
Mitochondria are involved in a plethora of cellular processes besides the above mentioned
roles in carbohydrate, fatty acid and amino acid metabolism. Below I describe other mito-
chondrial processes that are crucial for cellular function.
Mitochondria are essential for the assembly of iron-sulphur (Fe-S) clusters and for haem
biosynthesis (Paul, Lill, 2015; Ye, Rouault, 2010). Fe-S clusters are small, highly conserved
inorganic protein cofactors, which act as electron carriers in a range of redox reactions
(e.g. in respiratory complexes) and have catalytic activity in some chemical reactions (e.g.
aconitase). They are found in the mitochondria, the cytosol and the nucleus, but they are
all synthesised in the mitochondria using the conserved iron-sulphur cluster (ISC) assembly
machinery. Cytosolic and nuclear Fe-S proteins also require the action of the cytosolic
iron-sulphur protein assembly (CIA) machinery (Paul, Lill, 2015). Iron-containing haem
groups are synthesised solely in the mitochondria, where they are used in cytochromes or are
exported from the mitochondria for use in haemoglobin and myoglobin (Ye, Rouault, 2010).
Mitochondria have a role in calcium storage and signalling. Mitochondria form intimate
connections with the ER (Lebiedzinska et al., 2009; Murley, Nunnari, 2016), which rapidly
takes up calcium to maintain calcium homeostasis. Mitochondria are also able to take up
calcium into the matrix through the mitochondrial calcium uniporter (MCU) on the MIM,
thereby acting as a calcium buffer. Movement of calcium into the mitochondria modulates
mitochondrial ATP production (Brand, Murphy, 1987; Mammucari et al., 2011; McCormack
et al., 1990).
Mitochondrial calcium is a major factor in a further role of mitochondria: the regulation of
cell survival. Mitochondria are key players in both programmed cell death by apoptosis and
necrotic cell death. In the mitochondrial pathway of apoptosis the release of mitochondrial
factors, such as Cyt c from the IMS, is a critical step in committing the cell to activating
apoptosis (Tait, Green, 2010). Necrosis often involves the opening of the mitochondrial
permeability transition pore (MPTP) and is triggered by the accumulation of calcium inside
mitochondria as well as ROS (Halestrap, 2005; Rasola, Bernardi, 2011). The opening of
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the MPTP causes the loss of ATP and the collapse of ion gradients, as the dysfunctional
mitochondria are unable to use ATP to maintain these gradients.
Mitochondria also play a range of roles in the immune response. Mitochondria release
various signals that act as damage-associated molecular patterns (DAMPs). For example,
mtDNA is released by damaged or necrotic cells and binds to the TLR9 receptor, leading to
activation of the NF-κB signalling pathway and proinflammatory gene transcription (Mills
et al., 2017). In this way the mitochondria signal to the nucleus that there is damage, enabling
the cell to adapt and kickstart repair mechanisms. Furthermore, the MOM acts as a platform
for signaling molecules such as mitochondria-associated viral sensor (MAVS), triggering
immune responses (Arnoult et al., 2011). Mitochondrial succinate can be released from the
cell, where it can act as an extracellular signal by binding to its receptor SUCNR1 (Rubic
et al., 2008), triggering an immune response. Once in the cytosol succinate can also stabilise
HIF1α (Murphy, O’Neill, 2018), discussed in more detail later.
1.4 Mitochondrial ROS production
Mitochondria are major sources of reactive oxygen species (ROS) within the cell, such as
H2O2 and O.−2 (Arnoult et al., 2011; Murphy, 2009; Tormos et al., 2011). Uncontrolled,
aberrant ROS production can overwhelm antioxidant defences and lead to oxidative damage,
both within the mitochondria and the rest of the cell, because ROS are damaging to lipids,
proteins and DNA (Figure 1.8). This oxidative damage contributes to a range of pathologies
(Smith et al., 2012). Lipid peroxidation can increase the permeability of the MIM to
protons, uncoupling OXPHOS and inhibiting ATP production (Murphy, 2012). Damage
to mtDNA can lead to mutations and deletions, contributing to the transformation and
development of cancer. ROS also have a beneficial redox signalling role within the cell,
enabling communication between the mitochondria and the cytosol and nucleus. For example,
the cytosolic transcription factor HIF is stabilised by mitochondrial ROS and leads to
transcriptional adaptation (Mills et al., 2016; Murphy, O’Neill, 2018).
The primary ROS produced by mitochondria is the superoxide anion O.−2 (Murphy, 2009),
which is formed by the one-electron reduction of O2. Despite there being many electron
donors within mitochondria they generally only donate or ‘leak’ an electron to O2 under
certain conditions, termed mode 1 and mode 2. Mode 1 occurs when there is a high
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Fig. 1.8 Overview of ROS production and its downstream effects in the cell. Mitochondrial ROS
production can cause oxidative damage to mitochondrial proteins, such as the respiratory chain
complexes, membranes and DNA. This damage can prevent the mitochondria from performing their
essential metabolic functions and ATP synthesis. Mitochondrial ROS can also lead to the release of
cytochrome c (Cyt c) via the mitochondrial outer membrane permeabilisation (MOMP), as well as
opening of the permeability transition pore (PTP), leading to apoptotic and necrotic cell death. ROS
can also act as a redox signal. From Murphy (2009).
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NADH/NAD+ ratio in the matrix and mode 2 occurs when ATP synthase cannot operate,
resulting in a high ∆p and reduced CoQ pool. Some ROS synthesis occurs when mitochondria
are making ATP (mode 3), but this rate is much lower. In the following sections, I outline the
sources of mitochondrial ROS, their metabolism and their role in redox signalling.
1.4.1 Sources of mitochondrial ROS
Complex I is one of the main sources of mitochondrial O.−2 . It is capable of producing
O.−2 during both forward and reverse electron transfer (RET) (Chouchani et al., 2014, 2016;
Murphy, 2009; Pryde, Hirst, 2011). O.−2 is produced during forward electron transfer when
O2 reacts with fully reduced FMN on Complex I. The proportion of FMN that is fully reduced
is set by the NADH/NAD+ ratio (as NADH is the electron donor to Complex I). A high
NADH/NAD+ ratio occurs when the respiratory chain is blocked by damage, mutation,
ischaemia, loss of cytochrome c or low ATP demand. O.−2 production by RET occurs when
mitochondria are operating in mode 2: a highly reduced CoQ pool combined with a high ∆p
forces electrons back into Complex I, reducing NAD+ to NADH at the FMN site. This can
lead to the transfer of e− to O2, forming O.−2 . O
.−
2 production by RET at Complex I has been
shown to occur during IRI (Chouchani et al., 2014) (Section 1.9).
Complex III is also capable of producing ROS under certain conditions (Murphy, 2009;
Quinlan et al., 2011). The UQ.−/UQ couple formed during the Q cycle is highly reducing,
making it thermodynamically capable of donating an electron to O2, forming O.−2 . Under
normal physiological conditions, complex III produces only a small amount of ROS. However,
in the presence of its inhibitor antimycin, complex III can produce ROS by stabilisation of a
semiquinone radical at the Qo site (Nicholls, Ferguson, 2013; Quinlan et al., 2011).
1.4.2 Mitochondrial superoxide and hydrogen peroxide metabolism
Superoxide produced in the mitochondrial matrix cannot diffuse through membranes and is
thus contained in the matrix. However, superoxide can be metabolised to generate other, more
damaging ROS (Figure 1.9). Superoxide dismutases (SODs) catalyse the dismutation of O.−2
to oxygen and hydrogen peroxide (H2O2) (Murphy, 2009). O.−2 can also form peroxynitrite
by spontaneous reaction with nitric oxide (.NO) produced by nitric oxide synthases (NOSs).
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Fig. 1.9 Overview of mitochondrial superoxide and hydrogen peroxide metabolism. Superox-
ide (O.−2 ) is produced in the matrix and metabolised to hydrogen peroxide (H2O2) by manganese
superoxide dismutase (MnSOD). H2O2 is metabolised to H2O by the peroxidases peroxiredoxin
(Prx) and glutathione peroxidase (Gpx). Oxidised Prx can be regenerated by thioredoxin (Trx).
Reduced Trx levels are controlled by thioredoxin reductase (TrxR), which in turn is regulated by the
NADPH/NADP+ pool. Gpx uses GSH to reduce oxidised peroxidases, such as Prx. The oxidised
Gpx is recycled by glutathione reductase (GR). Furthermore, H2O2 can leave the mitochondria as it is
membrane permeable. TH: transhydrogenase. Figure adapted from Murphy (2009).
In the presence of Fe2+, H2O2 can form the hydroxyl radical (.OH) by the Fenton reaction
(Murphy, 2012).
O.−2 , whether produced during pathological processes or for signalling purposes, must be
removed by conversion to H2O2 to stop it causing uncontrolled damage. As well as being
responsible for a large amount of ROS production, mitochondria also house a number of
pathways for ROS metabolism. In addition, many mechanisms to remove ROS also exist
in the cytosol. O.−2 is converted to H2O2 and O2 by SODs. Mammals possess 3 SODs:
SOD1 (CuZn-SOD) is mostly cytoplasmic; SOD2 (Mn-SOD) is found in the matrix; SOD3
is extracellular. Loss-of-function (LOF) SOD2 mutations in mice cause early mortality,
highlighting the importance of this mitochondrial defence mechanism (Nicholls, Ferguson,
2013). H2O2 can oxidise thiols on proteins, which is the basis of thiol-dependent redox
signalling. For redox signalling to occur there must also be mechanisms to re-reduce thiols.
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A group of mitochondrial thiol systems in the mitochondrial matrix are responsible for
transmitting, modulating and sensing redox signals, as well as preventing oxidative damage
by removing ROS. This "firewall" is dependent on a continued NADPH supply, which is
maintained by the transhydrogenase, malic enzyme and NADP-dependent IDH enzymes
(Murphy, 2009). As the electrons of NADPH are also used in the biosynthesis of fatty acids,
cholesterol, amino acids and nucleotides (Chandel, 2015), NADPH may serve as a link
between cellular metabolism and redox signalling, relevant in both the mitochondrial matrix
(from IDH2 and malic enzyme 3) and the cytosol (from IDH1, malic enzyme 1 and the PPP).
1.4.2.1 The peroxiredoxin/thioredoxin system
Peroxiredoxins (Prx) are thiol peroxidases that act to maintain the redox balance of the
cell by scavenging H2O2 (Murphy, 2012). Mammals possess 6 Prx isoforms with different
subcellular locations. Prx1, 2 and 6 are cytoplasmic, Prx3 is mitochondrial, Prx4 is found in
the ER and Prx5 is found in multiple locations, including the mitochondria and peroxisomes,
although Prx3 is the highest capacity mitochondrial Prx. A redox-sensitive cysteine in the Prx
active site is oxidised by H2O2, generating H2O. When oxidised, the Prx forms homodimers
through reversible inter-protein disulphide bridges and a sulfenic acid (-SOH) on the Prx.
These oxidised Prxs are temporarily inactivated. This can be readily reversed by thioredoxin
(Trx), which reduces the disulphide bond to a dithiol (-SH) (Chae et al., 1994; Cox et al.,
2010; Murphy, 2012). Persistent oxidation can lead to other thiol modifications, such as
sulfinic acid (-SO2H), reversible by sulfiredoxin, and sulfonic acid (-SO3H), which is an
irreversible modification.
Trxs reduces disulphide bonds on proteins, including Prxs. Trx2 is found in the mitochondrial
matrix and Trx1 is cytosolic. An active thiol within Trx acts as a nucleophile to attack the
disulphide bond, forming a transient disulphide bridge with the protein. A second Trx2
is required to reduce this intermediate, reducing the target protein’s disulphide bond. The
resulting disulphide bond on Trx2 is reduced by the enzyme thioredoxin reductase (TR2),
which requires NADPH as a reducing modality (Murphy, 2012) (Figure 1.10).
30 Introduction
Fig. 1.10 The peroxiredoxin/thioredoxin system. Peroxiredoxins (Prxs) reduce H2O2 to H2O,
generating a sulfenic acid (-SOH) on the Prx. This can lead to inter-molecular homodimers of Prx,
linked by disulphide bridges. Hyperoxidation can generate sulfinic acid (-SO2H) and sulfonic acid
(-SO3H) modifications. Sulfinic acid modifications are reversible by sulfiredoxin (SRX) whereas
sulfonic acid modifications are irreversible. Hyperoxidised Prxs are inactive (irreversibly or reversibly)
and are a marker of oxidative damage. Prx dimers are reduced by thioredoxins (Trx), which are in
turn regenerated by thioredoxin reductase (TR) and NADPH.
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1.4.2.2 The mitochondrial glutathione system
Glutathione (GSH) is a small peptide that has protective roles in antioxidant defence, mainte-
nance of thiol status and detoxification (Mari et al., 2009; Murphy, 2012). It is synthesised
in the cytoplasm by γ-glutamylcysteine synthetase and glutathione synthetase and imported
into the mitochondria. The matrix pool of GSH is thought to be 1-5 mM (Booty et al., 2015)
and the cytosolic pool 5-15 mM (Mari et al., 2009; Smith et al., 1996). It was previously
thought that GSH was transported into mitochondria by the dicarboxylate carrier (DIC)
and the oxoglutarate carrier (OGC), but Booty et al. (2015) suggests this is not the case.
Once in the matrix, GSH is oxidised to glutathione disulphide (GSSG) through the action
of glutathione peroxidase (Gpx1) which reduces H2O2 to H2O. GSSG is reduced back to
GSH by glutathione reductase (GR), using NADPH as an electron donor. GR maintains
the mitochondrial matrix GSH pool highly reduced (95-99 %) with some oxidised GSSG.
The NADP+ pool is in turn reduced by transhydrogenase and IDH (Murphy, 2012; Nicholls,
Ferguson, 2013).
Glutathione peroxidase (Gpx1) uses GSH to detoxify peroxides (Figure 1.11). There are
2 Gpx isoforms in the matrix: soluble Gpx1 degrades H2O2, whilst Gpx4 is adsorbed to
the MIM (on the matrix side) and degrades phospholipid hydroperoxides, preventing lipid
peroxidation (Murphy, 2012; Nicholls, Ferguson, 2013).
Glutaredoxins (Grx) catalyse protein deglutathionylation, which occurs when oxidised protein
thiols react with GSH. Grx2 is mitochondrial and Grx1 is located in the cytosol. Glutathione-
S-transferases (GSTs) use GSH to detoxify electrophiles such as xenobiotics and products of
oxidative damage (Murphy, 2012).
1.4.3 Mitochondrial redox signalling
Mitochondria are now understood to be signalling hubs which are essential to the health
and fate of the cell. A key way they interact with the rest of the cell and modulate cellular
function is through redox signalling.
H2O2 is a ROS signal. It can diffuse through membranes, unlike superoxide. In order to be
an effective signal, it must be rapidly responsive to changes in mitochondrial status so that a
meaningful and accurate message is relayed to the rest of the cell (Finkel, 2012; Holmström,
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Fig. 1.11 The mitochondrial glutathione system. A) Glutathione peroxidase (Gpx) uses reduced
glutathione (GSH) to reduce H2O2 to H2O. The oxidised glutathione (GSSG) is reduced to GSH by
glutathione reductase (GR). B) Glutaredoxin (Grx) catalyses the exchange of GSH with protein (Pr)
thiols. C) Glutathione-S-transferase (GST) detoxifies electrophiles (RX) using GSH.
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Finkel, 2014; Janssen-Heininger et al., 2008). This is achieved because the generation of
superoxide by RET at complex I (one process by which H2O2 can be made) is extremely
sensitive to the ∆p and the redox state of the Q pool, as discussed above (Chouchani et al.,
2016; Murphy, 2009). Both of these vary in direct response to mitochondrial activity: when
mitochondria are inactive and become overloaded with electrons ROS production is increased,
and is decreased when mitochondria are active (Chouchani et al., 2016; Murphy, 2009).
The level of ROS produced by RET can also be modulated by other, more physical, changes
to complex I. One of these is post translational modifications (PTMs) to complex I such as
phosphorylation (Covian, Balaban, 2012). Furthermore, RET is affected by the proportion
of complex I in the active state. Complex I is known to adopt the deactive state during
ischaemia (Gorenkova et al., 2013) but it is not known whether this is a mechanism to regulate
RET and ROS signalling. Complex I can function as an isolated complex or as part of a
supercomplex with other respiratory chain complexes (Moreno-Loshuertos, Enríquez, 2016).
The physiological role of supercomplexes is not known (Blaza et al., 2014) but it is postulated
that they increase efficiency of OXPHOS and reduce aberrant ROS production (Moreno-
Loshuertos, Enríquez, 2016). Complex I incorporation into supercomplexes is proposed to
be related to changes in mitochondrial ROS formation (Lopez-Fabuel et al., 2016). There are
thought to be different supercomplex assemblies, each with different specificities for receiving
electrons from NADH or FADH2, meaning that they can respond to the NADH/FADH2 ratio
derived from available fuel sources. The adaptation of the superassemblies is postulated
to be mediated by redox signalling. For example, the incorporation of complex II into the
supercomplexes was increased by phosphorylation of its subunit FpSDH by the tyrosine-
kinase enzyme Fgr, which is activated by H2O2 (Acín-Pérez et al., 2014).
RET is biologically relevant, both positively and negatively, in a range of physiological
conditions. It is involved in the metabolic adaptation of macrophages during inflammation
(Mills et al., 2016), triggering the immune response during viral infection (Buskiewicz
et al., 2016) and in extending lifespan in fruit flies (Scialo et al., 2016). RET plays a major
pathological role during reperfusion, the return of blood flow after a period of ischaemia,
such as during a heart attack, stroke or surgery. The RET that occurs generates a burst of
superoxide through complex I which leads to tissue damage, termed ischaemia-reperfusion
injury (IRI). This is discussed in greater detail in Section 1.9.
H2O2 can diffuse out of the mitochondria into the cytosol, although at present it is unclear
whether this is through a protein-mediated process (as for the transport of H2O2 across
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the PM) or merely direct permeation through the MIM (Murphy, 2009). If the transport is
protein-mediated this would confer an extra layer of control over H2O2 signalling. Once
in the cytosol, it can alter enzyme activity by reversible oxidation of cysteine thiols or by
acting on redox sensitive proteins such as Prxs and Trxs. H2O2 can also alter mitochondrial
metabolism, such as acting on metal-centre proteins (Winterbourn, 2013) such that another
signal is produced that can leave the mitochondria and signal to the rest of the cell.
H2O2 primarily acts as a signal by affecting the activity of proteins. The main way it
achieves this is the redox modification of a cysteine residue on the target protein. Cysteine
residues contain active thiol groups, which are maintained under a reduced state in normal
physiological conditions (Menger et al., 2015). Changes in cellular redox state can lead
to oxidative thiol modifications, such as disulphide bonds, S-sulfenylation, S-nitrosation,
S-acetylation or S-glutathionylation (Paulsen, Carroll, 2013). These modifications affect the
function of the protein by changing its activity, binding interactions, lifetime and subcellular
localisation (Holmström, Finkel, 2014). Most of these redox modifications are reversible,
meaning that the proteins can respond to the cellular redox state, such as the reversible
inactivation of tyrosine phosphatases via cysteine thiol oxidation (Meng et al., 2002).
1.5 Mitochondrial metabolite transport
In order for mitochondria to perform these roles, metabolic substrates such as keto acids,
amino acids, nucleotides, cofactors, vitamins and protons need to be imported into, and
excreted from, the mitochondria. The MIM has to be impermeable to proteins, metabolites
and protons to maintain its electrochemical potential gradients. Therefore, carriers are needed
to move metabolites in and out of the mitochondria, across the MIM. The combined action of
the impermeable MIM and the selective action of metabolite transporters on the MIM enable
the coupling of metabolism between the mitochondria and the cytosol (Figure 1.12). Below,
I outline mitochondrial transporters in general and describe some specific transporters and
their role in metabolism and compartmentalisation.
1.5 Mitochondrial metabolite transport 35
Fig. 1.12 Mitochondrial carriers. Schematic representation of a mitochondrion depicting the various
carriers of the mitochondrial inner membrane (MIM) as well as the major metabolic pathways that
they contribute to (shown in red). ATP synthase and respiratory chain complexes are blue and
green respectively. Known mitochondrial carriers are depicted in yellow whilst unknown carriers are
depicted in purple. Blue arrows show the direction of proton transport over the MIM. From Kunji,
Robinson (2010).
1.5.1 Mitochondrial carriers
There are many different types of mitochondrial carriers in humans, and their mutation can
lead to an array of diseases, exemplifying their importance for the maintenance of normal
metabolism (Palmieri, 2008). For example, a deficiency in AAC caused by mutations in the
SLC25A4 gene results in exercise intolerance, lactic acidosis and hypertrophic cardiomy-
opathy (Palmieri, 2008). As many metabolites are charged, their transport is affected by
the ∆ψ and/or ∆pH across the MIM, and transporters often use these gradients to drive the
accumulation of a metabolite on one side of the MIM. There are different strategies that
can be used to harness or exploit the ∆ψ and/or ∆pH to influence transport. Proton symport
with a neutral species is driven by the ∆p. Proton symport with a negative species is an
electroneutral mechanism, driven by ∆pH only. Uniport of either a positive or negative
species, such as Ca2+, is an electrogenic process driven by the ∆ψ . The exchange of two
metabolites can be electrogenic or electroneutral depending on their respective charges and
is a useful mechanism of accumulating highly negatively charged species, such as ATP and
ADP, that would otherwise be excluded due to the high inside negative membrane potential.
The antiport of an anion or positively charged metabolite with protons is electroneutral.
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Fig. 1.13 SLC25A carrier monomer structure. A topological model of the structure of an SLC25A
carrier monomer. SLC25A carriers have 6 transmembrane helices arranged in 3 repeats of 2 helices.
Each repeat is connected to the next by a long hydrophilic matrix loop which protrudes into the
membrane. Both the N- and C-termini face the cytosol.
Below, I outline the SLC25A mitochondrial carrier family, the largest mitochondrial carrier
family in humans, and cover some of the main carriers of this family, before discussing other
important carriers that are not part of this family.
1.5.2 The SLC25A carrier family
The SLC25A family is the largest family of mitochondrial carriers in humans, with 53
transporters (Palmieri, 2014). These are nuclear-encoded single polypeptide chain proteins
with 6 TM α-helices and 3 matrix helices (Figure 1.13). It is thought that they generally
function as monomers, with a single substrate binding site in a large central water-filled cavity
formed by the TM helices. Access to the binding site is controlled by 2 gates made from 2-3
salt bridges. At any one time only one of these gates is open, avoiding an open channel which
would dissipate ion gradients across the MIM (Kunji, Robinson, 2010; Palmieri, 2004).
Some carriers are expressed in all tissues (e.g. the ADP/ATP carrier and the phosphate
carrier), whereas some are tissue specific or have isoforms with different tissue distributions,
reflecting the different metabolic roles mitochondria play in different tissues (Palmieri, 2004).
Most transporters function as exchangers (substrate in/product out) but some are uniporters
or exchange H+ (driven by the ∆p). Carriers that perform substrate-proton symport possess
negatively charged residues (e.g. aspartate or glutamate) in the substrate binding site. Proton
coupling allows the movement of the substrate against its concentration gradient by using the
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∆p to power it (Kunji, Robinson, 2010). Tables 1.1 and 1.2 outline the substrates, transport
mechanism and tissue distribution of some of the major SLC25A family carriers.
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1.5.2.1 The ADP/ATP carrier
The ADP/ATP carrier (AAC) exchanges cytosolic ADP3− for mitochondrial ATP4− (Figure
1.4) (Klingenberg, 2008) and serves to link energy metabolism between the mitochondria
and the cytosol (where ATP is consumed). It is inhibited by carboxyatractyloside (CATR)
which binds to the cytosolic-facing conformation, and by bongkrekic acid (BKA) which
binds to the mitochondrial-facing conformation (Nicholls, Ferguson, 2013). There are 3
isoforms of the AAC in humans, with different tissue specificity: AAC1 (heart and skeletal
muscle); AAC2 (ubiquitous); AAC3 (low in main tissues and abundant in highly proliferative
cells). The expression levels of the carriers are regulated by the energy requirements of the
cell, which maps onto the tissue specificity (Palmieri, 2004). Deficiency in AAC has been
reported in some cases of myopathy or cardiomyopathy, as well as in autosomal dominant
progressive external ophthalmoplegia (adPEO).
1.5.2.2 The phosphate carrier
The mitochondrial phosphate carrier (PiC) catalyses the electroneutral transport of H2PO4−,
with current evidence pointing towards it acting as a H+ symporter (Figure 1.4). It has
2 isoforms (A and B). Pi transport, at the expense of the pH gradient across the MIM, is
essential for OXPHOS (Klingenberg, 2008). Pi also has other roles in the mitochondria, such
as its involvement in the conversion of succinyl CoA to succinate, catalysed by succinyl-
CoA synthetase (Palmieri, 2004). Pi also facilitates the uptake of other metabolites into
mitochondria by exchange. The tissue specificity of the carrier matches that of the AACs.
1.5.2.3 The citrate carrier
The citrate carrier (CIC) catalyses the electroneutral exchange of tricarboxylates (e.g. citrate,
isocitrate, malate or phosphoenolpyruvate (PEP), Figure 1.14). It has high activity in liver
and low activity in heart and brain. Its activity is affected by hormones and starvation status,
with reduced activity during starvation and diabetes that can be corrected by exogenous
insulin (Palmieri, 2004). The CIC is essential for fatty acid and sterol biosynthesis because
it exports mitochondrial citrate to the cytosol, which is needed for fatty acid and sterol
biosynthesis.
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1.5.2.4 The dicarboxylate carrier
The dicarboxylate carrier (DIC) catalyses the electroneutral exchange of dicarboxylates
(e.g. succinate and malate), Pi and inorganic sulphur compounds (e.g. sulphite, sulphate
and thiosulphate) (Figure 1.14) (Dolce et al., 2014). One main function of the DIC is
anaplerotic: it supplies substrates for the TCA cycle to the matrix. It can also play a role in
gluconeogenesis by exporting TCA cycle intermediates to the cytosol, which are converted
to PEP. Consistent with its role in gluconeogenesis the DIC is most abundant in liver and
kidney (Nicholls, Ferguson, 2013; Palmieri, 2004). OAA in the matrix is converted to malate
which is transported by the DIC to the cytosol, where it is converted back to OAA and then
to PEP. In ischaemia, it is thought that succinate leaves the mitochondria via the DIC to act
as a signal. The DIC is inhibited by substrate analogues such as butylmalonate.
1.5.2.5 The ornithine carrier
The ornithine carrier (ORC) transports ornithine, lysine, arginine and citrulline via an
exchange mechanism. It has 2 isoforms in man: ORC1 and ORC2 (Nicholls, Ferguson,
2013; Palmieri, 2004). ORC1 has higher levels of expression in most tissue and ORC2 is
basically absent in brain, heart and kidney. The import of lysine, arginine and histidine also
allows for synthesis of mitochondrially translated proteins. Arginine hydrolysis (when there
is excess arginine from diet) generates ornithine, which is then metabolised by ornithine
aminotransferase in the matrix. Polyamine biosynthesis in the cytosol requires the export of
ornithine. The ORC plays a role in the urea cycle, discussed in Sections 1.3.5 and 1.5.4.4.
1.5.2.6 The oxoglutarate carrier
The oxoglutarate carrier (OGC) catalyses the electroneutral exchange of mitochondrial
oxoglutarate for cytosolic dicarboxylates (Palmieri, 2004). The OGC plays an important role
in the MAS.
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1.5.2.7 The glutamate carrier
The glutamate carrier catalyses the neutral symport of glutamate and a proton into the
mitochondria (Palmieri, 2004). This carrier has a major role in metabolism because glutamate
is an important metabolite, especially in cancer cell metabolism (Chandel, 2015).
1.5.2.8 Uncoupling proteins
Uncoupling proteins (UCPs) are a family of carriers with 5 different isoforms (UCP1-5).
Despite their structure being known for some time, the function and physiological role of
most of the isoforms is still under debate. The isoforms are known to have different tissue
specificities: UCP1 (brown adipose tissue), UCP2 (ubiquitous); UCP3 (skeletal muscle);
UCP4 and UCP5 (brain). UCP1 is known to transport H+ across the MIM from the cytosol
into the mitochondria, thus dissipating the electrochemical proton gradient and uncoupling the
mitochondria (Busiello et al., 2015) and has a role in thermogenesis (Chouchani et al., 2019).
The mild uncoupling mediated by UCP2 and UCP3 is thought to regulate mitochondrial ROS
production (Brand, Esteves, 2005).
1.5.2.9 The aspartate-glutamate carrier
Humans have 2 aspartate/glutamate carriers (AGC): AGC1 is predominantly expressed
in brain, skeletal muscle and heart, whereas AGC2 is primarily found in heart and liver
(Nicholls, Ferguson, 2013). AGC1 is involved in the MAS (Section 1.5.4.5) whilst AGC2
exports aspartate from the mitochondria to participate in the urea cycle. Both isoforms
catalyse the exchange of aspartate, glutamate and cysteinesulphinate, with aspartate and
cysteinesulphinate transported as anions and glutamate cotransported with an H+ (Palmieri,
2004). Therefore, aspartate export and glutamate import is stimulated when the membrane
potential is positive inside.
1.5.2.10 The carnitine-acylcarnitine carrier
Acylcarnitines enter the mitochondria in exchange for matrix carnitine via the acylcarnitine-
carnitine carrier (Figure 1.7). Acylcarnitines are cleaved by carnitine N-acyltransferase II in
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the matrix, generating acyl-CoA for β -oxidation and carnitine, which is transported back
across the membrane in exchange for more acylcarnitines (Nicholls, Ferguson, 2013).
1.5.3 Other transporters
Despite the SLC25A family being the largest, several other important mitochondrial metabo-
lite carriers are not in this family. Some of these carriers are discussed below.
1.5.3.1 The pyruvate carrier
The mitochondrial pyruvate carrier (MPC) family imports pyruvate formed in glycolysis
into the mitochondrial matrix across the MIM (Bricker et al., 2012; Herzig et al., 2012).
Pyruvate is at a branch point of metabolism (Bender, Martinou, 2016), as it has roles in
both the cytosol and the mitochondria. In the cytosol it can be converted to lactate by
LDH, regenerating NAD+ and allowing glycolysis to continue. When in the mitochondrial
matrix, pyruvate can be carboxylated to oxaloacetate by pyruvate carboxylase (PC), which
can enter gluconeogenesis or be shunted into anaplerosis, or metabolised to AcCoA by
PDH, which can feed in to OXPHOS and ATP generation. Therefore, the decision to enter
the mitochondria or not is a crucial determinant of metabolic homeostasis. The subunits
MPC1 and MPC2 are inner mitochondrial membrane proteins and both are required for
pyruvate transport (Bricker et al., 2012; Herzig et al., 2012). It is proposed that the functional
carrier is a heterodimer. The MPC family is structurally distinct from the SLC25A carrier
family, but shares some homology and three-dimensional structure with a bacterial family of
transporters called SemiSWEET (Vanderperre et al., 2015; Xu et al., 2014). However, the
exact three-dimensional structure of the MPC is yet to be solved. The MPC adopts a proton
symport mechanism and is therefore driven by the ∆p. It is involved in various shuttles,
including the citrate-pyruvate shuttle (Figure 1.14) and the pyruvate-malate shuttle (Figure
1.15).
1.5.3.2 The ATP-binding cassette proteins
The ATP-binding cassette (ABC) transporters are a diverse family of membrane proteins,
found in bacteria, archaea, fungi, plants and mammals. They are comprised of a pair
44 Introduction
of conserved cytoplasmic ABC domains, or nucleotide-binding domains (NBDs) which
hydrolyse ATP to power conformational changes in the transmembrane domains (Locher,
2016). This conformational change switches the NBD dimer between an open and closed
state, allowing the movement of substrate across the membrane. Humans have 48 ABC
transporters, present in the MIM and other cellular membranes. Unlike bacteria, mitochondria
contain only a few ABC transporters, suggesting they were lost during their evolution from
α-proteobacteria. 5 mammalian ABC transporters have been localised to the mitochondria
(Lill, Kispal, 2001). ABC7 and MTABC3 are functionally homologous to the yeast Atm1p
and are thought to have a role in the maturation of cytosolic Fe/S proteins (Lill, Kispal,
2001).
1.5.4 Transport shuttles
Often the SLC25A and other transporters are grouped into ‘shuttles’ and their combined
action forms a cycle with the net transport of a specific metabolite from one side of the MIM
to the other and the replenishment of substrates needed to keep the shuttle going. However,
this is complicated in vivo and the actual contributions to metabolism of these shuttles are
unknown.
1.5.4.1 The citrate-pyruvate shuttle
In the cytosol citrate is cleaved by ATP-citrate lyase (ACL) to oxaloacetate (OAA) and
AcCoA. AcCoA is used for fatty acid and sterol syntheses. OAA produced in the cytosol
is reduced to malate which is converted to pyruvate (via malic enzyme). This generates
cytosolic NADPH and H+ which are also required for fatty acid and sterol synthesis. Pyruvate
re-enters the mitochondria via the citrate-pyruvate shuttle (Palmieri, 2004). Malate needs to
be returned to the cytosol to enable citrate to leave the mitochondria, so it is exported via
the DIC in exchange for Pi. Pi is returned to the cytosol via exchange with H+, enabling
the continued export of citrate to the cytosol for fatty acid synthesis (see Figure 1.14).
NADPH production is important for fatty acid synthesis (Chandel, 2015; Kastaniotis et al.,
2017). It is thought that NADPH is generated in the cytosol by malic enzyme, the isocitrate-
αketoglutarate shuttle and the pyruvate-malate shuttle and pentose-phosphate pathway. The
CIC is also involved in the isocitrate-oxoglutarate shuttle which results in the net import of
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Fig. 1.14 The citrate-pyruvate shuttle. Pyruvate re-enters the mitochondria and malate is recycled
across the MIM to drive citrate out of the matrix into the cytosol where it is required for fatty acid
synthesis. The cycling of malate across the MIM requires the concerted action of the CIC, the
DIC and the PiC. Enzymes are written in blue. PyC: pyruvate carrier; CIC: citrate carrier; DIC:
dicarboxylate carrier; PiC: phosphate carrier; CL: ATP-citrate lyase; CS: citrate synthase; MDH:
malate dehydrogenase; PC: pyruvate carboxylase.
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Fig. 1.15 The pyruvate-malate shuttle. The pyruvate-malate shuttle results in the generation of
cytosolic NADPH. PyC: pyruvate carrier; DIC: dicarboxylate carrier; PC: pyruvate carboxylase;
MDH: malate dehydrogenase. Enzymes are written in blue.
αKG into the mitochondria and export of isocitrate, and cytosolic NADPH generation by
IDH.
1.5.4.2 The pyruvate-malate shuttle
The DIC is involved in the pyruvate-malate shuttle, whereby pyruvate is imported by the
pyruvate carrier (MPC) and converted to malate inside the mitochondria (Palmieri, 2004).
Malate is exported by the DIC in exchange for phosphate, and converted to pyruvate again
by malic enzyme in the cytosol, generating cytosolic NADPH (Figure 1.15).
1.5.4.3 The citrate-malate shuttle
The citrate-malate shuttle is proposed to import cytosolic malate in exchange for citrate
via the CIC and the reconversion of citrate to malate via OAA would generate the electron
acceptor NAD+ which can be used in glycolysis (Palmieri, 2004).
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Fig. 1.16 The urea cycle. Urea is synthesised in the liver to remove excess nitrogen generated from
amino acid breakdown. ORC: ornithine carrier; ASS: argininosuccinate synthase; ASL: argininosucci-
nate lyase; OTC: ornithine transcarbamoylase.
1.5.4.4 The urea cycle
The urea cycle synthesises urea in the liver in order to excrete nitrogen generated from amino
acid breakdown, discussed in Section 1.3.5 (Morris, 2002). The cycle occurs in both the
cytosol and the mitochondrial matrix. ORC exchanges cytosolic ornithine for mitochondrial
citrulline. Ornithine is combined with carbamoyl phosphate to make more citrulline Figure
1.16.
1.5.4.5 The malate-aspartate shuttle
The malate-aspartate shuttle (MAS) serves to transport cytosolic NADH electrons into the
mitochondria and requires the combined action of the OGC and the AGC (Barron et al.,
1998; Palmieri, 2004; Wiesner et al., 1988). The MAS can be split into 2 phases: the
transport of electrons into the matrix and the regeneration of cytosolic OAA (Figure 1.17).
NADH reduces cytosolic OAA to malate, which is transported into the mitochondria via
48 Introduction
Fig. 1.17 The malate-aspartate shuttle. The malate-aspartate shuttle is a mechanism of importing
NADH electrons into the mitochondria. It requires the concerted action of 2 carriers: the OGC and
the AGC. AGC: aspartate-glutamate carrier; OGC: oxoglutarate carrier; GOT: glutamate oxaloacetate
transaminase; MDH: malate dehydrogenase.
the OGC, in exchange for αKG (also known as oxoglutarate). Once in the matrix, malate
is reoxidised by NAD+, regenerating NADH and OAA. OAA is converted to aspartate,
concomitantly converting glutamate to αKG. The aspartate is exported to the cytosol by the
AGC in exchange for glutamate and a proton. Cytosolic aspartate is converted to OAA and
αKG is converted to glutamate.
1.5.4.6 The glycerophosphate shuttle
The glycerophosphate shuttle is a mechanism that links glycolysis, oxidative phosphorylation
and fatty acid metabolism (Figure 1.18) and as such is important in cell bioenergetics. It is
comprised of two glycerol-3-phosphate dehydrogenases: the soluble cytosolic form (cGPDH)
which is NADH-dependent, and the membrane-bound mitochondrial form (mGPDH), which
is FAD-dependent. They catalyse oxidation of glycerol-3-phosphate (G3P) to dihydroxyace-
tone phosphate (DHAP), regenerating cytosolic NAD+ from glycolytic NADH so that ATP
production may continue. Concomitantly, electrons are transferred to CoQ and FADH2 is
generated inside the mitochondria (Mrácˇek et al., 2013).
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Fig. 1.18 The glycerophosphate shuttle. The enzymes of the glycerophosphate shuttle (cytosolic
glycerol-3-phosphate dehydrogenase (cGPDH) and mitochondrial GPDH (mGPDH)) and glycerol
kinase (GK) are shown in blue. Direction of electron transfer is depicted by red dotted lines. DAP:
dihydroxyacetone phosphate; ETC: electron transfer chain; ETF DH: ETF:Q dehydrogenase; FFA:
free fatty acids; G3P: glycerol-3-phosphate; Q: Coenzyme Q. Figure adapted from Mrácˇek et al.
(2013).
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1.6 Compartmentalisation of metabolism
Metabolism is compartmentalised by physical containment within membrane-bound or-
ganelles, or within the cytosol (i.e. separated from organelles). Furthermore, metabolic
enzymes can be organised into large quaternary structures, such as the fatty acid synthase
homodimer or the glutamine synthetase polymer. This spatial organisation facilitates the
movement of the product of one enzyme to the next enzyme, creating an “assembly line” and
maximising metabolic output and efficiency (Zecchin et al., 2015).
Metabolic compartmentalisation is an important area to study because an understanding of
the compartments, and how they are altered in diseases, could lead to the development of
therapies. Drugs could be targeted to, and specifically activated in, particular subcellular
compartments by their specific conditions. For example, hereditary leiomyomatosis and renal
cell cancer (HLRCC) is caused by a heterozygous loss-of-function mutation in fumarate
hydratase (FH) (Czibik et al., 2014). FH catalyses the conversion of fumarate to malate,
thus its mutation leads to the accumulation of fumarate. Currently it is not known where
this fumarate accumulates and what its downstream implications are, although it has been
suggested to stabilise HIF-1α (Czibik et al., 2014). There is further evidence that fumarate
hydratase and succinate dehydrogenase can act as tumour suppressors and that their mutation
can activate tumour maintenance pathways (King et al., 2006). A deeper understanding of the
compartmentalisation of these two metabolites and others would thus help in the development
of cancer therapies.
The above points highlight the need for isolating mitochondria in some way from the rest of
the cell in order to study their metabolism. Below, I outline historic and current methods of
mitochondrial isolation from tissue and cultured cells before discussing work that attempted
to measure mitochondrial metabolism from isolated mitochondria.
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1.7 Mitochondrial Isolation Methods
1.7.1 Isolation of mitochondria from mammalian tissues
The majority of mitochondrial isolation methods from tissue used today stem from the work
of Pallade and Hogeboom (Hogeboom et al., 1948), whose method was developed from
Bensley, Hoerr (1934). A key component of Bensley’s method was the use of differential
centrifugation to isolate the more dense mitochondria from the rest of the cellular components.
First, freeze-thawed guinea pig liver homogenate was centrifuged at a low speed for 3
minutes, to remove cell debris (such as nuclei, broken cells and red blood cells). This was
followed by a second centrifugation at a higher speed for either 10 min or a series of 3 min
centrifugations, which they claim reduced the loss of mitochondria at this stage. They state
that a "considerable loss" of mitochondria occurs whilst removing the cell debris. The final
supernatant, containing the mitochondria as well as connective tissue, fat, soluble proteins
and glycogen, was centrifuged at a high speed for a longer period. The resulting precipitate
contained the mitochondria, albeit they admit to contamination from fat, cell fragments
and connective tissue. They washed the mitochondrial pellet with 0.85 % NaCl solution
followed by centrifugation, which they stated caused some mitochondrial swelling. A caveat
to this method is the use of freeze-thawed tissue homogenate because the process of freeze-
thaw lyses membranes, including mitochondrial membranes. Therefore, this method is not
compatible for metabolomic studies as the mitochondrial metabolites will not be contained
in the mitochondria and compartmentalisation is lost before the extraction. Furthermore, the
speed and temperature of the centrifugation steps were not recorded in the paper.
Pallade and Hogeboom were concerned that the use of saline or water in the Bensley method
was generating artefacts due to the rupturing of cellular membranes. They addressed this by
the use of a hypertonic sucrose solution to homogenise the tissue (Hogeboom et al., 1947,
1948). They worked with rat liver and used both nearly isotonic levels of sucrose (250 mM)
and hypertonic sucrose solutions (880 mM sucrose). They found the use of 250 mM sucrose
for homogenisation did not result in agglutination and allowed separation of the mitochondria
from nuclei. The hypertonic sucrose solution was found to be protective for mitochondria.
They also observed that the use of saline resulted in agglutination of mitochondria and
firm attachments to nuclei. KCl, K2SO4 and phosphate buffers were also found to cause
agglutination. They used EM studies to investigate the structure of mitochondria isolated
52 Introduction
in increasing concentrations of sucrose, and decided on 880 mM sucrose as the optimal
homogenisation buffer concentration in terms of osmotic support as this had a high proportion
of rod-like mitochondria, which they used as an indicator of healthy mitochondria. Their
procedure was as follows: rat livers were forced through a tissue masher with a mesh screen
of 1 mm. 5 g of the resulting "pulp" was homogenised in a Potter-Elvehjem tissue grinder
in 50 mL of 880 mM sucrose. 40 mL (4 x 10 mL in 15 mL tubes) of the homogenate was
centrifuged 3 times for 10 min at 600 x g. In the first of these centrifugations the homogenate
was placed on a 1 mL cushion of high density sucrose. This formed a 2-phase system in
which nuclei and cell debris entered the denser sucrose phase. The supernatants were then
centrifuged for 20 min at 24,000 x g and the resulting mitochondrial pellet was resuspended
in 35-40 mL of 880 mM sucrose before a final centrifugation at 24,000 x g to remove any
soluble substances from the mitochondria. They used a 30◦ angle type centrifuge, refrigerated
at 4◦C.
Weinbach (1961) et al. devised a similar method for rat liver and kidney mitochondria but
reduced the sucrose content to 250 mM, close to isotonic levels. The tissue was homogenised
in a nine-volume ratio using a Delepine Press motorised homogeniser (1,000 rpm for 1 min),
kept at 4oC. They also reduced the time and speed of the centrifugation steps to 600 x g for
10 min followed by 8,500 x g for 10 min (reduced from 3 x 600 x g for 10 min then 24,000 x
g for 20 min). The mitochondrial pellet was resuspended such that 2 mL of 250 mM sucrose
was added per g of liver tissue. This was recentrifuged at 8,500 x g for 10 min and the final
mitochondrial pellet resuspended in 250 mM sucrose at 1 mg wet weight/mL. Weinbach et
al. highlighted the importance that "meticulous attention" must be given to the "minutiae"
of the isolation procedure, such as keeping all equipment and isolation components cold by
storing on ice and performing as many steps as possible in the cold room.
Corcelli et al. (2010) argue that isoosmotic sucrose/mannitol buffers, such as those used in
the methods of Bensley, Hoerr (1934), Hogeboom et al. (1948) and Weinbach (1961) above,
are not isotonic or physiological. Corcelli argues these osmolytes can lead to changes in the
mitochondrial matrix composition due to abnormal movement of ions and water across the
membrane. This in turn could alter matrix metabolism and therefore mitochondria isolated in
this way are not suitable for metabolomic analysis. They were able to isolate coupled and
functionally active mitochondria using a more physiological KCl buffer (180 mM KCl, 1 mM
EDTA, 5 mM 3-(N-morpholino)propanesulfonic acid (MOPS), pH 7.25), despite the general
perception that KCl isolation buffer results in the formation of mitoplasts (mitochondria
whose outer membrane has been removed) and agglutination (Hogeboom et al., 1947, 1948).
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Corcelli et al. (2010) homogenised rat livers in either mannitol buffer (220 mM mannitol,
75 mM sucrose, 1 mM EDTA, 10 mM HEPES, pH 7.4) or the KCl buffer listed above. The
homogenate was centrifuged at 500 x g for 10 min and the supernatant was centrifuged for
a further 10 min at 5,000 x g. They state that they were able to obtain active mitochondria,
but that they were less pure than those isolated using the sucrose/mannitol buffer. They also
found a lower cardiolipin content in mitochondria isolated in KCl buffer. As cardiolipin
is a phospholipid found almost exclusively in the MIM, this could perhaps indicate that
the method is altering or damaging the mitochondria. It can be seen that although Corcelli
made efforts to make the mitochondrial isolation process more physiological, they introduced
additional problems, and sacrificed the purity of the mitochondria for physiological relevance.
For some applications this compromise may be acceptable, but for mitochondrial metabolite
localisation studies this is not practical.
Isolated mitochondria are contaminated with organelles such as lysosomes and ER fragments
(microsomes), either due to their similar densities causing them to co-pellet or due to
physical interactions with the mitochondria. There are various methods to purify these crude
mitochondrial fractions. One common technique is purification by a discontinuous Percoll
gradient. Percoll is a mixture of colloidal silica particles coated with polyvinylpyrrolidone
(Pertoft et al., 1978). It has a low osmolality and is non-toxic. It is diluted to generate layers
with densities between 1.00 g/mL and 1.2 g/mL and layered in centrifuge tubes to form a
discontinuous gradient. The advantage of a discontinuous gradient is the formation of a
distinct band of mitochondria, facilitating their retrieval. The method of Wettmarshausen,
Perocchi (2017) describes layering 80%, 52% and 26% Percoll in an ultracentrifuge tube. A
diluted crude mitochondrial fraction, isolated in 220 mM mannitol, 70 mM sucrose, 5 mM
HEPES-KOH pH 7.4, 1 mM EGTA-KOH, pH 7.4, is placed at the top of the Percoll gradient
and centrifuged at 44,000 x g for 45 min at 4◦C. The mitochondria settle at the interface of
26% and 52% Percoll, so these two layers are removed, diluted ten-fold and moved to a fresh
tube. This is centrifuged at 8,000 x g for 10 min at 4◦C to obtain a purified mitochondrial
pellet.
Another method of purifying crude mitochondrial fractions is the use of a sucrose gradient.
A method described by Colbeau et al. (1971) involves centrifugation of crude mitochondria,
isolated by classical differential centrifugation in 0.27 M sucrose buffered by 2 mM Tris-HCl,
pH 7.6, through a 2-layer sucrose gradient of 41.4% (w/v) and 39.3% (w/v) sucrose (buffered
by 2 mM Tris-HCl, pH 7.6) and centrifuging at 55,000 x g for 2 hours. The mitochondria
form a pellet at the bottom of the tube. In this case, the lysosomes were removed by pre-
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treatment with Triton WR-1339, which is taken up by lysosomes and reduces their density,
causing them to stay at the top of the sucrose gradient whilst the mitochondria enter the
bottom.
The Percoll and sucrose gradient purification methods both add significant time to an already
long extraction protocol. All of the isolation methods from tissue described above require
significant time, have impure mitochondrial pellets, or both. For many applications, such as
functional studies, this is a reasonable compromise but for metabolomic studies this additional
time is not an option. Ideally, the method of mitochondrial isolation for metabolomic studies
should concomitantly isolate and purify the mitochondria away from cellular contaminants,
saving valuable time.
1.7.2 Isolation of mitochondria from mammalian cells in culture
In the 1970s and early 1980s many new methods for isolating mitochondria from mammalian
cells in culture were published, some of which were also based on differential centrifugation.
The method of Zuurendonk, Tager (1974) did not use differential centrifugation; instead, their
method relied on the distinct cholesterol content of mitochondrial membranes. They added
digitonin to their isolation buffer, which binds to cholesterol and forms pores in membranes.
Because the MIM contains no cholesterol, and the plasma membrane (PM) and membranes
of other organelles do (Colbeau et al., 1971), by adding the correct amount of digitonin
the mitochondria can be selectively retained and contaminating organelles are destroyed by
membrane lysis, increasing the yield and purity of the mitochondrial pellet. Zuurendonk
and Tager used the method of Berry, Friend (1969) to isolate liver cells, whereby the liver is
perfused with a buffer containing the enzymes collagenase and hyaluronidase. They then
isolated the mitochondria from these liver cells by mixing 1.5 mL of the cell suspension
with 5 mL of a buffer containing 250 mM sucrose, 20 mM MOPS, 3 mM EDTA and 0.5 or
1 mg/mL digitonin. After incubation for 10, 20 or 40 s the suspension was centrifuged for
20 s at 3,000 x g using a swing-out rotor, pre-cooled to 0oC. The mitochondrial pellet was
found to contain 90 % of total adenylate kinase and glutamate dehydrogenase activity (both
mitochondrial enzymes), and the supernatant contained 80 % of the lactate dehydrogenase
activity (a cytosolic enzyme), indicating good separation of mitochondria from the cytosol.
Siess, Wieland (1975) then built on the method of Zuurendonk and Tager and combined
the use of digitonin and differential centrifugation. They incubated 0.1 mL rat liver cells
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(corresponding to 35-40 mg fresh liver, in calcium-free Krebs-Henseleit bicarbonate buffer +
1.5 % gelatin, 80 mM CaCl2) in 1 mL of 250 mM sucrose, 20 mM MOPS, 3 mM EDTA and
4 mg/mL digitonin. This was mixed for 15 sec, before 1 mL was placed on top of 0.5 mL of
a silicone oil mixture (AR200:AR20, 1:1) layered above 0.12 mL of 12 % perchloric acid
(PCA). 30 sec after digitonin was added, the tube was centrifuged for 10 sec, allowing the
denser mitochondria to pass through the oil and enter the acid. To perform analyses on the
mitochondrial pellet the oil phase was removed by suction and the pellet was resuspended in
a total of 0.312 mL of PCA. This was important work which combined the benefits of both
density centrifugation and digitonin addition.
Wiesner et al. (1988) used a similar method to isolate mitochondria from mammalian cells
in culture to look at the distribution of metabolites from the MAS, but used a layer of
bromododecane instead of silicone oil. Rat myocytes were isolated from heart tissue by
Langendorff perfusion with collagenase, and then separated from the isolation medium by
injection into 250 mM sucrose buffered with 20 mM MOPS and 2 mM Tris-EGTA. This
was layered on 350 µL bromododecane above 100 µL of 2 M PCA. Mitochondria were
subsequently isolated from the cells by adding the cell suspension to the buffered 250 mM
sucrose solution with the addition of 0.6 mg/ mL digitonin, which was then layered on 350
µL bromododecane above a layer 100 µL of 2 M PCA and centrifuged. As they have not
published the length or speed of this centrifugation step it is difficult to analyse whether this
method is suitable for metabolomics.
However, the addition of digitonin was considered controversial by some, with Soboll et al.
(1978) proposing that phosphorylation of mitochondrial ADP may occur during isolation if
digitonin is used, generating artificially high mitochondrial ATP/ADP ratios. Brocks et al.
(1980) investigated this by studying metabolic stability during mitochondrial isolation from
rat liver cells. They followed the general procedure of Zuurendonk, Tager (1974), except they
lowered the temperature of the whole isolation process to -5◦C, and increased the digitonin
concentration from 4 mg/mL to 15 mg/mL. They performed the whole experiment in the
cold room and added 0.2 mL of cell suspension to 1 mL of digitonin medium (15 mg/mL
digitonin, 3 mM EDTA and 0.1 mL toluene), pre-cooled to -12 ◦C. After shaking, the mixture
was layered on 0.5 mL silicone oil mix (AR200/AR20 2:1 w/w) above 0.12 mL of 12 % PCA
and centrifuged in an Eppendorf centrifuge for 10-15 sec. They found that mitochondrial
levels of aspartate and malate were twice as high when mitochondria were isolated at -5◦C
than 4◦C. However, at -5◦C there would be some shearing of the mitochondrial membranes
56 Introduction
due to ice crystal formation, so the metabolite compartmentation may well have been lost
during this isolation procedure.
Others argued that the incubation time needed for the digitonin to work was sufficient for
spontaneous metabolic reactions to occur and consequently the use of digitonin was redundant.
Based on this argument, the method of Tischler et al. (1977) for isolating mitochondria from
rat liver cells made use of centrifugation through silicone oil but did not use digitonin. Instead,
they disrupted the cell membrane by forcing the cells through a small diameter needle (needle
gauge ranged from 22 to 25) under high pressure, generated by the addition of a three-way
valve. The turbulent flow of a solution through a narrow aperture generates shearing forces
sufficient to break the plasma membrane, but was optimised such that minimal mitochondrial
shearing was caused. 100 µL of the broken cell suspension was then layered on 350 µL
silicone oil (a mixture of 500 and 200 silicone oil from Dow Corning, 4:1 ratio, density
1.029 g/mL) into 100 µL of 21% (w/v) PCA. This was centrifuged at 12,000 x g for 10 sec
to isolate mitochondria. They were able to measure mitochondrial and cytosolic metabolite
pools but acknowledge that there is some "uncertainty" about how closely these measured
values reflect actual values in the intact cell.
A different approach for mitochondrial isolation from cells is to use magnetic sorting.
Hornig-Do et al. (2009) adapted a protocol previously used to separate cells – magnetic
cell separation (MACS), incorporated in Miltenyi kits (Miltenyi Biotec, Bergisch Gladbach,
Germany). Superparamagnetic beads are conjugated to an anti-TOM22 antibody, which
binds to the mitochondria and isolates them in a gradient magnetic field. They report that the
quality, enrichment and purity is comparable to standard isolation procedures. However, the
whole process takes 1-2 hours, rendering it irrelevant for metabolomic studies. Similar to
this method is the use of immunopurification. This was used in the method of Chen et al.
(2016a), in which an epitope-tagged recombinant protein expressed on the MOM binds to
magnetic beads. This work is discussed in greater detail in Section 1.7.3.
All of the above methods have attempted to overcome the challenge of achieving speed and
high quality mitochondria, but have compromised in either speed or quality.
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1.7.3 Metabolomic studies on isolated mitochondria
As written by Van Vranken, Rutter (2016), “the whole (cell) is less than the sum of its
parts”. Many metabolomic studies have been performed on isolated mitochondria with a
view to study mitochondrial metabolism, with varying levels of success. Below, I describe
the methods and findings of some of these studies.
Siess, Wieland (1975) isolated rat hepatocytes via a modified digitonin method. They
measured the subcellular distribution of a range of metabolites and reported the mitochon-
drial/cytosolic concentration gradients for malate (1.0); citrate (8.8); 2-oxoglutarate (1.6);
glutamate (2.2); aspartate (0.5); oxaloacetate (0.7), acetyl-CoA (13) and CoASH (40). This
is in contradiction to the studies of Chen et al. (2016a) which suggested that all metabolites
had a higher concentration in the cytosol than the mitochondria.
Ross-Inta et al. (2008) used isolated mitochondria to study the mitochondrial pool of free
amino acids. Rat liver mitochondria were isolated by a Percoll method and the amino acids
were measured using a commercially available kit. They found that the mitochondrial pool of
free amino acids is significantly higher than that of the cytosol, except for citrulline, glutamic
acid, hydroxyPro, 1-methyl- histidine, proline, sarcosine, and Tau.
Roede et al. (2012) used a metabolomic approach to study isolated mice liver mitochondria.
They were able to distinguish male from female and WT from mutant thioredoxin-2 transgenic
(TG) mice based purely on their mitochondrial metabolite signature.
The work of Matuszczyk et al. (2015) measured metabolites of whole Chinese hamster ovary
(CHO) cells and “cytosol-depleted” CHO cells, which they claimed were equivalent to the
mitochondrial fraction. To obtain this fraction they used digitonin as a lysis detergent and
then filtered the CHO cells to remove the cytosol. This method has the major disadvantage of
“lumping together” all organelles except the nucleus, meaning that the mitochondrial fraction
is actually just a non-cytosolic fraction. They based this technique on the assumption that
central metabolites will be either in the mitochondria or the cytosol, and disregard the fact
that metabolites are present in other organelles such as ER, peroxisomes and lysosomes. The
fractions were analysed by liquid chromatography-isotope dilution mass spectrometry. They
reported that the ATP pool was significantly lower in the mitochondria than the cytosol. This
is an expected and logical result as the mitochondria exports the majority of its ATP to the
cytosol for use in various cellular processes.
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Pan et al. (2018) performed a gas-chromatography mass spectrometry (GC-MS) study on
isolated mitochondria from yeast. They were able to distinguish WT from mutant-complex II
and complex IV by principal component analysis, with altered TCA cycle-related metabolites,
amino acids, fatty acids, purine and pyrimidine intermediates and others.
To date, the quickest method of isolating mitochondria from cells for metabolomic analysis
was published by Chen et al. (Chen et al., 2017, 2016a). They devised a new isolation buffer
from KCl, based on work by Corcelli, which contains only KCl and KH2PO4 and is therefore
compatible with LC-MS analysis. They developed an immunopurification (IP) strategy to
capture HA-tagged mitochondria from HeLa cells in 12 min. They report good integrity of
mitochondria, based on the mitochondria retaining MitoTracker Deep Red dye, with less
contamination from other organelles than conventional differential centrifugation methods,
based on immunoblot analyses of subcellular compartments.
They used their method to investigate the subcellular location of polar mitochondrial metabo-
lites and state that they can distinguish between cytosolic and mitochondrial pools of metabo-
lites. However, their total extraction time of 12 min is still slow relative to metabolism and
allows plenty of time for dismutation, although they claim that their results between their
normal workflow and one lengthened by 4 min are similar. They point out that they do not
know the behaviour of the mitochondria at time points less than 12 min, which I would argue
is a fundamental flaw with their method as there could be a large amount of metabolism
occurring in these initial 12 min.
Chen et al. found the expected cofactors and redox pairs NAD, NADH, FAD, NADP, GSH,
GSSG and SAM in the mitochondria, as well as other known mitochondrial metabolites
involved in the TCA cycle, energy production and fatty acid metabolism. They report a lack
of cytosolic metabolites such as fructose 1,6-bisphosphate and the lysosomal metabolite
cystine in their mitochondrial samples, which does indicate good separation of mitochondria
from the rest of the cell. When measuring metabolism at the whole cell level, ETC inhibition
caused little perturbation to NADH/NAD+ and GSH/GSSG ratios. When ETC inhibition
was repeated on mitochondria isolated via their method, these ratios were markedly changed.
However, the major issue I find with their results is most metabolites have a lower concen-
tration in the matrix than the cytosol. Although the concentration of matrix metabolites
is not known, it seems logical that the concentration of some of them should be higher
than in the cytosol: for example, fumarate plays a major role in the mitochondria-specific
TCA cycle and has no specific fumarate transporter. The consistently lower mitochondrial
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concentrations signal many possibilities. It could be that their isolation procedure damaged
many mitochondria, which became leaky and lost their metabolites, or their mitochondrial
yield was much lower than they expected. Alternatively, in the 12 min of the isolation
procedure the metabolites may have reacted with each other, degraded or were transported
out of the mitochondria and distributed throughout the cell.
1.8 Methods to measure metabolites
The study of metabolism is inherently challenging because metabolites are a broad range of
molecules, with different reactivities, structural diversity and broad concentration ranges (Lu
et al., 2017). This diversity has led to the development of many ways to measure cellular
metabolites, with each method generally more suited to measuring a particular metabolic
subtype. Therefore, to measure all groups of metabolites accurately, multiple analytical tools
must be used. Mass spectrometry (MS) is a popular way to measure metabolites, and LC-MS
is the most popular MS technique for metabolomics.
1.8.1 LC-MS
LC-MS combines two analytical techniques: physical separation by liquid chromatography
(LC) and mass analysis by mass spectrometry (MS). During the LC stage, the sample is
separated by distribution between a stationary and a mobile phase. Effective separation at this
stage is important because it reduces ion suppression, which is often an issue when analysing
metabolites from tissue. Ion suppression occurs when a highly abundant ion blocks the
electrospray of other metabolites in the MS and hence suppresses their detection (see below).
This can be a major issue in biological samples due to the presence of highly abundant
metabolites and salts, such as NaCl and KH2PO4.
After the sample has been separated by LC, it is passed to the MS, which measures the
mass-to-charge ratio (m/z) of charged molecules. To be detected by the MS, the sample
must be ionised. In the commonly used technique of electrospray ionisation (ESI), a high
voltage is applied to the liquid sample to create an aerosol of charged droplets (Jang et al.,
2018). ESI often produces multiple-charged ions and results in very little fragmentation (Pitt,
2009). These ions are then sent to the mass analyser, such as an Orbitrap or a quadrupole. An
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Orbitrap mass analyser detects the oscillations of the ions around a spindle-shaped electrode,
in which the electrostatic attraction is balanced by centripetal force around the spindle (Jang
et al., 2018). The frequency of the oscillations is dependent on the m/z. The m/z and the
retention time can together be used to identify the analyte.
Multiple LC approaches must be employed to analyse all metabolites classes, due to their dis-
tinct chemical and physical properties. For example, the study of lipids is termed lipidomics,
emphasising the different analytical approaches they require compared to water-soluble
metabolites (Jang et al., 2018).
There are a variety of approaches to study metabolism by LC-MS. These are steady state, flux
or stable isotope tracing analysis. Metabolite concentration and pathway flux are two distinct
parameters, and information on both is necessary to be able to draw strong conclusions (Jang
et al., 2018). Metabolomic MS methods can be either targeted or non-targeted. A targeted
MS study is one in which a select group of metabolites are quantified, whereas a non-targeted
approach will study the global metabolome, and is typically not quantitative.
1.8.2 Other metabolite analysis techniques
LC-MS is not appropriate for all metabolites. GC-MS is a technique commonly used for low
molecular weight and volatile metabolites and uncharged species that do not ionise under
electrospray.
For some metabolites and experimental conditions, no MS method is appropriate. For
example, glycogen cannot be measured by MS due to its heterogeneity. Instead, glycogen
and other metabolites are often measured by enzymatic assays, in which the accumulation of
a product, such as NADH, is followed on a spectrophotometer. There are many commercially
available kits which claim to perform these assays. However, these should be approached
with caution in an in vivo setting because they are often dependent on H2O2, which can
confound quantification due to the multitude of enzymes and other components present in
tissue that can react with H2O2. Genetically encoded sensors can be designed which fluoresce
upon binding to certain metabolites, such as NADH (Zhao et al., 2011) or glucose (Hou et al.,
2011). Although these techniques have the advantage of being able to dynamically follow
metabolic changes in real time, their use is limited to cultured cells.
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The other leading approach for metabolomics in tissue and cells is nuclear magnetic resonance
(NMR) spectroscopy. This has a lower sensitivity than MS (Markley et al., 2017) but does
not need such extensive sample preparation. It is also better at detecting metabolites that do
not ionise easily and can distinguish between metabolites of the same mass, which is an issue
with MS. By using stable isotope labels, NMR is often employed for studying metabolic flux
and can even be used in living organisms (Markley et al., 2017).
1.9 Metabolism during ischaemia reperfusion injury
Ischaemia reperfusion injury (IRI) occurs when the blood supply to an organ is blocked
(ischaemia) and then restored (reperfusion). It occurs during heart attack, stroke and many
types of surgery. Whilst there is no blood flow during ischaemia there is a lack of oxygen and
nutrients. However, the return of blood flow is paradoxically more damaging to the tissue
because early upon reperfusion there is a burst of ROS production from mitochondria (Loor
et al., 2011; Zweier et al., 1987). This can cause direct damage to the mitochondria, causing
calcium dysregulation and further disruption to ATP production (Murphy, Steenbergen, 2008)
which was already in deficit because of the previous lack of oxygen.
1.9.1 Ischaemia
During ischaemia, both cellular and mitochondrial metabolism are remodelled in an attempt
to keep the cell alive without oxygen and maintain energy homeostasis, ion homeostasis
and pH. During early ischaemia, intracellular acidosis and breakdown of nucleotides occurs,
which accumulates Pi and reduces pH. The low pH and high Pi stop contraction of the
ischaemic zone, which is protective in the short-term. The cell is also forced to break down
nucleotides, leading to accumulation of nucleotide breakdown products such as xanthine
and hypoxanthine (Chouchani et al., 2014; Harmsen et al., 1981; Pacher et al., 2006). These
are metabolised by xanthine oxidase (XO) in the cytosol and are thus not involved in
mitochondrial metabolism (Figure 1.19).
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Fig. 1.19 Purine catabolism. A) Adenine nucleotide depletion in ischaemia and action of xanthine
oxidase to generate ROS in reperfusion. During ischaemia cellular ATP is catabolised in multiple
steps to hypoxanthine. During reperfusion the accumulated hypoxanthine is metabolised to xanthine
by xanthine oxidase (XO) which can further metabolise xanthine to uric acid. XO uses oxygen for
catalysis and can generate the superoxide radical (O2.−) which is metabolised to H2O2 by superoxide
dismutase (SOD). Scheme from Pacher et al. (2006). B) The purine nucleotide cycle. AMP is
deaminated to IMP. The synthesis of AMP from IMP yields fumarate.
1.9.1.1 Glycolysis in ischaemia
A protective mechanism employed in early ischaemia is anaerobic metabolism via glycolysis.
This allows the cell to generate ATP in the absence of oxygen (Figure 1.5). As glycolysis
continues, lactate accumulates and is not removed due to the lack of blood flow. It was
previously thought that the accumulation of lactate was deleterious due to increased H+, but
there is evidence that lactate has more direct damaging effects, for example in influencing
ion homeostasis and ROS production (Cross et al., 1995; Lin, Suleiman, 2003). In aerobic
conditions, lactate is a respiratory substrate for the heart and is imported into cardiac myocytes
via a specific monocarboxylate/proton cotransporter (MCT) on the cardiac sarcolemmal
membrane. However, during ischaemia, lactate is exported from the cell along with H+ in
an attempt to limit intracellular acidosis associated with lactate accumulation (Halestrap
et al., 1997). Thus the MCT can be seen to play a crucial role in maintaining intracellular pH.
However, glycolysis is blocked after a time due to a high NADH/NAD+ ratio.
1.9 Metabolism during ischaemia reperfusion injury 63
1.9.1.2 Mitochondrial responses to ischaemia
Numerous studies have found succinate to be increased during ischaemia (Chouchani et al.,
2014; Hochachka, Dressendorfer, 1976; Taegtmeyer, 1978). Further work by Chouchani
et al. (2014) reported succinate to be a universal metabolic signature of ischaemia. Succinate
was found to accumulate 3-19-fold across a range of tissues exposed to IRI. Its accumulation
during ischaemia was driven by reversal of Complex II (succinate dehydrogenase), caused by
excess fumarate. The fumarate is thought to be generated by 2 sources. One is the increased
uptake of malate (from aspartate and oxaloacetate) which is converted to fumarate in the mi-
tochondria. The second source of fumarate is thought to be from increased AMP breakdown
by the purine nucleotide cycle (PNC), generating adenylosuccinate, which is metabolised to
fumarate by adenylosuccinate lyase (Figures 1.19 and 1.20). The proposal of the PNC as a
source of fumarate is supported by the finding that inhibition of adenylosuccinate lyase by
AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) limits succinate accumulation
(Chouchani et al., 2014). As there is no fumarate transporter in the MIM, fumarate is thought
to enter the mitochondria via partial reversal of the MAS, and in exchange for succinate by
the DIC (Figure 1.20). Transamination of aspartate to oxaloacetate could also contribute to
succinate accumulation and feeds in by conversion to malate driven by high NADH levels.
This is supported by the transaminase inhibitor aminooxyacetate (AOA) reducing ischaemic
succinate accumulation (Chouchani et al., 2016). However, this model is not fully accepted
in the field yet. Zhang et al. (2018) propose that reversal of complex II plays only a minor
role in succinate accumulation in ischaemia. Instead, they postulate that canonical function
of the TCA cycle generates the remainder of the succinate. However, they used a hypoxic
cardiomyocyte model and a different ischaemic model to that used in Chouchani et al. (2014).
1.9.1.3 Fatty acids in ischaemia
In aerobic conditions, the heart is dependent on fatty acid oxidation as its main fuel source, by
mitochondrial β -oxidation. This is not possible during ischaemia due to the lack of oxygen.
As well as a reduction in fatty acid oxidation, cellular uptake of fatty acids is reduced,
with FAT/CD36 (a fatty acid translocase) expression reduced by 32% in the sarcolemma
during ischaemia (Heather et al., 2013). In contrast, the expression of the glucose transporter
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Fig. 1.20 Proposed mechanisms of succinate accumulation in ischaemia. The mechanisms that
generate the fumarate that drives reversal of SDH are shown. NADH accumulates during ischaemia
and passes its electrons to the CoQ pool via complex I. Fumarate is generated during ischaemia by the
breakdown of accumulated AMP by the purine nucleotide cycle (PNC) in the cytosol. Fumarate can
then be metabolised to malate by cytosolic fumarate hydratase. Malate is also generated in the cytosol
from oxaloacetate. Malate then enters the mitochondria in exchange for succinate by the action of the
dicarboxylate carrier (DIC). Once in the mitochondrial matrix malate is converted to fumarate. AOA:
Aminooxyacetate. From Chouchani et al. (2016).
GLUT4 is increased during ischaemia by 90% in the sarcolemma, allowing glucose uptake
for glycolysis.
In the first hour of ischaemia free fatty acids increase due to catecholamine stimulation of
adipose tissue lipolysis. The accumulation of free fatty acids during ischaemia is damaging
for a number of reasons. Fatty acid oxidation consumes more O2 than glucose oxidation,
leading to oxygen wasting. Fatty acids can bind to albumin, increasing the uptake into the
ischaemic myocardium which can lead to ventricular fibrillation. Fatty acids inhibit PDH,
which stops glucose oxidation, and blocks β -oxidation. This leads to accumulation of long
chain acylcarnitines and acyl-CoAs. Fatty acids inhibit Na+K+-ATPase pump, leading to
high intracellular Na+ and Ca2+, contributing to Ca2+ overload and arrhythmia (Oliver,
2015). The sequestration of fatty acids into the TAG pool is cardioprotective (Kolwicz et al.,
2015).
Adenosine is protective in ischaemia. It is thought to be protective by partially inhibiting
glycolysis, limiting glycolytic ATP production, and therefore proton production. This is
proposed to be how adenosine stops intracellular acidosis during ischaemia, and less H+
produced also means Na+/H+ exchange is limited, preventing Na+ and Ca2+ overload
(Fraser et al., 1999).
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1.9.2 Reperfusion
1.9.2.1 Mitochondrial responses to reperfusion
Upon reperfusion, Complex II reoxidises succinate back to normoxic levels within 5 min
(Chouchani et al., 2014), the same time frame that mitochondrial ROS are generated during
IRI. Therefore, Chouchani et al. proposed that succinate was responsible for mitochondrial
ROS generation during IRI. In this way, succinate acts as an electron sink in the absence of
oxygen, and is then used to drive ROS by RET upon reperfusion (Murphy, 2016).
It was previously thought that the ROS produced during reperfusion was non-specific, but it
has been recently proposed that there are widely conserved metabolic pathways that generate
the ROS (Chouchani et al., 2016). During ischaemia, the lack of the terminal electron
acceptor oxygen cause the ETC, enzymes and electron carrier pools (NADH and CoQ)
to become reduced. Concomitantly ATP depletion, lack of ion homeostasis, pH changes
and calcium overload lead to non-functioning mitochondria (Burwell et al., 2009). The
large amount of electrons close to the ETC led to the assumption that mitochondrial ROS
production was an inevitable and nonspecific response, with electrons uncontrollably spilling
onto various sites to form O2.−. However, there is evidence that Complex I is the major
site of mitochondrial ROS production upon reperfusion, mostly from studies using selective
pharmacological inhibition (Chen et al., 2006; Lesnefsky et al., 2004; Niatsetskaya et al.,
2012). These studies also hint to the specific mechanism of O2.− production by Complex
I because rotenone reduces O2.− production, indicating that forward electron transfer is
unlikely to play a role (Chen et al., 2006; Lesnefsky et al., 2004). RET is the proposed
method of ROS production at Complex I as the ∆P is high and the CoQ pool is reduced
(4∆P > 2∆Eh) (Figure 1.21). RET is most likely as it requires a reduced CoQ pool and a
high PMF, both of which occur physiologically during IRI. For RET to occur, mechanisms
of ∆P dissipation must be inhibited, such as ATP synthesis and proton leak. This occurs
in IRI because the adenine nucleotide pools are depleted by metabolism to inosine and
hypoxanthine (Figure 1.19) (Grover et al., 2004). They can also be further metabolised by
the PNC.
The high levels of ROS generated upon reperfusion can lead to opening of the MPTP
(Bernardi et al., 2015; Burwell et al., 2009; Halestrap, 2005). This dysregulation of cal-
cium levels, prevention of ATP synthesis and MPTP opening leads to both necrotic and
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Fig. 1.21 Proposed mechanisms of superoxide production in ischaemia-reperfusion injury. A)
During forward electron transfer 2 electrons are donated to complex I from NADH. These pass along
a series of Fe-S clusters to Q, reducing it to QH2. A high NADH/NAD+ ratio or blockage of the ETC
cause electrons to back up and hyper-reduce the FMN of complex I, leading to reduction of O2 to
superoxide. The ∆Eh between NADH/NAD+ and Q/QH2 drives the pumping of four protons across
the MIM, maintaining the proton motive force (∆p), which allows ATP synthesis to continue. For
forward electron transfer to occur, the ∆Eh must be greater than the energy required to pump four
protons against the ∆p: 2∆Eh>4∆p. B) Reverse electron transport can occur when the ∆p is high
and/or the CoQ pool is reduced, such that 4∆p>2∆Eh (opposite to forward electron transfer). This
allows electrons to flow backwards through complex I onto the FMN. Here, they can reduce NAD+ to
NADH, or O2 to superoxide. The red arrows in complex I indicate the direction of electron transfer.
Cyt c: Cytochrome c; FMN: flavin mononucleotide; SDH: succinate dehydrogenase. From Chouchani
et al. (2016).
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programmed cell death (apoptosis) upon reperfusion (Loor et al., 2011). Damaged mito-
chondria release damage-associated molecular pattern molecules (DAMPs) which trigger
the inflammatory response, leading to longer-term damage to the organ (Arslan et al., 2011;
Mills, O’Neill, 2014; Mills et al., 2017).
1.9.3 Succinate signaling in IRI
Succinate leaves the mitochondria by the DIC in exchange for cytosolic malate and enters
the cytosol, where it can regulate the transcription factors hypoxia inducible factor 1 and
2 (HIF-1 and HIF-2) (Tannahill et al., 2013). HIFs are heterodimers of HIFα and HIFβ
proteins. Under normoxic conditions prolyl hydroxylase (PHD) hydroxylates HIFα , which
directs HIFα for degradation. Under ischaemic conditions succinate enters the cytosol and
inhibits PHD, leading to stabilisation of HIF-1α (Tannahill et al., 2013; Tormos, Chandel,
2010). HIF-1α is then able to induce the cytokine IL-1β , involved in the inflammatory
response (Mills, O’Neill, 2014; Mills et al., 2016; Tannahill et al., 2013). Thus, succinate
can act as a pro-inflammatory signal.
Extracellular succinate binds and activates its G protein-coupled receptor GPR91 (He et al.,
2004), renamed SUCNR1 after its ligand was discovered. This receptor is found in many
tissues and cell types, including cardiomyocytes, hepatocytes and dendritic cells (Tretter et al.,
2016). SUCNR1 stimulation caused IP3 signalling and calcium mobilisation (Sundström
et al., 2013), with transient phosphorylation of extracellular regulated kinase (ERK)1/2
(Tretter et al., 2016). Activation of SUCNR1 leads to hypertension by release of renin,
involved in the renin-angiotensin system (He et al., 2004). The receptor provides another
mechanism for succinate involvement in immunity, as its activation on dendritic cells triggers
pro-inflammatory cytokines and T helper cell activation (Rubic et al., 2008).
An interesting avenue of future research in this area is to investigate what proportion of the
accumulated succinate leaves the cell compared to what proportion is oxidised, where exactly
the succinate signal goes to and any organ-specific responses.
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1.9.4 Metabolite compartmentalisation in IRI
The above sections demonstrate that compartmentalisation of metabolism plays a role in
the pathology of ischaemia. The small mitochondrial compartment allows succinate to
increase to a certain concentration (yet to be exactly quantified) such that upon reperfusion
the mitochondria produce the burst of ROS which causes much of the damage of IRI.
The accumulated succinate is also important in the initiation of the immune response,
causing inflammation that can persist for days after the initial injury and contributes to IRI
(Arslan et al., 2011). The ∆p that is necessary for RET to occur accumulates because the
mitochondrial adenine nucleotide pools are depleted, meaning ATP synthase cannot function
and the ∆p is not consumed. The adenine nucleotide pools can not be regenerated by the
action of the PiC and APC.
1.10 Summary and Aims
Above, I have outlined the key ways in which mitochondria contribute to the general work-
ings of the cell, in particular to metabolism. Mitochondria synthesise various important
biomolecules, e.g. haem, and are involved in the production of fatty acids. They are important
in various metabolic pathways, including the TCA cycle, amino acid metabolism, fatty acid
oxidation and the urea cycle. Besides this, they also have other diverse roles in apoptosis
and necrosis, Fe-S centre assembly, calcium storage and signalling. The recently reported
phenomenon of mitochondrial signalling was introduced, whereby the mitochondria relay
information to the rest of the cell. This signalling can be through ROS, which are mostly
generated at complex I of the ETC (Murphy, 2009). The importance of compartmentalisation
of metabolism was discussed, including how this enables mitochondria to perform their
functions. The role of mitochondrial metabolism in IRI was discussed, which highlighted
the gaps in our understanding of mitochondrial metabolism in this and other disease states.
In order to understand further what is occurring in mitochondria during IRI (and other
diseases) we need a robust method to isolate mitochondria rapidly and in such a way that the
information obtained is accurate.
Aim 1. Fundamental to this project was the development of a method that could isolate
mitochondria from mouse tissue rapidly and coolly enough such that the mitochondrial
metabolites from the isolated mitochondria could be analysed by LC-MS. In Chapter 3, I
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describe the approach taken to develop such a method. The chapter describes the optimisation
of each step of a method, based on some aspects of various mitochondrial isolation methods,
described in Section 1.7. The initial development of the method was performed in rat,
before progressing to mouse tissue. In Chapter 4, I then describe the analysis of isolated
mitochondria using this method, confirming that the method yields functional, coupled, pure
mitochondria.
Aim 2. The second aim of this thesis was to employ the method to elucidate and understand
the differences between cytosolic and mitochondrial metabolite pools in mouse heart and
liver, under control conditions. In order to do so, an LC-MS approach had to be developed.
In Chapter 5, I describe the development and rationale of the LC-MS approach used and
some preliminary results. The use of metabolic and transport inhibitors to prevent metabolite
distribution is explored. In Chapter 6, I present the LC-MS metabolomic data from control
mouse heart and liver, examining the differences between the cytosolic and the mitochondrial
compartments.
Aim 3. The third aim of this thesis was to use the results of the control cytosolic and
mitochondrial pools described in Chapter 6 to understand differences in the metabolic
behaviours between these two compartments in disease conditions. Our lab is particularly
interested in ischaemia-reperfusion injury (IRI) which occurs during heart attack, stroke and
many surgical procedures such as organ transplant. Chapter 6 outlines the results obtained
from ischaemic mouse heart and liver, and explores how mitochondrial metabolism differs to
the cytosol, and how this compares to normoxic metabolism.

Chapter 2
Materials and Methods
2.1 General materials and methods
2.1.1 Chemicals and consumables
All chemicals and consumables were obtained from Merck (previously Sigma-Aldrich), UK
unless otherwise stated.
2.1.2 Animals
Rat tissue was harvested from female Wistar rats (Charles River Laboratories, UK) at 8-
12 weeks of age. Mice tissue was harvested from female C57BL/6 mice (Charles River
Laboratories, UK) at 6-8 weeks of age. Animals were kept on 12 h light/dark cycles in
specific pathogen-free animal facilities with ad libitum access to food and water. Animals
were culled within the same 3 h window of the day. All animal experiments were approved by
the UK Home Office under the Animals (Scientific Procedures) Act 1986 and the University
of Cambridge Animal Welfare Policy. For rapid mitochondrial extraction experiments, mice
were culled by cervical dislocation. For glycogen assays mice were culled by exsanguination
under anaesthesia by Jack L. Martin (see Section 2.4.1.2).
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2.1.3 Quantitative and qualitative protein assays and reagents
2.1.3.1 Antibodies
Primary antibodies
All primary antibodies were monoclonal and were raised in either rabbit or mouse.
• rabbit-glyceraldehyde 3-phosphate dehydrogenase (GAPDH): (Sigma, G9545) 1:10,000
• mouse- pyruvate dehydrogenase (PDH): (Abcam, UK, ab110333) 1:1,000
• mouse-Ndufb8: (Abcam, UK, ab110242) 1:2,000
• mouse-Ndufs3: (Abcam, UK, ab14711) 1:2,000
• rabbit-inositol trisphosphate receptor (IP3R): (Cell Signaling Technology, USA,
D53A5) 1:500
• mouse-GM130: (BD Biosciences, 610822) 1:500
• rabbit-lysosomal-associated membrane protein 1 (LAMP1): (Abcam, UK, ab24170)
1:1,000
• rabbit-peroxisomal biogenesis factor 14 (Pex14): (Proteintech, USA, 10594-1-AP)
1:750
• rabbit-Lamin B1: (Proteintech, USA, 12987-1-AP) 1:500
Secondary antibodies
All secondary antibodies were raised in goat and were specific for either rabbit or mouse
IgG.
• IRDye® 680RD goat anti-mouse IgG (H+L): (LI-COR Biosciences: 926-68070)
1:10,000
• IRDye® 800CW goat anti-rabbit IgG (H+L): (LI-COR Biosciences: 926-32211)
1:20,000
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2.1.3.2 Bicinchoninic acid (BCA) assay
Protein concentration of tissue fraction lysates and mitochondrial pellets were determined us-
ing a Pierce BCA Protein Assay Kit (ThermoScientific, UK) for use with 96-well microplates
(Corning®, Costar®) and a microplate reader (SpectraMax® Plus 384 Microplate Reader,
Molecular Devices, UK). Samples were measured against a 7-part Bovine Serum Albumin
(BSA) standard curve (0 – 2 mg/mL). Samples and standard curve were diluted in appropriate
buffer and measured in triplicate. Reagent A (1 % (w/v) BCA, 2% (w/v) Na2CO3, 0.16%
(w/v) Na2C4H4O6, 0.4% (w/v) NaOH and 0.95% (w/v) NaHCO3, pH 11.25) was mixed with
reagent B (4% (w/v) CuSO4.5H2O) in a 50:1 ratio. 200 µL of reagent A:B mix was added to
10 µL of samples and standards and incubated at 37◦C for 30 min. Absorbance was measured
at 562 nm.
2.1.3.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Lysates of isolation fractions were heated in an appropriate volume of 4X Laemmli sample
buffer (125 mM Tris (pH 6.8), 4% (w/v) sodium dodecyl sulphate (SDS), 40% (v/v) glycerol,
25 mg/mL bromophenol blue and freshly added reducing agent (5% (v/v) β -Mercaptoethanol
(BME)) for 5 min at 95◦C. 10 µg protein was loaded per lane of mini-PROTEAN® TGX™
Precast 4-20% gradient gels (BIO-RAD). Proteins were electrophoresed at 100 V (until the
loading dye ran off the gel) in running buffer (25 mM Tris (pH 8.3), 192 mM glycine, 0.1%
(w/v) SDS). Precision Plus Protein Dual Color standards (BIO-RAD) or MagicMark™ XP
Western Protein Standard (ThermoFisher) was loaded on all gels.
2.1.3.4 Western blotting
Electrophoresed proteins were transferred onto polyvinylidene difluoride (PVDF) membranes
using either a wet or semi-dry transfer method. For wet transfer the proteins were transferred
to Immobilon®-FL PVDF membranes (Merck Millipore: IPFL00010) for 1 h at 100 V, 4◦C.
The PVDF membranes were activated in methanol for 15 s before pre-equilibration of the
membranes, gels, filter papers and fiber pads in pre-chilled transfer buffer (25 mM Tris,
192 mM glycine, 20% (v/v) methanol, pH 8.4 (unadjusted) at 4◦C). For semi-dry transfer
the membranes were transferred using Trans-Blot® Turbo™ Transfer packs (BIO-RAD:
1704157) at 2.5 A (constant), 25 V (max) for 7 min. Post-transfer, the membranes were
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blocked for 1 hour at RT in Odyssey® Blocking Buffer (PBS) (LI-COR Biosciences: 927-
40000) with gentle shaking (Bibby Stuart Platform Rocker STR6 at 30 revolutions/min (rpm)).
The membranes were then incubated with primary antibodies overnight at 4◦C in 4 % (v/v)
blocking buffer in PBST (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4,
0.05 % (v/v) Tween-20). The membranes were incubated in secondary antibodies in 4 %
(v/v) blocking buffer/PBST for 1 hour at RT with shaking, protected from light. Dilutions of
primary and secondary antibody used were specific for the antibody (see Section 2.1.3.1).
Excess primary and secondary antibodies were removed from the membrane by washing
in PBST (4 buffer changes in 1 hour) with gentle shaking (30 rpm). Final washes were
performed in the absence of Tween-20 (PBS only). The signal intensities of the target bands
were measured as fluorescence emission at 680 nm or 800 nm (depending on the secondary
antibody used) with the Odyssey® CLx Infrared Imaging System (LI-COR Biosciences).
The signal intensities of target bands were normalised against control bands using Image
Studio™ Lite software (LI-COR Biosciences).
2.1.3.5 Coomassie protein stain
Coomassie Brilliant Blue R-250 (BIO-RAD: 161-0436) was used to visualise protein sepa-
ration on SDS-PAGE gels, according to the manufacturer’s guidelines. Gels were scanned
using an Epson perfection V750 Pro scanner.
2.2 Mitochondrial Isolations
2.2.1 Conventional isolation methods
2.2.1.1 Isolation of rat liver mitochondria
This procedure was adapted from work by Chappell, Hansford (1972). In preparation,
all equipment was washed in deionised water and then STE buffer (250 mM sucrose, 5
mM Tris, 1 mM EGTA, pH 7.4) and kept at 4◦C. After culling the rat by stunning and
cervical dislocation the liver was removed and placed in ice-cold STE buffer. From this
point onwards the whole experiment was performed on ice. The liver was rinsed in STE
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to remove blood, and clots and connective tissue were removed. The liver was chopped
and washed 3 times in fresh STE. Approximately 40 mL of STE was added and transferred
to a 55 mL Potter-Elvehjem tissue grinder (Wheaton, USA). The liver was homogenised
gently with 3 strokes of a loose-fitting PTFE pestle (Wheaton, USA) followed by 8 strokes
of a tight-fitting PTFE pestle (Wheaton, USA). The homogenate was transferred to a 50
mL centrifuge tube. Unbroken cells were pelleted by centrifuging at 1,000 x g for 3 min
at 4◦C in a Sorval RC-5B centrifuge using the Sorval SS-34 rotor. The supernatant was
transferred to a fresh centrifuge tube and centrifuged at 10,000 x g for 10 min at 4◦C to pellet
the mitochondria. The supernatant was discarded and a small amount of STE buffer added
to resuspend the mitochondrial pellet using a glass rod, leaving the central pellet of blood
behind. The mitochondria were transferred to a fresh centrifuge tube, topped up with fresh,
cold STE and centrifuged at 10,000 x g for 10 min at 4◦C. The final mitochondrial pellet was
resuspended in 5 mL STE and transferred to a Falcon tube.
2.2.1.2 Isolation of rat heart mitochondria
This procedure was adapted from work by Tyler, Gonze (1967). Rat hearts with aortas
removed were washed in ice cold STEB buffer (STE buffer with 0.1 % (w/v) fatty acid-
free BSA) to remove atrial and ventricular blood. The tissue was chopped and rinsed
thoroughly with STEB. The tissue was homogenised in a 55 mL Potter-Elvehjem tissue
grinder (Wheaton, USA) in 40 mL STEB with 10 strokes of a loose-fitting PTFE pestle
(Wheaton, USA) followed by 8 strokes of a tight-fitting PTFE pestle (Wheaton, USA). The
homogenate was split between two 50 mL centrifuge tubes and centrifuged at 1,000 x g,
5 min at 4◦C to pellet blood and cell debris. The supernatant was filtered through two
layers of pre-wetted muslin into fresh 50 mL centrifuge tubes and centrifuged at 10,000
x g for 10 min at 4◦C to pellet mitochondria. The supernatants were discarded and each
mitochondrial pellet was resuspended in 20 mL STEB buffer, avoiding any pelleted blood.
The resuspended mitochondria were combined and placed in a fresh 50 mL centrifuge tube
and fully resuspended using 3 strokes of the loose-fitting PTFE pestle. This was centrifuged
at 10,000 x g for 10 min at 4◦C, supernatant was removed and pellet resuspended in fresh
STEB an re-centrifuged. The resulting final mitochondrial pellet was resuspended in 400 µL
STE buffer (no BSA) and kept on ice.
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Fig. 2.1 Schematic of method to rapidly isolate mitochondria from mouse heart and liver. The
main steps to isolate mitochondria are shown against an approximate timeline. The red line depicts
the initial period of warm ischaemia before the organ is placed into cold buffer, and the blue line
depicts steps performed at 4◦C. The range of options for the lower layer are shown, highlighting the
method can be used for LC-MS, protein analysis and enzymatic assays. The red arrows and text
indicate when each fraction is obtained and the nomenclature of each fraction.
2.2.2 Rapid isolation of mitochondria from mouse tissue
2.2.2.1 Ischaemic mouse model for rapid extraction followed by LC-MS analysis
Liver and heart were rapidly extracted (20-35 secs) from female C57/Bl6 mice and placed
into 2 mL Eppendorf tubes containing 500 µL phosphate buffered saline (PBS; 137 mM
NaCl2, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 (pH 7.4)) and a cut pipette tip
(to suspend the tissue above the liquid), pre-warmed in a heat block at 37◦C. Tubes were
incubated at 37◦C for 6, 12, and 30 min before organ was removed and mitochondria isolated
according to the protocols described below.
2.2.2.2 Rapid isolation of mouse liver mitochondria
This protocol describes the final optimised method for isolating mitochondria from mouse
liver, and the main steps, common to mouse liver and mouse heart, are depicted in Figure
2.1. All work involving dioctyl phthalate (DOP) must be performed in the fume cupboard.
In preparation, all equipment was washed in deionised water and then in 200 mM sucrose
STE buffer. All equipment and reagents were kept on ice until needed. Before culling the
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animal, 4 separate 1.5 mL Eppendorf tubes were prepared by layering 300 µL Liver Oil Mix
(60:40 silicone oil:dioctyl phthalate; density: 1.066 g/mL at RT), above 100 µL of either:
23 % glycerol (density: 1.0598 g/mL at RT; for WB), 25 % formic acid (density: 1.055 g/mL;
for LC-MS) or heavy Seahorse assay buffer (HSAB, density: 1.049 g/mL; for Seahorse).
These tubes were kept on ice in a metal heat-block until required. The liver was then rapidly
extracted from a female C57/Bl6 mouse (within 30-35 secs of culling the animal) and placed
into ice-cold ‘Liver Homogenisation Buffer’ (200 mM sucrose, 5 mM Tris, 1 mM EGTA,
100 µg/mL digitonin, pH 7.4; density: 1.0248 g/mL at RT) to remove excess blood. The
whole liver was then placed in a 7 mL glass tissue grinder (Kimble Chase, UK, 885300-0007)
containing 5 mL ‘Liver Homogenisation Buffer’ pre-cooled on ice to 4◦C. From this point
onwards the whole experiment was performed on ice. The tissue was homogenised by 3
strokes using pestle A (loose fitting) followed by 3 strokes of pestle B (tight fitting). A
fraction of this homogenate was retained for analysis and termed "Homogenate". 1 mL
aliquots of the homogenate were placed in 2 mL Eppendorf tubes and 4 of these tubes were
centrifuged in parallel at 1,000 x g for 1 min at 4◦C to pellet cell debris. A fraction of this
supernatant was retained for analysis and termed "Supernatant". 4 aliquots of 200 µL of the
resulting supernatant was mixed with ice-cold 500 µL ‘Spin Buffer’ (150 mM sucrose, 5 mM
Tris, 1 mM EGTA, 25 mM ammonium bicarbonate, pH 7.4; density: 1.0200 g/mL at RT)
to reduce the density of the suspension. 700 µL of each of these 4 aliquots were carefully
layered above the oil in the 4 1.5 mL Eppendorf tubes that were prepared in advance. These
were centrifuged for 1 min at 9,727 x g at 4◦C in a swing out rotor (Heraeus, #75007592)
fitted in a Heraeus Biofuge Primo R centrifuge (Thermo Scientific). The layer above the oil,
termed the "Cytosolic" layer, and the majority of the oil were aspirated off and the tip of the
tube was placed in a dry ice and ethanol bath. Once the lower layer had frozen solid, the
remaining oil (which does not freeze solid) was washed off using dry ice-cold hexane. The 4
mitochondrial pellets were then pooled to obtain the final mitochondrial pellet.
2.2.2.3 Rapid isolation of mouse heart mitochondria
This protocol describes the final optimised method for isolating mitochondria from mouse
heart, and the main steps that are common to the mouse heart and mouse liver protocol are
depicted in Figure 2.1. All work involving DOP must be performed in the fume cupboard.
In preparation, all equipment was washed in deionised water and then in 150 mM sucrose
STE buffer. All equipment and reagents were kept on ice until needed. Before culling the
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animal, 4 separate 1.5 mL Eppendorf tubes were prepared by layering 300 µL Heart Oil Mix
(38:62 silicone oil:dioctyl phthalate; density: 1.0158 g/mL at RT), above 100 µL of either:
15 % glycerol (density: 1.0390 g/mL at RT; for WB), 15 % formic acid (density: 1.033 g/mL;
for LC-MS) or heavy Seahorse assay buffer (HSAB, density: 1.049 g/mL; for Seahorse).
These tubes were kept on ice in a metal heat-block until required. The heart was then rapidly
extracted (within 20-25 secs of culling the animal) from a female C57/Bl6 mouse and placed
into cold ‘Heart Homogenisation Buffer’ (25 mM sucrose, 5 mM Tris, 1 mM EGTA, 87.5
mM ammonium bicarbonate, 100 µg/mL digitonin, pH 7.4; density: 1.0075 g/mL at RT) to
remove excess blood. The heart was rapidly chopped with scissors into a 7 mL glass tissue
grinder (Kimble Chase, UK, 885300-0007) containing 3 mL ‘Heart Homogenisation Buffer’,
pre-cooled on ice to 4◦C. From this point onwards the whole experiment was performed on
ice. The tissue was homogenised by 3 strokes using pestle A (loose fitting) and 3 strokes of
pestle B (tight fitting). A fraction of this homogenate was retained for analysis and termed
"Homogenate". 1 mL aliquots of the homogenate were placed in 2 mL Eppendorf tubes and
4 of these tubes were centrifuged in parallel at 1,000 x g for 1 min at 4◦C to pellet cell debris.
A fraction of this supernatant was retained for analysis and termed "Supernatant". 650 µL of
this supernatant was carefully layered on to the Heart Oil Mix in the 4 1.5 mL Eppendorf
tubes that were prepared in advance. These were centrifuged for 1 min at 9,727 x g at 4◦C
in a swing out rotor (Heraeus, #75007592) fitted in a Heraeus Biofuge Primo R centrifuge
(Thermo Scientific). The layer above the oil, termed the "Cytosolic" layer, and the majority
of the oil were aspirated off and the tip of the tube was placed in a dry ice and ethanol bath.
Once the lower layer had frozen solid, the remaining oil (which does not freeze solid) was
washed off using dry ice-cold hexane. The 4 mitochondrial pellets were then pooled to obtain
the final mitochondrial pellet.
2.3 LC-MS
2.3.1 Preparation of samples
As soon as each fraction was obtained, 40 µL of homogenate, supernatant and top fractions
were added to 400 µL of 25 % formic acid (liver samples) or 15 % formic acid (heart samples).
After obtaining a mitochondrial pellet by centrifugation through oil into either 25% (liver)
or 18% (heart) formic acid (see Section 2.2.2) the pellets were vortexed. All samples were
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then centrifuged for 10 min at 17,000 x g. Supernatants of quadruplicate mitochondrial
samples were pooled and dried under vacuum (miVac Quattro concentrator, Genevac) along
with homogenate, supernatant and top fractions for 4 hours, with temperature capped at
40oC. Dried samples were resuspended in 75 µL of H2O, agitated for 10 min at 4◦C to
resuspend metabolites. A final centrifugation for 1 min at 17,000 x g, 4oC was run to
remove any remaining particulates. The supernatants were transferred to high recovery vials
(9512S-3MP-RS or Low adsorption vials, 29659-U, Sigma) and stored at -80◦C until LC-MS
analysis.
2.3.2 Liquid Chromatography-Mass Spectrometry
LC-MS analyses were performed by Ana S. H. Costa, Efterpi Nikitopolou and Laura Tronci
(MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, University
of Cambridge, UK) on a Q Exactive Orbitrap (Thermo Fisher Scientific) mass spectrometer
coupled to an Ultimate 3000 RSLC system (Dionex). The liquid chromatography system
was fitted with either a ZIC-HILIC column (150 mm × 4.6 mm) or a ZIC-pHILIC column
(150 mm × 2.1 mm) (both described in further detail in Section 5.1.1) and respective guard
columns (20 mm × 2.1 mm) (all Merck, Germany). The ZIC-HILIC column mobile phase
was: 0.1 % formic acid in water (aqueous) and 0.1 % formic acid in acetonitrile (organic). The
ZIC-pHILIC column mobile phase was: 20 mM ammonium carbonate + 0.1 % ammonium
hydroxide (aqueous) and acetonitrile (organic). The mass spectrometer was operated in full
MS and polarity switching mode. Samples were randomised in order to avoid bias due to
machine drift and processed blindly. The acquired spectra were analysed using XCalibur Qual
Browser and XCalibur Quan Browser software (Thermo Fisher Scientific) by referencing to
an internal library of compounds.
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Fig. 2.2 Schematic of glycogen assay G6P: Glucose-6-phosphate; G6PDH: Glucose-6-phosphate
dehydrogenase; 6PG: 6-Phosphogluconic acid.
2.4 Assays
2.4.1 Measuring glycogen in tissue samples
2.4.1.1 Background
The protocol was adapted from Zhang (2012), to be suitable for 96-well plate format.
Glycogen is acid hydrolysed to glucose. As glycogen is not base hydrolysed, background
glucose is measured by incubating the tissue in NaOH. Hexokinase phosphorylates glucose
to glucose-6-phosphate (G6P). Glucose-6-phosphate dehydrogenase (G6PDH) oxidises G6P
to 6-phosphogluconic acid (6PG), generating NADPH. The accumulation of NADPH is
measured at 340 nm using a SpectraMax® Plus 384 Microplate Reader (see Figure 2.2).
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2.4.1.2 Ischaemic mouse model for glycogen analysis
The following procedure was performed by Jack L. Martin. Female C57BL/6 mice were
anaesthetised with isoflurane (Abbott Laboratories, US) and O2 at 2 L/min. Heparin (100 µL
bolus (25 iU); Leo Pharma A/S, Denmark) was administered intravenously into the inferior
vena cava (IVC) 5 min prior to exsanguination by division of the IVC and aorta. Hearts were
excised by division of the major vessels and the still-beating heart was rapidly frozen using
Wollenberger clamps at liquid nitrogen temperature, taking <5 s to go from beating heart
to frozen. For cold ischemia (CI), the heart was placed directly in PBS at 4◦C. For warm
ischaemia (WI), the excised heart was placed into 2 mL Eppendorf tubes containing 500 µL
PBS and a cut pipette tip (to suspend the tissue above the liquid), pre-warmed in a heat block
at 37◦C. For analysis at various times, ∼20 mg sections were cut off the heart and clamped
at liquid nitrogen temperature as above. Tissues were stored at -80◦C until analysis.
2.4.1.3 Assay method
5-10 mg of frozen tissue was added to 1.5 mL Eppendorf tubes containing 250 µL of either
2 M NaOH or 2 M HCl (both pre-heated to 100◦C) and minced with scissors. The weight
of tissue added to each tube was recorded. The tubes were incubated at 100◦C for 1 hour,
with vigorous shaking every 10 min. After incubation the tubes were left to cool to RT and
neutralised with 250 µL of 2 M HCl or 2 M NaOH and 500 µL of 400 mM TRIS, pH 7.4.
The pH was adjusted to pH 7 using HCl or NaOH, and the volume added was recorded. The
samples were vortexed and centrifuged at 17,000 x g for 10 min. Glucose standards (0, 0.01,
0.02, 0.04, 0.08 and 0.16 mg/mL glucose) were made up in H2O by serial dilution. 60 µL
standard and samples were added in duplicate to a 96-well plate. 200 µL Glucose Assay
Reagent (G3293, Sigma) was added to each well, incubated at RT for 5 min and absorbance
at 340 nm was measured. The average absorbance of each sample was interpolated using the
standard curve and multiplied by the final volume after pH adjustment to give µg of glycogen
(or glucose for NaOH control) in original sample. This was divided by the weight of tissue
added and the NaOH control was subtracted from the HCl sample to give µg glycogen per
mg of frozen tissue.
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2.4.2 GSH Recycling Assay
2.4.2.1 Sample preparation
The GSH recycling assay was used to measure total GSH (Figure 2.3) (Griffith, 1980; Tietze,
1969). Mitochondrial samples were obtained by following Section 2.2.2 with either 100
µL of 15 % (w/v) 5-sulfosalicylic acid (SSA; density: 1.07995 g/mL) or 15 % (heart) or
23 % (liver) glycerol as the bottom layer (glycerol was used when WB analysis was run
in parallel). Isolated mitochondria from duplicate tubes were combined and pellets were
resuspended. For 15 % SSA samples, 400 µL of H2O was added to dilute SSA to 5 % (w/v).
For glycerol samples, 40 µL of mitochondria were added to 40 µL of 10 % SSA to achieve a
final concentration of 5 % SSA.
2.4.2.2 Assay method
10 µL of homogenate, supernatant and top fractions were placed in 90 µL of 5 % (w/v)
SSA immediately and placed in dry ice while the mitochondrial fraction was obtained.
Mitochondria, homogenate, supernatant and top fractions were vortexed to ensure maximal
extraction of GSH and GSSG and then centrifuged at 16,000 x g for 10 min at 4◦. 10 µL of
supernatant was analysed in triplicate on a 96-well plate. A standard curve of 0, 5, 10, 25, 50
and 100 µM GSH was made in 5 % (w/v) SSA. Samples were incubated in 0.5 mM NADPH,
0.5 mM 5,5’-dithio-bis-[2-nitrobenzoic acid] (DTNB) and 4 U/mL glutathione reductase
(GR ) from bakers yeast in NaE buffer (143 mM sodium phosphate, 6.3 mM EDTA, pH 7.5).
Production of 2-nitro-5-thiobenzoic acid (TNB) was followed by measuring absorbance at
412 nm using a 96-well plate spectrophotometer (Molecular Devices, USA) for 10 min at
25◦C. Kinetic rates of samples were compared to standard curve to determine µM of GSH in
the sample.
2.4.3 ATP/ADP Ratio Assay
This assay was performed by Anja V. Gruszczyk at the MRC Mitochondrial Biology Unit.
ATP and ADP levels were measured by detecting luciferase/luciferin bioluminescence using
an AutoLumat LB-953-Plus multi-tube luminometer (Berthold), fitted with an autoinjector,
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Fig. 2.3 Schematic of GSH recycling assay. GR: Glutathione reductase; DTNB: 5,5’-dithio-bis-[2-
nitrobenzoic acid]; TNB: 2-nitro-5-thiobenzoic acid.
and quantified against standard curves of purified ATP and ADP. Mitochondrial fractions
were spun into PCA (HClO4 (4.2 % (v/v))) and pooled to a total volume of 400 µL. Cytosolic
fractions were diluted 2:1 (133 µL: 266 µL) with PCA to a final concentration of 2% PCA.
The mitochondrial and cytosolic fractions were pH neutralised with KOH immediately before
use. For ATP measurements, 100 µL of sample was added to 400 µL Tris-acetate (TA)
buffer (100 mM Tris, 2 mM Na2EDTA, 50 mM MgCl2, pH 7.75 with glacial acetic acid)
in luminometer tubes. Luciferase/luciferin solution (DTT (7.5 mM), BSA (0.4 mg/mL),
firefly luciferase (1.92 µg protein/mL), D-luciferin (120 µM)) was made up immediately
prior to use, protected from light, and 100 µl was added to each sample tube via auto
injection. Reactions were performed at 30◦C and light emission (RLU) was recorded 30
s post injection. ADP was measured by first degrading endogenous ATP with 2X ATP
sulfurylase solution, followed by incubation at 30◦C for 30 min with agitation (500 rpm)
before heat inactivation. 200 µL of each ATP sulfurylase-treated sample was added to 400
µL TA buffer in luminometer tubes (in duplicate). To convert endogenous ADP to ATP, 10 µl
pyruvate kinase/ phospho(enoyl)pyruvate solution (type II PK from rabbit muscle (5 U), PEP
(100 mM)) was added to one of the duplicate tubes (and to all ADP standards) and incubated
at 30◦C for 30 min prior to ATP measurement. The PK/PEP-blank tubes served as blanks
for quantification. Quantification was performed with GraphPad Prism 7.0. ATP and ADP
values (nmol/µL) were expressed as ATP/ADP ratios.
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Fig. 2.4 A typical trace from a Seahorse XF96 Analyser depicting mitochondrial respiration.
Basal respiration, ATP production, proton leak, maximal respiration and spare respiratory capacity
can all be measured by the Seahorse XF96 Analyser.
2.5 Mitochondrial Respiration and Function Assays
2.5.1 Seahorse XF96 respirometry
2.5.1.1 Background
The Seahorse XF96 Analyser allows the real-time measurement of respiration in live cells.
Respiration (measured as Oxygen Consumption Rate (OCR)) is measured by adding sequen-
tial injections of selective respiratory chain and F1Fo-ATP synthase inhibitors to measure
key parameters of respiration (see Figure 2.4). In this work, CII-driven respiration was
measured by the use of the SDH substrate succinate. CI-mediated respiration was blocked by
the addition of rotenone.
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2.5.1.2 Buffers and reagents
• Seahorse Assay Buffer (SAB): sucrose (300 mM), mannitol (220 mM), KH2PO4 (10
mM), MgCl2 (5 mM), HEPES (2 mM), EGTA (1 mM), 0.2 % (w/v) fatty acid-free
BSA, pH 7.2, density 1.015 g/mL
• Heavy Seahorse Assay Buffer (HSAB): sucrose (700 mM), mannitol (220 mM),
KH2PO4 (10 mM), MgCl2 (5 mM), HEPES (2 mM), EGTA (1 mM), 0.2 % (w/v) fatty
acid-free BSA, pH 7.2, density 1.049 g/mL
• Seahorse XF96 well culture plates (Agilent)
• Seahorse XF96 sensor cartridges (Agilent)
• Calibrant solution (Agilent)
• Stock solutions: Rotenone (4 mg/mL), FCCP (10 mM), antimycin A (5 mM) (all made
in EtOH)
2.5.1.3 Preparation of mitochondria
To measure respiration in isolated mitochondria instead of cells, the XF96 protocol was
adapted using changes described in Iuso et al. (2017). Mitochondria were isolated from
mouse and rat heart and liver using the rapid method outlined in Section 2.2.2. The lower
layer was HSAB so that the buffer was dense enough (1.049 vs. 1.015 g/mL) to sit beneath
the oil. After isolation the mitochondria were resuspended in SAB and protein content was
quantified. Mitochondria were then diluted to 100 µg/mL in cold SAB supplemented with 4
µg/mL rotenone and 5 mM succinate. 2 µg of mitochondria was added to each well of the
96-well Seahorse plate, leaving the outside wells as blank. The plate was centrifuged for 20
min at 2,000 x g at 4◦C to attach the mitochondria to the bottom of the plate. The wells were
made up to 180 µL with pre-warmed SAB supplemented with rotenone and succinate.
2.5.1.4 Seahorse XF96 analyser preparation and running
The XF96 sensor cartridge was hydrated with 200 µL of Seahorse calibrant solution and
incubated in a CO2-free incubator at 37◦C overnight. Port additions were added to the
86 Materials and Methods
cartridge at 10X final concentration (Table 2.1). The XF96 sensor cartridge was placed in
the XF96 analyser and calibrated (∼30 min). Assays were performed at 37◦C according to
the manufacturer’s guidelines: https://www.agilent.com/en/products/cell-analysis/how-to-
run-an-assay.
Table 2.1 Seahorse XF96 port injections
Port Compound Conc. (10X) Injection vol. (µL) (10% of well vol.)
A FCCP 40 µM 20
B Antimycin 30 µM 22
2.5.2 Oroboros Respirometry
2.5.2.1 Background
The respiration of isolated mitochondria was assessed by the Oroboros Oxygraph-2K (O2K)
high resolution respirometer (Oroboros Instruments, Austria). The Oroboros is suitable
for small amounts of a broad range of biological samples, such as isolated mitochondria,
permeabilised tissues and intact cells. It measures dissolved oxygen (O2) gas in an aqueous
buffer solution. By following oxygen flux in the experimental chamber, respiration can be
measured. The addition of specific respiratory inhibitors enables analysis of OXPHOS and
whether respiration is coupled.
2.5.2.2 Oroboros preparation and running
Isolated mouse heart or rat liver mitochondria were measured whilst respiring with complex
II-mediated respiration. Prior to isolation of mitochondria 2 mL of pre-warmed SAB buffer
was added to the stirred (200 rpm), temperature-controlled (37◦C) chambers and the top
completely closed before opening to the height set by the Oroboros equilibration guide. The
buffer within the chamber was left to equilibrate for approximately 2 hours. The Oroboros
was calibrated to the stable oxygen concentration achieved.
Rat liver mitochondria (0.5 mg protein/mL) or mouse heart mitochondria were added in
2 mL of pre-warmed SAB buffer containing 4 µg/mL rotenone to a chamber of the O2K
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respirometer. Respiration was assessed in the presence of succinate (1 mM). Uncoupled
respiration was assessed by the addition of 1 µM FCCP.
All compounds were injected into the chamber using gastight syringes (Hamilton Robotics,
UK), in a total volume of 2 µL.
2.5.3 Citrate Synthase Assay
The method was adapted from Srere (1969) to be suitable for a 96-well plate format. The
assay reactions are shown in Figure 2.5. Briefly, oxaloacetate (OAA) and acetyl-CoA are
converted to citrate and CoA by citrate synthase (CS). 5,5’-dithio-bis-[2-nitrobenzoic acid]
(DTNB) is used to convert CoA to CoA-SS-TNB. Production of TNB is monitored at 412
nm. 80 µL assay buffer (100 µM DTNB, 300 µM AcCoA in KPi buffer (25 mM KH2PO4))
was added to each well. 8 µg of homogenate, supernatant or mitochondrial protein in 100
µL KPi buffer was added and the reaction was started by the addition of 20 µL of 500 µM
OAA and mixed. Background activity was measured by replacing sample with KPi buffer.
To correct for any endogenous substances that could provide the thiol necessary to split the
DTNB a no-OAA control was also run. Absorbance at 412 nm was measured for 10 min at
30◦C. ε412 = 13,600 M−1cm−1.
Fig. 2.5 Schematic of citrate synthase assay. Oxaloacetate and acetyl-CoA are converted to citrate
and CoA by citrate synthase (CS). 5,5’-dithio-bis-[2-nitrobenzoic acid] (DTNB) is used to convert
CoA to CoA-SS-TNB. Production of TNB is monitored at 412 nm.
2.6 Statistical Analysis
Data analysis was performed with GraphPad Prism 7.0. Results were expressed as mean
± standard error of the mean (SEM). Results of the control vs. 30 min WI experiment
were analysed by two-way analysis of variance (ANOVA) and expressed as mean ± SEM.
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P-values < 0.0032 were considered statistically significant. For heat maps, metabolites were
normalised to taurine and the mean of 6 biological replicates was taken.
2.7 Collaborations
Collaborators were from the MRC Mitochondrial Biology Unit, University of Cambridge,
UK, unless otherwise stated. Mouse surgery for tissue glycogen analysis was performed by
Jack L. Martin (Department of Surgery and Cambridge NIHR Biomedical Research Centre,
University of Cambridge, UK). Human heart retrievals were performed by Jack L. Martin and
Kourosh Saeb-Parsy (Department of Surgery and Cambridge NIHR Biomedical Research
Centre, University of Cambridge, UK), with assistance from Anja V. Gruszczyk and Timothy
E. Beach (Department of Surgery and Cambridge NIHR Biomedical Research Centre, Uni-
versity of Cambridge, Cambridge, UK). Pig surgery for glycogen analysis was performed by
Kourosh Saeb-Parsy, Timothy E. Beach, Jack L. Martin and Mazin Hamed (Department of
Surgery and Cambridge NIHR Biomedical Research Centre, University of Cambridge, UK).
LC-MS metabolomics and analysis was performed by Ana S. H. Costa, Efterpi Nikitopolou
and Laura Tronci (at MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research
Centre, University of Cambridge, UK). Mice for rapid mitochondrial isolations were provided
by Carlo Viscomi. Georgina Bates and Thomas Bright assisted with rapid mitochondrial
isolations in mouse.
Chapter 3
Development of a rapid method for
isolating mitochondria from tissue
3.1 Introduction
Metabolites are spread across the cell in different organelles, forming distinct pools. These
pools can change independently of each other, which confounds metabolomic analysis, as
this is often performed at the whole cell or tissue level. Cytosolic pools of metabolites can be
larger than the mitochondrial pool, meaning the cytosolic pools can mask any changes that
are occurring specifically in the mitochondria because the overall cellular pool size may not
change. Also, if mitochondrial metabolite pools are bigger than the other pools they could
over-represent the pool and lead to conclusions that the whole cell is changing its levels
of that metabolite, whereas it is actually just the mitochondrial pool that is changing. This
separation must be performed as quickly as possible to limit the effect of spontaneous and
enzyme-catalysed metabolic reactions and their distribution throughout the cell. Therefore, a
reliable method of separating mitochondria as quickly as possible from the rest of the cell is
key to elucidating the metabolism of mitochondria.
Mitochondria form physical connections with the plasma membrane and other organelles,
such as the ER (Lebiedzinska et al., 2009). It is thought that these interactions are important
for facilitating transport of molecules, particularly phospholipids and other lipids needed
for membrane structure (Szyman´ski et al., 2017). These close interactions also enable
90 Development of a rapid method for isolating mitochondria from tissue
communication between the mitochondria and other organelles, helping to maintain calcium
homeostasis and other important functions like apoptosis (Giorgi et al., 2009; Raturi, Simmen,
2013). These physical interactions are an important factor to consider when isolating
mitochondria from tissue or cells, as the mitochondria must be purified away from the rest of
the cell, as far as this is possible, to reduce contamination from other subcellular organelles.
Contamination can confound metabolomic analysis as it would lead to erroneous conclusions
that some metabolites are present in the mitochondria, and also dilutes the signal from truly
mitochondrial metabolites. The strength of these interactions will vary with cell type.
A further consideration when isolating mitochondria from tissue is subpopulations of mito-
chondria in different regions of the same cell, which have distinct morphologies and different
interactions with other organelles (Kuznetsov, Margreiter, 2009). These mitochondria can
also have different biochemical properties, with varying membrane potential, volume and
uncoupling responses (Saunders et al., 2013). It is thought that these mitochondrial subpopu-
lations serve a physiological role. For example, muscle subsarcolemmal mitochondria were
found to have a more oxidised state of mitochondrial flavoproteins than the intermyofibrillar
mitochondria (Kuznetsov et al., 2006). This was hypothesised to be due to the subsarcolem-
mal mitochondria being nearer the periphery of the cell and thus exposed to a higher level of
oxygen. This may even act as a protective barrier to decrease oxidative damage, maintaining
a lower oxygen level in the rest of the cell. Importantly, subpopulations of mitochondria may
also reflect a metabolic heterogeneity of mitochondria, caused by specific microenvironments
or pools of metabolites. It is possible that subpopulations of mitochondria have different
densities and behave differently during the extraction process, particularly centrifugation
through oil. This may lead to only certain subpopulations of mitochondria being obtained
and analysed in the final mitochondrial pellet.
Linked to the issue of density is the fact that some mitochondria within the tissue will be
already damaged. This damage may be due to inherent "wear and tear" damage or due to
factors the sample is exposed to, such as ischaemia or DNA mutations. Furthermore, the
isolation process itself may damage the mitochondria (Picard et al., 2011). Mitochondrial
damage may also impact what groups of mitochondria, and therefore what metabolites, are
obtained in the final mitochondrial pellet. This idea is explored further in Section 4.5.
The method used to isolate mitochondria from tissue, or cells, is critical in determining
the value of the information that can be obtained from studies of the isolated mitochondria.
Metabolism requires the action of enzymes and metabolite transporters whose activity can be
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limited by low temperature, but some activity persists even at temperatures below 4◦C (Chen
et al., 2017). The speed of the isolation is thus paramount to limit enzyme-mediated and
spontaneous metabolic reactions and redistribution, so that a true picture of mitochondrial
and whole cell metabolism as it exists in the organism can be obtained. There are two major
challenges to isolating mitochondria from tissue so that they can be used for metabolomic
analysis: the first is to purify the mitochondria away from other cellular components and
the second is to quench metabolism and redistribution of metabolites. This is achieved by
performing the isolation quickly and at a low temperature (4◦C).
Section 1.7 of the Introduction described the various approaches to isolate mitochondria
from tissue and cultured mammalian cells. The general architecture of most of these methods
is based on various differential centrifugation steps, with or without the addition of digitonin.
All isolation methods face the same two major challenges: achieving satisfactory fractionation
(high as possible yields of enriched mitochondria, with no major contamination from other
organelles) and completing the fractionation as quickly as possible to limit the effect of
metabolic activity and redistribution of metabolites during the fractionation. In this section,
the development of a method that encompasses all of these requirements is described.
Components of previously published protocols were incorporated into the method, namely the
use of differential centrifugation to remove cell debris, followed by centrifugation through a
silicone oil layer into an acid layer. This acid serves to stabilise the mitochondrial metabolites,
and renders them suitable for analysis by LC-MS.
All mitochondrial isolation buffers require pH buffering, osmotic support and metal ion
buffering. In the case of STE buffer, the pH buffering is performed by 5 mM Tris. This pH
buffer has a pKa of 8.1 at 25◦C, and so is an effective buffer between pH 7 and pH 9 at room
temperature. STE also contains 1 mM EGTA. This chelating agent binds metal ions and has a
higher affinity for Ca2+ than Mg2+. Sequestering these ions helps the mitochondria maintain
their osmolarity, and also prevents the degradation of DNA and RNA by metal-dependent
nucleases.
The osmotic balance between the cytosol and the mitochondria regulates mitochondrial matrix
volume. Imbalances in the flux of ions, such as K+, Ca2+ and Na+, will lead to the movement
of water between the two compartments, changing the matrix volume (Kaasik et al., 2006).
In this way, mitochondria act as an osmometer (Devin et al., 1997), responding to changes in
cell osmolarity. Mitochondrial matrix volume has affects on cellular metabolism: Halestrap
(1989) showed that increased volume stimulated respiratory rate, pyruvate metabolism and
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fatty acid oxidation. This must be considered when choosing mitochondrial isolation buffers.
The external conditions should be kept such that they limit changes to mitochondrial volume,
which affect metabolite levels. Many studies have shown that in hypoosmotic sucrose
medium, the matrix volume and state 3 respiration increase in isolated mitochondria (Devin
et al., 1997; Halestrap, 1989; Halestrap et al., 1990). Conversely, in hyperosmotic medium,
the AAC is inhibited, leading to a decrease in OXPHOS (Devin et al., 1996). However, how
these affect the isolation of the mitochondria and their metabolite pools is unclear.
The first step of isolating mitochondria from tissue is the homogenisation of the tissue. This
is often performed by placing the tissue in a 1:10 w/v of tissue:buffer (Pallotti, Lenaz, 2001)
and using a manual plunger to break up the tissue into a homogeneous mix in which the
cells are ruptured. This step is important as a homogeneous mixture in which as much tissue
as possible is broken up will maximise the yield of mitochondria. For softer tissues such
as liver and kidney, this manual process is often sufficient, but for "tough", fibrous tissues,
such as heart and skeletal muscle, mechanical disruption using a motorised homogeniser,
such as an Ultra-Turrax disperser, is often used to further enhance tissue homogenisation.
This helps to obtain a homogenous mix by breaking down the muscle fibres and connective
tissue, whilst reducing the time and variability of the homogenisation step. In comparison,
the brain is a soft, heterogeneous organ but poses a challenge due to its high lipid content,
which make the tissue much less dense (Table 3.8). This means that the method of isolating
brain mitochondria must be different to the methods for other organs. Wettmarshausen,
Perocchi (2017) describes a method for isolating mitochondria from mouse brain using the
same differential centrifugation approach as for kidney and liver, but the centrifugation steps
are at a higher speed and for longer periods than for kidney and liver.
There are also additional challenges specific to metabolomic analysis of isolated mitochon-
dria by LC-MS. Sucrose is added to many mitochondrial isolation buffers to maintain the
osmolarity of the mitochondria, in concentrations upwards of 250 mM. It is also beneficial
for differential centrifugation as changing its concentration can increase the density of the
media with few side effects. However, sucrose cannot be used at such a high concentration
for MS studies as it disrupts analysis, so in the development of this rapid method for LC-MS
analysis, other components were required to be incorporated into the buffer to contribute to
the osmotic support and to provide density.
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3.2 Aim
The aim of this section was to develop a method of rapidly isolating mitochondria and cytosol
from rat and mouse liver and heart so that LC-MS could be used to analyse their different
metabolite pools. The overall goal was to understand the differences between mitochondrial
and whole cell metabolism, with enhanced accuracy compared to established methods.
3.3 Strategy
To explore mitochondrial metabolism, the method of mitochondrial isolation must be per-
formed in such a way that cell metabolism is quenched as rapidly as possible, preventing
interconversion and distribution of metabolites throughout the cell. To do this, I aimed to
cool and isolate the mitochondria as quickly as possible, to keep all components cold and
to transfer the isolated mitochondria into an acid that would stop metabolic reactions and
stabilise the metabolites for subsequent analysis. The strategy was to build on the previously
used method of centrifuging small batches of tissue homogenate through silicone oil in an
Eppendorf tube, as described in Burns, Murphy (1997); Siess, Wieland (1975); Smith et al.
(1999); Tischler et al. (1977), as the short path length for centrifugation and small volumes
allow the steps to be performed quicker than larger volumes of homogenate. The general set
up from these methods was adopted, with 100 µL of acid forming the lowest layer in a 1.5
mL Eppendorf tube, beneath 300 µL of silicone oil. 700 µL of diluted tissue homogenate
was then placed on top of the oil before centrifugation. Each step of this process (displayed
in Figure 3.1) was systematically optimised for use with LC-MS. The strategy was to first
Fig. 3.1 Simplified schematic of rapid isolation method. Each step of the rapid isolation procedure
is displayed. The text depicts the components that require optimising for tailoring the method for use
with LC-MS analysis.
identify suitable components for the lower layer and for the buffer that the organs would be
homogenised in, or transferred to, prior to centrifugation through oil. Acid was chosen as the
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lower layer for metabolomic analysis so that when the mitochondria entered this layer they
would burst and release their metabolites, which would then be stabilised by the acid. The
main requirement of this acid layer was to be compatible with LC-MS and to have a density
higher than the oil phase and close to 1.1 g/mL (the density of mitochondria). Identifying the
correct homogenisation buffer to use was more complicated because it needed to maintain
the osmolarity of the mitochondria, have a density less than the silicone oil layer to prevent
inversion of the layers upon centrifugation, and be compatible with LC-MS. The buffer
needed to be LC-MS compatible because although the mitochondria would end up in the acid
layer, it was unknown how much of the buffer would be brought into the lower layer with
the mitochondria. Also, it would be beneficial to be able to analyse cytosolic metabolism
by analysing the whole homogenate, the supernatant of the whole homogenate (from the
first centrifugation) and the "cytosolic" fraction (the layer left above the silicone oil after
the second centrifugation step, see Figure 3.1), without further processing. Based on the
acid and buffer densities the silicone oil layer was adapted to the correct density. Initial
optimisation experiments were performed on rat liver, due to the large amount of tissue and
mitochondria available. After the method was optimised in rat liver the conditions were
applied to rat heart and then translated to mouse heart and liver, which required only minimal
changes, highlighting the robustness of the method. The separation of mitochondria from
cytosolic components was assessed by western blot and the function of mitochondria was
assessed by various respiratory and enzymatic assays to establish whether any part of the
extraction process was damaging to the mitochondria. For some optimisation experiments 3
µM tetramethylrhodamine, methyl ester (TMRM) was added to the mitochondria with 1 mM
succinate before centrifugation through the oil. TMRM is a red dye that is taken up by active
mitochondria, and so helped visualise the mitochondria.
3.4 Initial optimisation experiments in rat liver
The following experiments outline how each step of the isolation process (displayed in
Figure 3.1) was optimised in rat liver for LC-MS metabolite analysis.
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3.4.1 Acid phase
The first part of the extraction method explored was the choice of acid to form the lowest
layer. Volatile ions should be used for MS, so the use of non-volatile ions and salts such as
phosphate should be reduced. These leave a residue in the capillary and the mass spectrometer,
which can reduce sensitivity and limit the function of the machine. 18 % perchloric acid
(PCA), 20 % trichloroacetic acid (TClA) or 50 % formic acid (FA) were chosen due to being
inert, compatible with LC-MS analysis and, at the concentrations listed in Table 3.1, their
densities fit the criteria of being close to the density of mitochondria (1.1 g/mL) (Rickwood,
Birnie, 1978). Perchloric acid was a potential candidate because when it is neutralised with
KOH it forms the precipitate potassium perchlorate (KClO4). This can be easily removed by
centrifugation, leaving the metabolites in solution, which can then be analysed by a number
of techniques. However, the KOH and PCA must be carefully balanced to avoid KOH or
PCA remaining in solution. This is achieved by addition of a pH buffer, such as MOPS.
TClA is an acid commonly used in LC-MS for protein removal by precipitation and has been
found to increase retention times and MS signals of polar metabolites (Cheng et al., 2010;
Huang et al., 2018). Formic acid was chosen because it is a weak acid that does not cause
ion suppression in MS.
Acid
18% PCA 20% TClA 50% FA
Density (g/mL) 1.166 1.126 1.11
Table 3.1 Densities of initial acids trialled. The initial acids tested were 18% PCA, 20% TClA and
50% FA. The concentrations were chosen based on their densities. Densities listed were calculated at
RT (20-24◦C) by weighing 1 mL of each acid. PCA: perchloric acid; TClA: trichloroacetic acid; FA:
formic acid.
3.4.2 Homogenisation buffer
The next step was to look at the buffer the tissue would be homogenised in. The standard
STE buffer used for mitochondrial isolations contains 250 mM sucrose. This level of sucrose
is incompatible with LC-MS analysis because it is "sticky", meaning it can form particulates
which can block the LC columns and lead to high back pressures, which can damage the
machine. It can also form background peaks, which can interfere with the visualisation of
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Buffer
AB (50 mM) HEPES (50 mM) KCl* STE**
Density (g/mL) 1.066 1.011 1.023 1.032
Table 3.2 Densities of initial buffers trialled. The initial buffers tested were 50 mM ammonium
bicarbonate (AB), 50 mM HEPES, KCl and STE. The concentrations were chosen based on their
densities and the molarity. Densities listed were calculated at RT (20-24◦C) by weighing 1 mL of
each buffer. Densities listed were calculated at RT (20-24◦C). *KCl: 120 mM KCl, 10 mM HEPES, 1
mM EGTA; **STE: 250 mM sucrose, 5 mM Tris, 1 mM EGTA.
other metabolite peaks. As it was unknown how much of the homogenisation buffer would
come through the oil layer with the mitochondria, a new buffer was sought. This buffer
must have no (or low) sucrose but must maintain the osmolarity of the mitochondria, be
compatible with LC-MS and be less dense than the acid layer to prevent inversion. 50 mM
ammonium bicarbonate (AB) buffer and 50 mM HEPES buffer were chosen as they were
estimated to match this criteria (densities listed in Table 3.2).
3.4.3 Silicone oil
Previous work by Burns, Murphy (1997) and Smith et al. (1999) used an oil with density
1.07 g/mL (Dow Corning 550) for the middle oil phase. The Poly(methylphenylsiloxane) oil
(MPS) (Sigma 378496, viscosity 450-550 cSt) had a density similar to this (1.102 g/mL at
RT) and was available. This was trialled for initial experiments as its density was compatible
for the acids and buffers used in Tables 3.1 and 3.2.
3.4.4 Interaction between phases
The interaction between the acid layer, silicone oil and the homogenisation buffer was then
tested at RT. 100 µL of each acid was placed in the bottom of a 1.5 mL Eppendorf tube,
being careful not to let any acid touch the sides of the tube as this could allow a path for
the layers to mix, leading to inversion. 300 µL of MPS silicone oil was placed carefully
on top of the acid. 700 µL of each buffer (supplemented with 40 µM Phenol Red) was
placed carefully on top. Phenol Red was added to help identify whether there was any
mixing between the buffer layer and the oil or acid layer. The tube was centrifuged in a
swing rotor centrifuge (Heraeus Biofuge Primo R with swing out rotor Heraeus, #7592) at
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Fig. 3.2 Schematic of direction of force in angled and swing out rotors. A) In a fixed angle rotor
the direction of force causes cytosolic contaminants (orange circles) to hit the side of the tube and then
slide through the oil into the lower layer down the side of the tube, contaminating the mitochondrial
pellet (brown circles). B) In a swing out rotor the direction of force is horizontal, meaning that the
only path to the lower layer is directly through the oil. This means that cytosolic contaminants are
trapped in the top phase and only mitochondria can enter the lower layer.
9,727 x g (10,000 min−1) for 1 min. A swing rotor centrifuge must be used because the
direction of the force is vertically down the tube, as opposed to angled (Figure 3.2). If the
direction of force is angled then non-mitochondrial components from the cytosolic layer
may hit the wall of the tube and begin to slide down the wall into the phases below, thus
contaminating the final mitochondrial pellet. This can also lead to inversion of the layers
due to inconsistent densities spread across a cross-section of the tube. A standard angled
rotor centrifuge consistently resulted in inversion of the layers. The pH of the cytosolic
fraction was measured (in triplicate) after centrifugation following 0, 5 and 10 min of resting
to determine whether any seepage would occur between the layers. The pH of the cytosolic
fraction remained stable after centrifugation (AB: pH 7.5, HEPES: pH 7) for all acids used
over 10 min. This demonstrated that there is no leakage between the layers.
3.4.5 Addition of homogenate and mitochondria
After determining that the layers did not acidify, rat liver mitochondria (RLM) were added to
identify if mitochondria are able to pass through the oil layer. Mitochondria were isolated in
KCl buffer (120 mM KCl, 10 mM HEPES, 1 mM EGTA) as it was hypothesised this could
maintain the osmolarity of the mitochondria for the entire duration of the prep, whilst also
being compatible with LC-MS. 100 µg (11.1 µL) or 1 mg (111 µL) of mitochondrial protein
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was made up to 700 µL with KCl buffer, layered on top of 300 µL of oil above 100 µL of
each acid (18% PCA, 20% TClA and 50% FA) and centrifuged in a swing rotor centrifuge
at 9,727 x g for 1 min. A layer of brown sediment was seen at the buffer:oil interface but
it was difficult to determine if the mitochondria had entered the acid phase. To determine
whether mitochondria would be visible in the acid phase, 100 µg of mitochondrial protein
was layered directly onto 100 µL of acid and centrifuged. A pellet was seen in the acid layer,
showing that a mitochondrial pellet would indeed be visible if the mitochondria were able to
pass through the oil.
After these experiments, it was unclear what was the cause of the failure to obtain a mitochon-
drial pellet after centrifugation through oil. It could have been because the KCl buffer that the
mitochondria were isolated in was not able to maintain the osmolarity of the mitochondria.
To establish whether a mitochondrial pellet could be obtained at all in the silicone oil system,
for the following preliminary experiments the mitochondria were isolated in the standard
STE buffer and then diluted into KCl buffer.
3.4.6 Further silicone oil phase optimisation
As initial attempts to get mitochondria to pass through the a single component oil phase were
unsuccessful, dioctyl phthalate (DOP) (density 0.985 g/mL at RT) was added to the silicone
oil. This was based on previous work by Scarlett et al. (1996) who mixed DOP with the
silicone oil in a ratio of 58:42 (v/v) silicone oil:DOP. They added the acid and oil mix to the
tubes and centrifuged briefly to ensure separation of the layers. After centrifugation, the tubes
were left on ice until the sample was ready. This technique was adopted into the method.
Smith et al. (1999) also used silicone oil mixed with DOP to purify isolated mitochondria
but in a ratio of 66:34 and Burns, Murphy (1997) used a ratio of 70:30 to purify hepatocytes.
To investigate whether the addition of DOP to the silicone oil phase would facilitate the
movement of mitochondria into the lower phase, a ratio of 60:40 MPS:DOP was used initially,
due to its density of 1.052 g/mL at RT. It was thought that this would be dense enough to
form distinct layers but not too dense that the movement of mitochondria through the oil is
inhibited. Mitochondria were isolated from mouse liver in STE using the standard method of
isolation (isolation performed by Lee Booty) and the mitochondrial pellet was diluted in KCl
buffer (120 mM KCl, 50 mM HEPES, pH 7.4) to 15 mg mitochondrial protein/mL. Various
stages of the fractionation were layered on the mix of 60:40 MPS:DOP and centrifuged, to
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assess the procedure. The experimental procedure and the results are displayed in Table 3.3
and explained below.
100 µL of the supernatant of homogenate was layered on 300 µL 60:40 MPS:DOP (density:
1.055 g/mL) above 100 µL 18% PCA and centrifuged. This resulted in a layer of beige
protein forming on top of the oil phase, possibly because there was too much protein. To
reduce the amount of protein 1 mg of mouse liver mitochondria (MLM) (66 µL in 700 µL of
KCl buffer) was added to 2 tubes with 60:40 MPS:DOP and centrifuged. Some mitochondria
were seen in the oil layer. It was hypothesised that the interface between the top phase and
the oil phase may have been blocking the passage of mitochondrial protein through the oil
into the acid. To investigate this further 250 µg (16.5 µL) of mitochondrial protein was
added directly into the oil layer of 60:40 MPS:DOP above 100 µL 18 % perchloric acid.
Before centrifugation the mitochondria formed a sphere in the middle of the oil layer but
after centrifugation at 16,250 x g the mitochondria were sat above the oil layer in the buffer.
This showed that the oil phase was too dense for the mitochondria to pass through. Therefore,
it was decided to make the oil layer less dense. The density of mitochondria is ∼1.1 g/cm3
(Rickwood, Birnie, 1978), so the lower density Poly(dimethylsiloxane-co-methyl-phenyl
siloxane) oil (DSMPS) (Sigma 378488, viscosity: 125 cSt) was chosen due to its density
of 1.066 g/mL at RT, compared to 1.102 g/mL for MPS. When used to make up the 60:40
oil:DOP mix, DSMPS lowered the density of the mix to 1.034 g/mL from 1.052 g/mL. To
ascertain whether lowering the density to this value was sufficient to obtain a mitochondrial
pellet, 16.5 µL of homogenate of supernatant (250 µg protein) was added onto this oil layer
and centrifuged. A protein pellet was seen at the bottom of the acid layer and a beige sphere
was seen suspended in the oil layer, which was hypothesised to be mitochondrial protein.
This was repeated except the 16.5 µL of supernatant was made up to 700 µL with KCl buffer
and the same result was seen. The results of these experiments are displayed in Table 3.3.
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Based on these experiments it can be concluded that DOP is beneficial and necessary for the
mitochondria to pass through the oil, although the reason for this is unclear. It can also be
seen how sensitive the system is to the density of the oil phase: the difference of only 0.018
g/mL between 60:40 MPS:DOP and 60:40 DSMPS:DOP allowed the mitochondria to enter
the acid phase.
The beige spheres often seen floating in or just above the oil layer were a concern as this
means they are the same density of the oil, and therefore slight fluctuations in the preparation
of the oil could cause them to enter the acid layer and contaminate it. What they contain was
not investigated at this stage but they may contain broken mitochondria and/or microsomes.
Investigations into the contents of the interface are described in Section 3.4.9.
3.4.7 Inversion of layers
Using silicone oil to isolate mitochondria, both with and without the addition of DOP, has
been attempted in several iterations in this lab (Burns, Murphy, 1997; Smith et al., 1999).
Despite different conditions being trialled there were often variable results: many attempts
resulted in inversion of the layers upon centrifugation or did not generate a mitochondrial
pellet. I also encountered these issues, and it occurred when using the same batches of
reagents that had previously not inverted and had resulted in mitochondrial pellets. It was
found that when reagents were weighed out and their densities were checked after mixing, the
density changed after being left for even short periods of time (5-10 min). It was hypothesized
that the phases were inverting because the heavier components of each mix sink to the bottom
of the layer over time. Therefore, if the tubes are made up too far in advance there will be a
density gradient within each layer (see Figure 3.3). This would also explain why sometimes
no mitochondria were able to pass through the oil, as the bottom of the oil layer was too
close in density to the mitochondria. This is in contradiction to Scarlett et al. (1996) who
leave their tubes (on ice) for some time before the experiment. To help prevent inversion the
reagents were made up in bulk to reduce any impact of minor errors in weighing out the oil,
DOP, and homogenisation buffer components. To investigate this hypothesis, all reagents
were thoroughly mixed before use and layered in the Eppendorf tubes less than 5 min prior
to use. This prevented inversion occurring. This showed that the success of this technique is
heavily dependent on the components being mixed well and that the density of the layers
must be correctly balanced. Speed and cold temperature are necessary for metabolomic
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studies, but were also shown to have important effects on the density of the oil and acid
phases.
Fig. 3.3 Density gradients form within each phase over time. Schematic of how density gradients
formed within each phase cause inversion upon centrifugation.
3.4.8 Further homogenisation buffer optimisation
3.4.8.1 STE vs. KCl buffer
In the experiments described in Table 3.3, mitochondria were isolated in standard STE buffer
and diluted in KCl buffer (120 mM KCl, 50 mM HEPES, pH 7.4). Subsequent attempts to
repeat the experiment using mitochondria isolated wholly in KCl buffer were unsuccessful,
with no mitochondrial pellets obtained. The lack of a pellet suggests that the KCl buffer used
was not able to sustain the osmolarity of the mitochondria for the duration of the isolation
process. Imbalances in osmolarity cause the mitochondria to swell and change density,
which could be what is preventing them passing through the oil. The ability to use KCl as
a homogenisation buffer would be beneficial due to its compatibility with LC-MS analysis.
Therefore, 2 different KCl buffers were trialled and compared to the standard STE buffer.
One of the KCl buffers was the same used in the method of Corcelli et al. (2010) (described
in more detail in Section 1.7.1), who were able to isolate coupled mitochondria using this
buffer. The buffer from Corcelli was used to directly compare how their buffer behaved in
my system, and KME2 was devised to have a lower KCl concentration and a higher buffering
capacity (50 mM MOPS compared to 5 mM). It was hypothesised that these three buffers
may be better able to buffer and sustain the osmolarity of the mitochondria compared to the
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initial KCl buffer used (120 mM KCl, 50 mM HEPES, pH 7.4). The buffer components are
listed below:
• KME1: 180 mM KCl, 5 mM MOPS, 1 mM EGTA, 0.1 % BSA, pH 7.25 (from Corcelli
et al. (2010))
• KME2: 100 mM KCl, 50 mM MOPS, 0.5 mM EGTA, 0.1 % BSA, pH 7.4
• STE: 250 mM sucrose, 5 mM Tris, 1 mM EGTA, pH 7.4
A rat liver was homogenised in STE using the conventional method (Section 2.2.1.1), except
the supernatant from the first fast centrifugation (at 10,000 x g) was split into 3 centrifuge
tubes (containing ∼10 mL each) and each was run in parallel to generate 3 separate mito-
chondrial pellets. These were resuspended in 5 mL of either KME1, KME2 or STE buffer
(for detailed protocol see Table 3.4). These mitochondria were then centrifuged through
oil. The general procedure was 300 µL oil (DSMPS:DOP 60:40 (1.034 g/mL at RT) or
65:35 (1.013 g/mL at RT)) was placed on 100 µL 18 % perchloric acid and left on ice until
required as described in Scarlett et al. (1996). After addition of either the supernatant, isolated
mitochondria or the white layer containing broken mitochondria, the tubes were centrifuged
at 9,727 x g for 1 min at 4◦C. The results of these experiments are displayed in Table 3.4.
Experiments 1-3 show that only when STE buffer was used were mitochondria able to pass
through the oil. The KCl buffers may have failed to do this due to altered mitochondrial
density due to swelling. It was hypothesised that too much mitochondrial protein was added,
but this was determined to not be the problem, because a trial with reduced mitochondrial
protein (1 mg and 0.5 mg) also had no pellet in the acid for KME buffers but consistently
showed pellets in the acid layer for STE samples.
Experiment 4 investigated whether broken mitochondria and microsomes pass through the
oil. A fraction of the white layer which forms above the supernatant of the final 10,000
x g centrifugation of a standard mitochondrial isolation, and is known to contain broken
mitochondria and microsomes, was collected. This was placed above the oil and centrifuged
to see where these fragments would migrate to in the prep. No pellet was obtained, which is
encouraging as it indicates that the oil phase will block broken mitochondria and endosomes
from entering the acid. Further investigations into damaged mitochondria are described in
Section 4.5.
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Experiment 5 shows that the system is capable of separating mitochondria from homogenate,
as a pellet was obtained when 70 µL of supernatant of homogenate (made up to 700 µL in
STE) was layered on the oil mix.
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3.4.8.2 Addition of digitonin to homogenisation buffer
An opportunity for further optimisation during initial experiments was that pellets obtained
from centrifuging the supernatant of homogenate through oil were not purely mitochondrial.
They may have contained peroxisomes, which have a density of ∼1.2 g/mL and so may
sediment with mitochondria (Wilcke et al., 1995). Microsomes, 100-300 nm vesicles com-
posed of ER and plasma membrane formed artefactually during cell homogenisation, may
also co-migrate due to their similar density to mitochondria (within the range of 1.1-1.25
g/mL, Norseth et al. (1982)). However, due to their smaller size (100-300 nm vs. 0.5-10 µM
for mitochondria), the microsomes should take longer to move down during centrifugation.
Therefore, the time of centrifugation should be optimised such that it is long enough for the
mitochondria to enter the acid phase but short enough to limit microsomes contaminating the
mitochondrial pellet. To further reduce the risk of contamination from microsomes and other
organelles, digitonin was added.
Digitonin is a non-ionic detergent which causes membrane permeabilisation by binding to
membrane cholesterol and forming permanent pores. It has been proposed that it functions
by binding to cholesterol in the inner leaflet of membranes and moving as a bound complex
to the outer leaflet (Frenkel et al., 2014). This can cause changes to the membrane curvature,
thus forming pores of 8-10 nm (Olofsson et al., 2009) which allow the passage of metabolites
and ions across the membrane. At high enough concentrations the addition of digitonin can
cause complete lysis of cholesterol-rich membranes. Because digitonin requires cholesterol
to act (Sudji et al., 2015), it can be exploited experimentally to selectively lyse cholesterol-
rich membranes. The MIM contains negligible levels of cholesterol (Colbeau et al., 1971),
compared to the PM, microsomes (18.4%; (Cheng, Kimura, 1983)) and ER membranes
(3-6 % of total lipid (Ridsdale et al., 2006)). The MOM contains more cholesterol than
the MIM (8.3% vs. 2.8%; Cheng, Kimura (1983)), but due to the short time frame that
the supernatant is exposed to digitonin, it is likely that the digitonin will mainly affect the
PM. Digitonin also aids the homogenisation process: by breaking the PM membrane the
mitochondria are more easily released from the cytosol. Therefore, it was hypothesised that
by optimising the amount of digitonin added microsomes and other organelles could be
selectively removed, whilst keeping the mitochondria intact. The digitonin was sourced from
Sigma which cites a 73.5% purity (based on TLC area %).
To investigate if digitonin could be beneficial in rapidly isolating mitochondria from rat
liver, 200 µg/mL of digitonin was added to the homogenisation buffer, along with TMRM
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and succinate for visualisation of the mitochondria. The addition of digitonin resulted in
a compact pellet in the lower layer, shown in Figure 3.4B, compared to no pellet when
digitonin was not added (Figure 3.4A). Therefore, digitonin was necessary to consistently
obtain mitochondrial pellets.
Fig. 3.4 Addition of Digitonin A) - Digitonin. B) + 200 µg/mL Digitonin. A rat liver was ho-
mogenised in 40 mL STE as described in Section 2.2.1.1. 1 mL aliquots were centrifuged at 1,000 x g
for 1.5 min. 2 mg of homogenate protein (41 µL) was added to a tube containing 3 µM TMRM and 1
mM succinate in STE buffer ± 200 µg/mL digitonin, to a total volume of 700 µL. Upon addition of
digitonin the tubes were incubated at RT for 5 min, shaking gently. This suspension was then layered
on 300 µL of 60:40 DSMPS:DOP above 100 µL 23 % glycerol. The tubes were centrifuged at 9,727 x
g for 1 min.
After this preliminary experiment, a range of digitonin concentrations in rat liver were
trialled to determine if there was an optimum digitonin concentration to use. The protein
composition of the pellets obtained from 0, 20, 50, 100, 200, 400 and 800 µg/ml digitonin
was assessed by WB. The extent of mitochondrial enrichment and cytosolic contaminants
appeared the same across all concentrations of digitonin. Therefore, 100 µg/mL digitonin
was chosen for subsequent experiments, as it is in the mid-range of the concentrations tested.
This meant that slight fluctuations in the weight of tissue homogenised would not lead to
artefactual variability due to digitonin levels, increasing the robustness of the method. 100
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µg/mL digitonin is also equivalent to values cited in the literature: James et al. (1996) found
30 µg digitonin/mg protein to permeabilise the PM of fibroblasts without damaging the
mitochondria. In my system, 2 mg of protein was added to the 700 µL loaded on top of the
oil. For the 100 µg/mL digitonin sample, this equates to 35 µg digitonin/mg protein.
3.4.8.3 Addition of ammonium bicarbonate to homogenisation buffer
The high sucrose concentration in STE buffer makes it incompatible with LC-MS. However,
as the sucrose concentration is diluted during the process of the isolation, this may improve
the compatibility. A calculation of the maximal possible amount of sucrose that could enter
the acid phase with the mitochondria was performed. This is the maximal possible value
because whilst passing through the oil a large proportion of the extracellular volume is likely
to be lost. If 1.5 mg of enriched mitochondrial protein in 200 mM sucrose STE is pelleted
by centrifugation then there is approximately 1.5 µL matrix and 1.5 µL extracellular space,
based on the frequently used approximate values of 1 µL of matrix and extracellular space
volumes per mg protein (Woelders et al., 1985). If all of these mitochondria pass through the
oil into 100 µL acid with the same amount of sucrose then the sucrose concentration would
be 3-4 mM. It was then decided to trial lower sucrose concentration STE buffers as the buffer
for the top layer, termed the "spin buffer" that the supernatant of homogenate is diluted into.
The Tris and EGTA concentrations were kept constant at 5 mM and 1 mM, respectively. The
sucrose was substituted with ammonium bicarbonate (AB) to maintain the osmotic support
that is lost with reduced sucrose concentrations, and to maintain the molarity at 200 mM.
AB was chosen as it is volatile and is often a component of the mobile phase for MS. STE
buffers with increasing concentrations of sucrose and decreasing concentrations of AB were
trialled for isolating mitochondria from rat liver. The buffer components and photographs of
the tubes after centrifugation through oil are shown in Figure 3.5A. Buffer 6 was the only
buffer to produce a large mitochondrial pellet upon centrifugation through oil. Although
the protein content of this pellet was unknown, it can be assumed to contain a sizeable
amount of mitochondrial protein due to the bright pink TMRM staining. To investigate the
protein composition of the pellets, the lower layers and the cytosolic fractions of each buffer
were analysed by WB (Figure 3.5B and D). This showed Buffer 6 to generate pellets with
maximal enrichment of mitochondrial protein, with no detectable cytosolic contamination.
Combined, these results clearly showed Buffer 6 (150 mM sucrose STE + 25 mM AB) to be
the best buffer.
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Fig. 3.5 Investigating sucrose:AB ratio in homogenisation buffer for rat liver. A rat liver was
homogenised in STE buffer and 1 mL portions of the homogenate were centrifuged at 1,000 x g for 1
min. The supernatants were combined and the protein concentration was assessed by BCA as 32.2
mg/mL. 2 mg (62 µL) of this supernatant was added to tubes containing 140 µL of digitonin to a final
concentration of 100 µg/mL and STE/AB buffer 1-7 (described in table) to a total volume of 700 µL.
Upon addition of digitonin, 3 µM TMRM and 1 mM succinate the tubes were incubated at RT for
2 min, shaking gently. All 700 µL of this suspension was layered on 300 µL 60:40 DSMPS:DOP
above 100 µL 23 % glycerol. This was centrifuged at 9,727 x g for 1 min. 100 µL of the cytosolic
fraction from each tube was removed and lysed with 75 µL lysis buffer. The oil mix and the majority
of the glycerol was removed before the mitochondrial pellet was lysed with 50 µL NP40 lysis buffer
(10 min on ice followed by 10 min centrifugation at max speed). Protein was quantified in all
samples before dilution to 10 µg in 40 µL lysis buffer and Laemmli loading buffer + 5 % BME. A)
Photographs of tubes after final centrifugation, with sucrose and AB concentrations displayed in
corresponding column in table underneath. Western blots. B and D) Western blots. 10 µg of protein
was loaded per lane. Marker: Protein Plus Dual Color standard. Mitochondrial marker: PDH (red
bands, 54 + 69 kDa), cytosolic marker: GAPDH (green band, 37 kDa). Mitochondrial Control: RLM
isolated by conventional method. Homogenate Control: supernatant of homogenate of rat liver from a
conventional isolation. C: Cytosolic fraction, M: Mitochondrial fraction. C and E) Coomassie stains
of membranes. F) Ratio of PDH/GAPDH band intensities.
3.4.8.4 LC-MS sucrose trial
To determine whether the use of these sucrose concentrations was compatible with LC-MS
analysis, a preliminary LC-MS analysis was run. Rat liver mitochondria were isolated in
250 mM sucrose STE with 100 µg/mL of digitonin, and the pellets were diluted in either
Buffer 4 (75 mM sucrose STE + 62.5 mM AB) , Buffer 5 (100 mM sucrose STE + 50 mM
AB) or Buffer 6 (150 mM sucrose STE + 25 mM AB) before centrifugation through oil into
25 % formic acid. 75 µL of the formic acid layer was removed and analysed by LC-MS.
Figure 3.6 shows the LC-MS signal was not dependent on the amount of sucrose and AB.
This confirms it is not necessary to remove all of the sucrose from the STE buffer. The first
graph suggests that sucrose is present at mM levels but does not interfere with the analysis of
other metabolites. 150 mM STE + 25 mM AB gave the most consistent results, and 75mM
STE + 62.5 mM AB the least successful. This is beneficial for the extraction as a higher
amount of sucrose will maintain the osmolarity of the mitochondria. This prevents them
from swelling or bursting, changing their density and preventing them passing through the
oil to be captured in the acid phase.
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Fig. 3.6 Preliminary LC-MS analysis of rat liver mitochondrial pellets diluted in 75, 100 and
150 mM sucrose STE buffer before centrifugation through oil. A) MS signal (AU) from metabo-
lites analysed on ZIC-HILIC column. B) MS signal (AU) from metabolites analysed on ZIC-pHILIC
column. A rat liver was homogenised in STE in the presence of 100 µg/mL of digitonin. 2 mg of
homogenate was added to either 150 mM sucrose STE + 25 mM AB, 100 mM sucrose STE + 50 mM
AB or 75mM STE + 62.5 mM AB and centrifuged through 60:40 DSMPS:DOP on top of 100 µL of
25 % formic acid. n=3 biological replicates, data is mean ±SEM.
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3.4.9 Interface protein
To determine whether mitochondria or other material become stuck at the interface between
the oil and the top phase, thus reducing the overall yield, the protein at this interface was
removed and analysed by WB to determine its composition. A rat liver was processed as
described in Figure 3.5 and after centrifugation through oil the protein left at the interface
was stained pink with TMRM, suggesting it contained mitochondrial protein (Figure 3.7).
WB analysis was performed as a secondary method of protein identification. This showed
that a mixture of mitochondrial and cytosolic protein is present at the interface (Figure 3.8).
This suggests that the method does not yield 100 % of the mitochondria from the homogenate.
Another possibility is that the mitochondrial protein seen at the interface is from broken
mitochondria, an idea discussed further in Section 4.5. The photographs of the tubes stained
with TMRM and centrifuged through oil (Figure 3.7) show the amount of protein at the
interface is greatly reduced with Buffer 6, as is the cytosolic contamination (Figure 3.8).
More protein is seen at the interface in lower sucrose concentration buffers (Figure 3.7).
This could be due to mitochondrial swelling preventing them passing through the oil. It
is possible that there is simply too much homogenate added and the entire surface of the
oil is covered with protein that will not pass through the oil, blocking the passage of intact
mitochondria. However, this is unlikely as there is a pellet seen when using Buffer 6 with the
same amount of protein. Therefore, I conclude Buffers 1-5 cause mitochondrial swelling and
limit their passage through the oil.
3.4.10 Effect of exogenous succinate on isolation of mitochondria
The maintenance of mitochondrial volume is an energy-dependent process, in which Na+ and
K+ are exchanged for H+. Healthy, energised mitochondria are more compact than damaged,
uncoupled mitochondria. Therefore, it could be that the succinate added in conjunction with
the TMRM in order to aid visualisation of the mitochondrial pellets was changing the shape
and/or density of the mitochondria. Furthermore, in physiological conditions exogenous
succinate will not be present. It is possible that in the absence of succinate the mitochondria
do not pass through the oil. To test this hypothesis, the extraction was trialled in rat liver
±succinate and ±TMRM to ascertain whether the mitochondria still pass through the oil.
Photographs of the mitochondrial pellets after centrifugation through oil are shown in Figure
3.9. Protein analysis by WB was also run to look at whether the level of mitochondrial
3.4 Initial optimisation experiments in rat liver 113
Fig. 3.7 Analysis of protein at buffer:oil interface in rat liver mitochondrial isolations. A rat
liver was processed as described in Figure 3.5. The protein concentration of the supernatant of
homogenate was 40.3 mg/mL, and 2 mg (49.6 µL) of protein was used. Photographs are displayed of
tubes after centrifugation through oil, with sucrose and AB concentrations depicted in corresponding
column in the table underneath. The location of the protein that was removed from the buffer:oil
interface is depicted by the arrow. 1 mM succinate and 3 µM TMRM were added for visualisation of
mitochondria.
protein in the pellets was changed ± succinate and ± TMRM. These results are displayed in
Figure 3.10 and show that the absence of added succinate (or TMRM) does not impact on
the mitochondria passing through the oil, as the level of enrichment of mitochondrial protein
is the same in the presence or absence of succinate.
3.4.11 General optimisation of the procedure
3.4.11.1 Centrifugation steps
The first centrifugation step at 1,000 x g to remove cell debris was trialled at 30 sec, 1 min
and 1.5 min. The 1.5 min centrifugation step did not result in a significantly larger cell debris
pellet, whereas 30 sec generated a very small pellet, so 1 min was decided as the optimum
time for this step. Also, performing 2 spins before the final centrifugation through oil was
trialled, to mimic the conventional method of mitochondrial isolation and to reduce cytosolic
contamination (as it was hypothesised that more cell debris would be removed). The first
spin was at 1,000 x g for 1 min, followed by centrifuging this supernatant at 2,500 x g for
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Fig. 3.8 Analysis of protein at buffer:oil interface in rat liver isolations by WB. The samples
from Figure 3.7 were processed for WB analysis as described in Figure 3.5. Components of buffers
1-7 are described in Figure 3.7. Left) Western blots. Mitochondrial marker: PDH (red bands, 54
and 69 kDa), cytosolic marker: GAPDH (green band, 37 kDa). C: Cytosolic fraction; I: interface
fraction; M: Mitochondrial fraction. Mito control: RLM isolated by conventional method; Snt control:
supernatant of rat liver homogenate isolated by conventional method. Marker: Protein Plus Dual
Color standard. Right) Coomassie stains of membranes.
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Fig. 3.9 Effect of Succinate and TMRM on mitochondrial isolation from rat liver. A rat liver was
processed as described in Figure 3.5 using the buffers described in the table. The protein concentration
of the supernatant of homogenate was 38.1 mg/mL, and 2 mg (52.5 µL) of protein was used. Top:
Photographs of tubes after centrifugation through oil, with sucrose and AB concentrations displayed
in corresponding column in table underneath, indicating presence or absence of 1 mM succinate and 3
µM TMRM.
30 sec. However, this was not beneficial in that the mitochondrial pellets obtained were not
larger than when one centrifugation step was used and only added more time to the extraction
process. The centrifugation steps were optimised to be 1 min at 1,000 x g to remove cell
debris, followed by 1 min at 9,727 x g through the oil. The centrifugation step in the swing
rotor centrifuge takes 25 sec to attain 9,727 x g. After 35 sec at full speed (1 min from
starting) it takes a further 35 sec to completely stop.
3.4.11.2 Weighed Tissue
At this stage, the protocol had been optimised to begin with a BCA assay to determine the
protein concentration of the supernatant of rat liver homogenate, and thus how much volume
to layer on the oil so that 2 mg of protein was used. This prolonged the isolation process by
30 min, which is not appropriate for the intended application of the method for metabolomic
analysis of tissues, as this needs to be performed as quickly as possible. To remove this step
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Fig. 3.10 Effect of Succinate and TMRM on mitochondrial isolation in rat liver. The samples
from Figure 3.9 were processed for WB analysis as described in Figure 3.5. Left) Western blots.
Mitochondrial marker: PDH (red bands, 54 and 69 kDa). C: Cytosolic fraction, M: Mitochondrial
fraction. Ctrl: RLM isolated by conventional method. Marker: Protein Plus Dual Color standard.
Right) Coomassie stains of membranes.
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the homogenisation step was scaled down by homogenising known weights of tissue pieces
in smaller volumes.
A female Wistar rat liver harvested at 8-12 weeks of age typically weighs 15 g. For standard
mitochondrial isolations this is normally homogenised in 25 mL of STE buffer. In order
to scale down the homogenisation step, smaller glass Potter-Elvehjem tissue grinders were
chosen, which have a maximum volume of 7 mL (as opposed to the 55 mL Potter-Elvehjem
tissue grinders used for a standard rat liver isolation). 5 mL of buffer was chosen as a suitable
volume that would fit in the grinder and give enough volume of homogenate to use. To scale
down tissue at the same proportion it was hypothesised 3 g (wet weight) of tissue in 5 mL
should be used (25 mL/5 mL = 5, 15 g/5 = 3 g). 2 and 5 g of tissue were also trialled. The
rat liver pieces (2, 3 and 5 g) were homogenised in triplicate in 5 mL STE buffer. 5 g of
tissue was too dense to produce a supernatant after the 1 min spin at 1,000 x g and was
not used. The protein concentration of the homogenate supernatant for the 2 g sample was
41.9 mg/mL and for the 3 g sample 48.4 mg/mL. 2 mg of protein from these samples is the
equivalent of 47.7 µL and 41.3 µL respectively, which are similar volumes to what was used
in previous experiments. If the isolation is proportionate to tissue amount, then 2 g and 3
g of tissue in 5 mL should yield 400 mg/mL and 600 mg/mL respectively. However, it is
unlikely to be exactly proportional as a large amount of protein is lost to the cell debris pellet
during the first centrifugation step. The fact that the 3 g sample only generated a slightly
higher protein concentration in the homogenate supernatant than the 2 g sample shows that
proportionally more protein is lost to the cell debris pellet from the 3 g sample, suggesting
that there is incomplete homogenisation with this amount of tissue. It is also possible that a
larger proportion of mitochondria became trapped in the cell debris pellet of the 3 g sample.
Figure 3.11 shows the mitochondrial pellets generated by 2 g and 3 g of tissue. Each
generated similar sized mitochondrial pellets, but the 3 g samples had more protein in the oil
and left in the top phase, further suggesting that there is incomplete tissue homogenisation
with this amount of tissue. 2 g of tissue appears to be the optimum total amount of liver
tissue. The whole rapid extraction method in rat liver was thus able to be scaled down in
volume and the total extraction time reduced by over 30 min.
In an attempt to further reduce the time and variability of the homogenisation step, mechanical
homogenisation using the Bullet Blender was trialled, instead of the manual method of a
Potter-Elvehjem tissue grinder. 200 mg (wet weight) of rat liver tissue was placed in a 2
mL Eppendorf tube containing 1.5 mL of STE buffer and 0.5 mm ceria-stabilised zirconium
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Fig. 3.11 Mitochondrial pellets from 2 and 3 g of rat liver. 2 and 3 g of rat liver were homogenised
in 5 mL of STE buffer. 5 x 1 mL portions were centrifuged at 1,000 x g for 1 min. 55 µL of supernatant
was added to a tube containing 100 µg/mL of digitonin (140 µL) in Buffer 6 (150 mM sucrose STE
+ 25 mM AB) to a total volume of 700 µL. 3 µM TMRM and 1 mM succinate was added. This
suspension was layered on 300 µL of 60:40 DSMPS:DOP above 100 µL of 23 % glycerol before
centrifugation at 9,727 x g for 1 min.
oxide beads (ZrOB05, Next Advance). This was homogenised in the Bullet Blender Storm24
machine (Next Advance) on speed setting 8 for 4 min. 1 mL of the homogenate was removed
and centrifuged for 1 min at 1,000 x g. 55 µL of the supernatant was added to 150 mM
sucrose STE + 25 mM AB buffer + 100 µg/mL digitonin to a total of 700 µL, and layered on
300 µL of 60:40 DSMPS:DOP above 100 µL 23 % glycerol. This was centrifuged at 9,727 x
g for 1 min. However, no mitochondrial pellets were seen. This could be because the Bullet
Blender was too harsh and lysed the mitochondria. Therefore, mechanical homogenisation
using the Bullet Blender was not pursued further.
3.4.11.3 Pellet extraction
Once the method was successfully optimised to consistently produce a mitochondrial pellet,
a way of extracting the pellet from underneath the oil mix was required. However, it proved
challenging to remove all trace of the silicone oil and DOP from the pellet. Attempts to wash
the oil away with 1 mL of 23 % glycerol or STE buffer followed by a 1 min centrifugation
at 9,727 x g were unsuccessful, as relatively large amounts of the oil mix were still visible.
As DOP is miscible with hexane, the most effective method attempted was to remove the
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cytosolic fraction and the majority of the oil, freeze the pellet and wash the oil off with
dry ice-cold hexane in a dry ice and ethanol bath (-72◦C, see Section 2.2.2). However, this
procedure is not suitable for most enzymatic assays and assays requiring intact mitochondria
(as freeze-thaw damages mitochondrial membranes). For these applications the mitochondrial
pellet was not frozen, and was removed from under the oil using a P1000 pipette tip after the
majority of the oil was removed by pipette. However, this retrieval method results in a lower
recovery of the mitochondrial pellet because some of the pellet is unavoidably lost. This is
because as more of the lower layer (generally glycerol) is removed, the remnants of the oil
phase become closer to the pipette tip. A compromise of lower mitochondrial yield with no
contamination from the oil/DOP phase must be taken in this situation, as the oil and DOP
may have adverse effects on enzymatic activity.
3.5 Rapid isolation of rat heart mitochondria
Initial attempts to isolate mitochondria from rat heart using the same conditions optimised for
rat liver were unsuccessful. It was hypothesised this was due to heart mitochondria having a
different density to liver mitochondria. To test this hypothesis, the density of the oil layer
was reduced and homogenisation buffers 2-7 were trialled. 50:50 DSMPS:DOP oil was
trialled initially due to its lower density of 1.026 g/mL compared to 1.034 g/mL of 60:40
DSMPS:DOP.
A rat heart was homogenised in 200 mM sucrose STE + 100 µg/mL digitonin. 180 µL
of supernatant of homogenate (∼2 mg) was added to 520 µL of buffers 2-7 with 1 mM
succinate and 3 µM TMRM. This was layered on 300 µL of 50:50 DSMPS:DOP oil above
100 µL of 23 % glycerol and centrifuged at 9,727 x g for 1 min. No pellets were seen in the
oil using any of the buffers. As these conditions were unsuccessful, the density of the oil
was reduced even further to 1.016 g/mL (38:62 DSMPS:DOP), as was the density of the
glycerol (reduced to 10% glycerol, density 1.026 g/mL) (see Table 3.5). Another rat heart
was homogenised as above and the protein concentration of the supernatant of homogenate
was measured as 4.2 mg/mL. When 2 mg of protein (476 µL in 700 µL) was layered on 10 %
glycerol and 38:62 DSMPS:DOP oil the lower phases inverted. After reviewing the densities
of the components used (displayed in Table 3.5 and Table 3.6), it was hypothesised that
the inversion occurred because the densities were too close together (38:62 DSMPS:DOP
= 1.016 g/mL and 10 % glycerol = 1.026 g/mL). Therefore, the glycerol concentration was
120 Development of a rapid method for isolating mitochondria from tissue
Buffer [Sucrose] (mM) [AB] (mM) Density at RT (g/mL)
2 25 87.5 1.008
3 50 75 1.008
4 75 62.5 1.012
5 100 50 1.015
6 150 25 1.020
7 200 0 1.025
Table 3.5 Densities of buffers 2-7. Densities compatible with 38:62 DSMPS:DOP and 10 % glycerol
are highlighted in blue. Densities were determined by weighing 1 mL of each buffer at RT (20-24oC)
and taking an average of 3 readings.
DSMPS:DOP Density at RT (g/mL) Glycerol Density at RT (g/ml)
60:40 1.034 23% 1.060
50:50 1.026 15% 1.039
40:60 1.017 10% 1.026
38:62 1.016
35:65 1.014
Table 3.6 Densities of different DSMPS:DOP ratio mixes and glycerol mixes. Compatible density
combinations are highlighted in blue. Densities were determined by weighing 1 mL of each buffer at
RT (20-24oC) and taking an average of 3 readings.
increased to 15 % (v/v, 1.039 g/mL) and the oil was kept at 38:62 DSMPS:DOP. Buffers 2, 3
and 4 (with 100 µg/mL digitonin) were trialled under these conditions (as the densities of
these buffers are compatible with 38:62 oil and Buffers 5-7 are not) and this resulted in pink
pellets in the glycerol layer and the layers consistently did not invert.
15 % glycerol, 38:62 oil and 25 mM sucrose STE + 87.5 mM AB (Buffer 2) were se-
lected as the optimal combination for rat heart, based on density compatibility and WB
analysis (Figure 3.12). A digitonin trial in rat heart showed that above 200 µg/mL digi-
tonin the mitochondrial enrichment becomes reduced and cytosolic contamination increases
(Figure 3.13A). 100 µg/mL digitonin was chosen to match the concentration used for liver,
and because it showed a good enrichment of mitochondrial protein, based on the ratio
of PDH:GAPDH of mitochondrial pellet:cytosolic fraction (Figure 3.13B). The digitonin-
induced permeabilisation is known to differ between cell types (Olofsson et al., 2009), which
may explain why digitonin had a different effect compared to rat liver.
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Fig. 3.12 Mitochondrial isolation from rat heart using homogenisation buffers 2, 3 and 4. A rat
heart was homogenised in 5 mL of STE buffer. 1 mL aliquots were centrifuged at 1,000 x g for 1 min
and the supernatants were combined. The protein concentration of the supernatant was assessed as 6.9
mg/mL. 2 mg of supernatant (290 µL) was added to 410 µL of buffer 2, 3 or 4, ± 100 µg/mL digitonin.
This was layered on 300 µL of 38:62 DSMPS:DOP above 100 µL of 15% glycerol and centrifuged at
9,727 x g for 1 min. Left) Western blots. Middle) Coomassie stains of membranes. Marker: Protein
Plus Dual Color standard. Primary antibodies: anti-PDH mouse, 1 in 2,000; anti-GAPDH rabbit, 1
in 10,000; anti-Ndufb8 mouse, 1 in 2,000. Right) Band intensities normalised to RLM control. C:
Cytosolic fraction, M: Mitochondrial fraction. Controls - Snt: Supernatant of homogenate from a
standard rat liver mitochondria isolation; RLM: rat liver mitochondria isolated by a standard isolation
method.
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Fig. 3.13 Digitonin titration in rat heart. A rat heart was homogenised in 5 mL of 25 mM sucrose
STE + 87.5 mM AB. 1 mL aliquots were centrifuged at 1,000 x g for 1 min and the protein concentra-
tion of the pooled supernatants was 7.8 mg/mL. 2 mg of supernatant (256 µL) was added to a tube
with 0, 20, 50, 100, 200 or 400 µg/mL digitonin to a total of 700 µL. This was layered on 300 µL
DSMPS:DOP above 100 µL of 15% glycerol and centrifuged for 1 min at 9,727 x g. A) Western blots
and Coomassie stains of membranes. Marker: Protein Plus Dual Color standard. Primary antibodies
(anti-GAPDH rabbit, 1 in 10,000; anti-PDH mouse, 1 in 2,000; anti-Ndufb8 mouse, 1 in 2,000). C:
Cytosolic fraction, M: Mitochondrial fraction. B) Ratio of intensity of bands of PDH of mitochondrial
pellet:GAPDH of cytosolic fraction. Data is mean ±SD.
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3.6 Rapid isolation of mouse liver mitochondria
Minimal changes to the protocol optimised for rat liver were required to isolate mitochondria
from mouse liver. A female C57BL/6 mouse liver harvested at 6-8 weeks of age is approx-
imately 2-3 g (wet weight). As described in Section 3.4.11.2, 5 mL of buffer is a suitable
volume to homogenise 2 or 3 g of rat liver tissue to generate a homogenate supernatant such
that adding∼50 µL of the supernatant of homogenate loads∼2 mg of protein into the system.
In rat liver isolations ∼50 µL of this homogenate supernatant is made up to 700 µL with STE
buffer + 100 µg/mL digitonin. When repeated in mouse liver it was found that a larger and
more consistent mitochondrial pellet is obtained when 200 µL of homogenate supernatant is
made up to 700 µL with 150 mM sucrose STE + 25 mM AB.
The optimised protocol for mouse liver mitochondria isolation was to homogenise the whole
mouse liver in 5 mL of "Homogenisation" buffer (200 mM sucrose STE + 100 µg/mL
digitonin), centrifuge 1 mL portions at 1,000 x g for 1 min, take 200 µL of the supernatant
and mix with 500 µL of "Spin" buffer (150 mM sucrose STE + 25 mM AB) before layering
on 60:40 DSMPS:DOP and centrifuging for 1 min at 9,727 x g.
3.7 Rapid isolation of mouse heart mitochondria
Preliminary experiments to optimise rapid extraction of mitochondria from rat heart used
∼200 µL (2 mg protein) of supernatant of the homogenate. When attempted in mice,
this amount of supernatant did not yield mitochondrial pellets. Increasing the volume of
supernatant loaded resulted in inversion of the layers upon centrifugation due to the higher
proportion of heavier 200 mM sucrose STE used for homogenisation. Therefore, instead of
homogenising the heart in 200 mM sucrose STE and diluting in Buffer 2 (25 mM sucrose
STE + 87.5 mM AB), the heart was homogenised directly in 3 mL of Buffer 2 + 100
µg/mL digitonin and 650 µL of supernatant was layered undiluted above the oil phase. This
consistently resulted in mitochondrial pellets and stopped inversion of the layers. Unlike in
the liver extraction method no separate ‘Spin Buffer’ is used: the homogenisation buffer with
ammonium bicarbonate is used throughout the whole experiment. This method could also be
used for the extraction from liver but it is was decided to maximise the sucrose concentration
when possible, to maintain the mitochondria in an optimum state.
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Liver Heart
Homogenising volume 5 mL 3 mL
Homogenising buffer
200 mM sucrose STE
+ 100 µg/mL digitonin
25 mM sucrose STE
+ 87.5 mM AB + 100 µg/mL digitonin
Loaded on oil
100 µL supernatant
+ 600 µL Spin Buffer* 650 µL supernatant
Oil ratio
(DSMPS:DOP) 60:40 38:62
Lower layer
25% formic acid
or 23% glycerol
15% formic acid
or 15% glycerol
Table 3.7 Details of isolation protocols for mouse liver and heart. *Spin buffer: 150 mM sucrose
STE + 25 mM AB.
3.8 Discussion
The above experiments describe the approach to develop a rationally-designed method to
isolate mitochondria from tissue within 5 min of culling the animal, to optimise the analysis
of mitochondrial and whole cell metabolites by LC-MS. The method was optimised in rat
liver, rat heart, mouse liver and mouse heart. The details of the optimised protocols for
mouse liver and heart are displayed in Figure 3.14. The mitochondrial preps are suitable for
metabolic analysis by LC-MS.
The optimised conditions were to homogenise 2 g of rat liver in 5 mL of STE + 100 µg/mL
digitonin. 1 mL aliquots of the homogenate are centrifuged for 1 min at 1,000 x g at 4◦C, and
∼50 µL of supernatant are made up to 700 µL with 150 mM sucrose STE + 50 mM AB. This
is layered on 300 µL of 60:40 DSMPS:DOP above 100 µL 23 % glycerol. This is centrifuged
at 9,727 x g for 1 min.
As with all experiments involving animals, steps are required to be taken to minimise the
numbers of animals used where possible. Thus, optimisation decisions were made logically,
based on data and observations sometimes from individual experiments. However, the
robustness of these decisions was confirmed in sequential optimisation steps.
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Fig. 3.14 Mitochondrial isolation protocol from mouse liver and heart. A) A mouse liver is
removed and homogenised in 5 mL of "Homogenisation Buffer": 200 mM sucrose STE + 100 µg/mL
digitonin. 1 mL portions are centrifuged at 1,000 x g for 1 min, and 200 µL of the supernatant is
mixed with 500 µL of "Spin Buffer": 150 mM sucrose STE + 25 mM AB. 700 µL of this mixture
is layered on 300 µL of 60:40 DSMPS:DOP and centrifuged for 1 min at 9,727 x g. For LC-MS
analysis the lower layer is 23% FA, and for protein analysis 23% glycerol is used. B) A mouse heart
is removed and homogenised in 3 mL of 25 mM sucrose STE + 87.5 mM AB + 100 µg/mL digitonin.
1 mL portions are centrifuged at 1,000 x g for 1 min and 650 µL of supernatant is layered on 300 µL
of 38:62 DSMPS:DOP and centrifuged for 1 min at 9,727 x g. For LC-MS analysis the lower layer is
15% FA, and for protein analysis 15% glycerol is used.
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Fig. 3.15 Densities of the phases for mouse liver and heart mitochondrial isolations.
In developing and optimising the method I discovered there are certain points that are
necessary and important for the successful isolation of mitochondria. The system is extremely
sensitive to density, both within and between the phases. When designing the three different
layers the densities must fall within the narrow window of being sufficiently distinct to
prevent inversion and mixing, yet not too separate that the mitochondria cannot pass between
the phases. The densities of each phase in a liver and heart mitochondrial isolation are
displayed in Figure 3.15. Furthermore, thoroughly mixing all reagents (buffers, oil mixes,
acids and glycerol) immediately (< 2 min) prior to use is extremely important and appears to
be the main reason behind limited success with this method in the past. Despite there being
no visible interface between the phases, even in the DSMPS:DOP mixes, density gradients
are present.
The speed at which the whole procedure is performed is also important, particularly for
metabolomic analysis. The most crucial step to perform quickly is the removal of the organ
from the animal, to limit the time the organ is subjected to WI. With extensive practice I
am able to remove the heart within 20 s of culling the animal, and the liver within 30 s.
The rest of the procedure is also performed as quickly as possible by placing all equipment
(centrifuges, fume cupboards and tissue grinders etc.) close together and having assistance
from another person. This was found to reduce the total time by up to 2 min, which is
significant in the timeline of this experiment.
The addition of digitonin was beneficial to the purity and yield of the mitochondrial pellet.
Contrary to reports from Tischler et al. (1977) that the incubation needed for digitonin to act
was long enough to allow metabolite dismutation, digitonin was able to act in the time frame
of the isolation procedure.
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DOP was seen to be necessary for generating a mitochondrial pellet. It is unclear what the
mechanism of this is but is more complex than simply reducing the density as a less dense
silicone oil with no DOP did not generate a pellet.
It is interesting that heart mitochondria require a much less dense oil than liver mitochon-
dria (1.0158 g/mL for heart compared to 1.0336 g/mL for liver). This implies that heart
mitochondria are less dense than liver mitochondria. Table 3.8 lists the densities of various
biological components. It shows that DNA and RNA are twice as dense as water. Starch
granules, which are abundant in liver, have a high relative density of 1.5, whereas lipids
and fatty acids have a lower relative density of 0.85. The heart relies heavily on fatty acid
oxidation in the mitochondria for energy generation. Therefore, heart mitochondria contain a
higher amount of less dense fatty acids and lipids, leading to less dense mitochondria. In
contrast, liver mitochondria contain denser starch granules, increasing the overall density of
liver mitochondria. Furthermore, liver mitochondria are more metabolically active than heart
mitochondria and contain more enzymes and protein-rich electron transport chain complexes.
The next step for the development of the method was to analyse the purity and function of
the isolated mitochondria, and this is picked up in Chapter 4.
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Component Density (rel. to H2O)
DNA 2.0
RNA 2.0
Starch granules 1.5
Chromatin 1.4
Proteins 1.2-1.4
Mitochondria 1.05-1.2
Hepatocyte 1.05-1.15
Erythrocyte 1.1
Skeletal muscle 1.06
Fibroblast 1.03-1.05
Membrane
(including proteins) 1.02-1.18
Phospholipid
(+ cholesterol) 1.01
Adipocyte 0.92
Palmitic acid 0.85
Table 3.8 Densities of various biological components in cells. The densities of biological compo-
nents relative to the density of H2O are listed. Table adapted from CellBiology Numbers website
(Milo, Phillips, 2016).
Chapter 4
Analysis of rapidly isolated mouse liver
and heart mitochondria
4.1 Introduction and aims
Chapter 3 described the approach to develop and optimise a method to rapidly isolate
mitochondria from tissue and focused on the densities and solute molarity of the phases used.
The success of the method was assessed by the visualisation of a mitochondrial pellet in the
lower layer after centrifugation, facilitated by staining the pellet pink with TMRM, and also
by western blot analysis. This chapter describes the assessment of the quality and purity of
the mitochondria isolated by this method in more detailed ways, to ascertain whether the
isolated mitochondria obtained could indeed be used for metabolomic analysis.
How well the mitochondria are separated from cytosolic contaminants is an important
question to address for this project. If there is a lot of cytosolic contamination then it
will not be possible to distinguish whether any given metabolite analysed is localised to
the mitochondria, cytosol or both. The level of cytosolic and mitochondrial protein in the
mitochondrial pellet was assessed by western blot. The level of contamination of other
organelles in the mitochondrial pellet was also assessed by western blotting.
Intact mitochondria are more likely to retain their metabolites as they pass through the
oil into the acid layer than damaged mitochondria. To assess whether the rapidly isolated
mitochondria are intact, respiratory assays were performed using the Seahorse and Oroboros
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systems. The hypothesis here was that if the mitochondria are capable of coupled respiration
then this indicates that they are able to generate a membrane potential, which requires an
intact inner membrane. If respiration rates increase upon uncoupling with FCCP this is a
further indication that the mitochondrial membrane is intact. It could be that there are only
small holes in the membrane, which would allow small metabolites to leave the mitochondria.
However, protons are smaller than metabolites, so if protons are unable to pass through
the holes then metabolites will also be trapped. In addition, ATP and ADP were measured
in the mitochondrial pellet to determine whether the mitochondria are able to bring their
metabolites through the oil.
Different mitochondrial isolation techniques will give different yields of mitochondria.
Ideally, the yield will be high but a higher yield can often mean a compromise in purity.
Hence, a low yield of mitochondria would not necessarily render the rapid isolation procedure
obsolete, especially if it as a result of enhanced purity. Furthermore, LC-MS is a sensitive
technique that does not require a large amount of material. Therefore, the isolation procedure
only needs to generate a high enough amount of mitochondria for the LC-MS to detect
any low abundance metabolites and that is representative of the endogenous mitochondrial
population. Conversely, a low yield may mean that only a specific subset of more stable
mitochondria are obtained in the final mitochondrial pellet, which may distort the outcome.
Mitochondrial recovery was assessed by the proportion of citrate synthase activity in the
mitochondrial pellet compared to the activity in the fraction that was layered onto the oil.
As discussed in Section 3.1, mitochondria can be damaged by the isolation process or other
factors. This damage can result in the loss of membrane potential whilst maintaining intact
mitochondria or it may break the mitochondrial membranes. Whether damaged mitochondria
pass through the oil into the final mitochondrial pellet is not necessarily an indicator of the
success of the isolation procedure. However, it is important to establish if the pellet contains
damaged mitochondria, as this has implications for the interpretation and normalisation of
the MS results. Damaged mitochondria lose their membrane potential, leading to swelling
from the movement of water due to osmotic imbalances between the mitochondria and the
cytosol. This swelling can reduce the density of mitochondria, preventing them passing
through the oil and from being incorporated into the final mitochondrial pellet. Furthermore,
more extensive or prolonged damage can cause the mitochondria to burst. This generates
dense membrane fragments and clumps, which may also be able to pass through the oil. In
this case, the protein from these damaged mitochondria will be detected in the pellet, but
the metabolites will (probably) have been released into the top layer before centrifugation
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through the oil. To investigate this, mitochondria were damaged by the addition of the
pore-forming antibiotic alamethicin before centrifugation through oil. This is assuming that
damaged mitochondria will lose their metabolites before passing through the oil, but it could
be that they retain larger metabolites if only small holes are made in the membrane.
The digitonin will act mostly on the MOM, thus releasing any metabolites in the IMS.
However, as the MOM is permeable to small metabolites, these pools are likely to be very
similar to cytosolic pools and therefore of less interest for this project.
Metabolites are involved in metabolic reactions but can also act as signals. One way in
which they do this is by interacting with proteins. Metabolites are known to bind to enzymes,
either in the active site as substrates or cofactors, or allosterically to modify protein activity
(Chandel, 2015; Piazza et al., 2018). They can also bind non-enzymatic proteins such as
transporters, transmembrane receptors and transcription factors (Evans, 1988; Li et al., 2010;
Piazza et al., 2018). In order to incorporate these metabolites into the analysis, the LC-MS
extraction method will release any metabolites bound to protein (discussed in Section 5.1.2).
4.1.1 Aim
The aim of this Chapter was to assess whether the procedure was suitable for use with
metabolomic analysis. To do this, 4 main questions were addressed. 1) Are the mitochon-
dria sufficiently separated from the cytosol? - analysed by western blotting; 2) Are the
mitochondria intact? - analysed by Seahorse and Oroboros respirometry; 3) What is the
recovery of mitochondria in the extraction? - analysed by citrate synthase activity; and 4)
Do damaged mitochondria pass through the oil? - analysed by GSH and protein assays on
alamethicin-treated mitochondria. These questions are addressed in the following sections.
4.2 Are the mitochondria sufficiently separated from the
cytosol?
The overarching aim of this project was to elucidate the metabolic differences between the
mitochondria and the rest of the cell under various conditions in tissue. Therefore, it was
important that the method resulted in enrichment of mitochondria in the pellet whilst also
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purifying them away from the cytosol and other cellular organelles (discussed in Section
3.1).
4.2.1 Protein composition analysis of mitochondrial pellets
The separation of mitochondria and cytosol was assessed via WB. The level of cytosolic
contamination in the mitochondrial pellets was measured by probing for the abundant
cytosolic protein GAPDH. The extent of mitochondrial enrichment was assessed by probing
for the mitochondrial matrix protein PDH. Figure 4.1 shows that the level of mitochondrial
protein is greatly enriched in the rapidly isolated mitochondrial pellets, with largely reduced
levels of cytosolic protein. This indicates the mitochondria are removed from the cytosol by
the procedure.
4.2.2 Contamination from other organelles
Mouse liver and mouse heart mitochondria isolated by the rapid method were analysed by
WB to determine the purity of the mitochondria and the level of contamination from other
cellular organelles. Rat heart and liver mitochondria isolated by the conventional method
were included on the blot as a comparison of the two methods. Figure 4.2 shows that, in
general, the rapidly isolated mitochondria have qualitatively similar levels of other organelle
contamination compared to standard isolated mitochondria. An exception was that heart mi-
tochondria isolated by the standard method have less peroxisome contamination than rapidly
isolated heart mitochondria (no Pex14 band in control heart). Overall, liver mitochondria
have lower levels of contamination from other organelles than heart mitochondria.
4.2.3 Detection of mitochondrial and cytosolic metabolite pools
A preliminary LC-MS experiment in mouse heart was run to determine if distinct metabolite
pools could be detected from the different fractions collected during the isolation procedure.
The data shown in Figure 4.3 are non-normalised ion intensities for a range of metabolites
whose distribution in the cell is known. Although the intensities are not normalised, they
clearly show that distinct metabolite pools can be detected, and reflect what is known about
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Fig. 4.1 Protein composition of mitochondrial isolation fractions. The amount of mitochondrial
(PDH) and cytosolic (GAPDH) protein was assessed in fractions from rapid isolations of mouse heart
(A) and liver (B). Electrophoresed proteins were transferred using the semi-dry transfer method. Hom:
Homogenate of tissue; Snt: supernatant of tissue homogenate; Cyto: cytosolic fraction; Fast: rapidly
isolated mitochondria; Slow: control mitochondria isolated via the standard method.
the cellular distribution of these metabolite pools. For example, a higher aconitate signal is
detected in the mitochondrial fraction compared to all other fractions, whereas the lactate
signal in the mitochondrial fraction was lower than all other compartments. Importantly,
very little of the cytosolic metabolite fructose-6-phosphate was detected in the mitochondrial
fraction but was abundant in all other fractions. Succinate is known to be distributed
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Fig. 4.2 Western blot of cellular organelles in rapidly isolated mouse heart and liver mitochon-
dria. A) Liver mitochondria; B) Heart mitochondria. Proteins: IP3R (ER); GM130 (Golgi apparatus);
LAMP1 (Lysosome); Nucleus Lamin B1 (Nucleus) and Pex14 (Peroxisome). Electrophoresed proteins
were transferred using the wet transfer method. Controls: rat heart and liver mitochondria isolated by
the standard method.
across the cell, which is reflected in the broadly similar signals across all fractions. This
indicates that the isolation procedure is capable of separating different cellular metabolite
pools. Nevertheless, this data is preliminary and requires normalisation to make any further
inferences and to reduce variability.
4.3 What is the recovery of mitochondria?
The mitochondrial yield of an isolation procedure is an important measurement, but is
not the only indication of its success. Here, a balance must be found between recovery
of mitochondria and purity, as a high recovery is often at the expense of a lower purity
mitochondrial sample, and vice versa. The recovery of mitochondria can be measured in a
variety of ways. Chen et al. (2017) use the combined abundance of GSH and GSSG as a proxy
for mitochondrial yield. However, this does not take into account damaged mitochondria
which may lose their metabolites, and in Section 4.5 I explain why this is not appropriate
here. In addition, GSH is also found in the cytosol which makes the recovery hard to quantify.
Instead, I have calculated the mitochondrial recovery using the activity of the mitochondrial
citrate synthase enzyme.
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Fig. 4.3 Preliminary LC-MS signals of cellular metabolite pools in mouse heart. Mitochondria
were rapidly isolated from mouse hearts into 100 µL 15% formic acid and analysed by LC-MS. The
graphs show raw LC-MS signals of aconitate, succinate, fructose-6-phosphate and lactate in mouse
heart fractions from the ZIC-pHILIC column analysis. Data is mean ±SEM, n=6. H: Homogenate; S:
Supernatant; C: Cytosol; M: Mitochondria.
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4.3.1 Citrate synthase activity
Citrate synthase (CS) is a mitochondrial matrix enzyme and its activity is therefore a useful
and widely used measure of the amount of mitochondria in a sample (Kudin et al., 2004).
Here, the CS activity was measured in each fraction of mouse liver and heart mitochondrial
isolations to determine both the mitochondrial enrichment and recovery. Figure 4.4A
demonstrates that the highest amount of CS activity in a rapid liver mitochondria isolation
is in the mitochondrial fraction, at 220 µM TNB/min/µg protein, with very low activity
recorded in all other fractions. Based on this experiment, Table 4.1 shows that there is an
8.8-fold higher rate of CS activity in the liver mitochondrial pellet and a 86.0% recovery of
CS activity from the liver isolation. In comparison, although heart mitochondria did display
the highest CS activity of all fractions (Figure 4.4B), the CS activity was only increased by
1.2-fold (Table 4.1), whereas the CS activity recovery was 47.2%. These results are similar
to values obtained in this lab for rat heart mitochondria. These experiments also indicate the
mitochondria are not grossly damaged by passing through the oil or by other steps of the
extraction method, as the CS enzyme is still functional.
4.4 Are the mitochondria intact?
The CS assays in Section 4.3.1 demonstrate the mitochondrial enzyme CS is retained after
passing through the oil. However, they did not identify whether the mitochondrial inner
membrane is intact, as a low level of damage could lead to the loss of small metabolites whilst
retaining CS activity. The mitochondria could be damaged by the digitonin or by shearing
during homogenising and pipetting. To assess this, respiratory assays of the mitochondrial
pellet were performed.
4.4.1 Seahorse analysis of mitochondrial respiration
Measuring mitochondrial respiration and coupling would identify whether the mitochondria
are intact because complete, non-leaky membranes are required to generate a membrane
potential and drive coupled respiration. One method to assess this was if there was a
stimulation of OCR upon addition of FCCP. The Seahorse was chosen as a method to
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Liver
Volume
(mL)
CS Activity
(µM TNB/min/µg protein)
Total CS
(nmol TNB/min)
Homogenate 0.2* 0.025 1.57
Mitochondria 0.1 0.220 1.83
8.8-fold enrichment 86.0% recovery
Heart
Volume
(mL)
CS Activity
(µM TNB/min/µg protein)
Total CS
(nmol TNB/min)
Homogenate 0.65** 0.144 6.93
Mitochondria 0.1 0.177 3.27
1.2-fold enrichment 47.2% recovery
Table 4.1 Calculations of purity and recovery of CS activity in mouse liver and heart mitochon-
drial isolations. The purity of the mitochondrial pellet can be inferred from the enrichment of CS
activity, which is calculated by taking the CS activity (µM TNB/min/µg protein) of the mitochondrial
pellet as a fraction of the CS activity in the homogenate. The mitochondrial recovery is calculated
by taking the total CS activity (nmol TNB/min) of the mitochondrial pellets in 100 µL as a fraction
of the total CS activity in the 200 µL of liver homogenate or 650 µL of heart homogenate that was
used in the experiment. *0.2 mL: 200 µL of supernatant of liver homogenate was centrifuged through
the oil (diluted with 500 µL of buffer). **0.65 mL: 650 µL of supernatant of heart homogenate was
centrifuged through the oil.
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Fig. 4.4 CS activities and yields in mouse heart and liver mitochondrial isolations. A) CS activity
in mouse liver. Mitochondria were rapidly isolated from 4 mouse livers, as described in Section 2.2.2.2.
100 µL fractions of homogenate, supernatant and top were retained for analysis. The mitochondrial
pellet was obtained by removing the majority of the oil by pipette and then retrieving the pellet
by pipette. A BCA assay was performed on all fractions before dilution to 8 µg in 100 µL total
volume in 25 mM KPi buffer. The CS assay was performed as described in Section 2.5.3. B) CS
activity in mouse heart. Mitochondria were rapidly isolated from 3 mouse hearts, as described in
Section 2.2.2.3. C) Protein concentrations of liver fractions from (A); (D) protein concentrations of
heart fractions from (B). Mitochondria were diluted into 150 mM sucrose STE. Homogenate and
supernatant samples were diluted 1 in 50 and cytosolic and mitochondrial samples were diluted 1
in 10. Protein concentration was then assessed by the BCA assay. All data is mean ±SEM, n=4
for liver experiments, n=3 for heart experiments. H: Homogenate; S: Supernatant; C: Cytosol; M:
Mitochondria.
measure mitochondrial respiration due to its capability of measuring microgram quantities of
mitochondria in multiple conditions at the same time (Iuso et al., 2017; Rogers et al., 2011).
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Approximately 1/3 of a rat liver was used to isolate mitochondria via the standard method
(Section 2.2.1.1) as a control and the remaining 2/3 of the liver was used to isolate mitochon-
dria via the rapid method (Section 2.2.2) with the following adaptations. The supernatants
of the first spin were pooled and either 100 µL or 400 µL were made up to 700 µL with spin
buffer (5 of each condition). The total 700 µL was placed on 300 µL of 60:40 DSMPS:DOP
above 100 µL of either heavy seahorse assay buffer (HSAB: 700 mM sucrose, 220 mM
mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1 mM EGTA, 0.2 % (w/v) fatty
acid-free BSA, pH 7.2, density 1.049 g/mL, Section 2.5.1) or KHS buffer (120 mM KCl,
10 mM HEPES, 325 mM sucrose, density 1.044 g/mL). HSAB is a modified, more dense
version of the standard seahorse assay buffer (SAB), so that the buffer was dense enough to
form the lower layer underneath the oil. After centrifugation through oil, the mitochondria
from each condition were pooled and resuspended in SAB buffer for protein quantification,
as outlined in Section 2.5.1. The OCR traces are shown in Figure 4.5.
After optimising the conditions with rat liver mitochondria, the respiration of mouse liver
mitochondria was assessed using the Seahorse. The respiratory traces (Figure 4.6A) show
minimal differences between mouse liver mitochondria isolated by the rapid or standard
method and Figure 4.6B shows that both exhibit strong stimulation upon addition of FCCP.
Therefore, mitochondria rapidly isolated from mouse liver are intact and capable of coupled
respiration.
Attempts to analyse mouse heart mitochondria respiration using Seahorse respirometry
were unsuccessful. Mouse heart mitochondria isolated using the rapid method are hard to
resuspend (without further damaging them), possibly due to the lower sucrose concentration
of the heart isolation buffer. This makes quantification of mitochondrial protein more difficult
as it is not a homogenous mixture. This also means that each well of the Seahorse plate may
contain different amounts of mitochondria, leading to inconsistent readings. It could also be
that the mitochondria in this suspension do not attach to the Seahorse plate. To overcome
these issues, the respiration of mouse heart mitochondria was assessed using the Oroboros
system.
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Fig. 4.5 Seahorse analysis of respiration in rat liver isolated by different buffers. Control mito-
chondria were isolated via the standard method from 1/3 of a rat liver and the remaining 2/3 was
used to rapidy isolate mitochondria as described in Section 2.2.2 with the following adaptations. The
supernatants of the first spin were pooled and 100 µL or 400 µL were made up to 700 µL with spin
buffer (5 of each condition). The total 700 µL was placed on 300 µL of 60:40 DSMPS:DOP above
100 µL of either: 23 % glycerol, HSAB (700 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 5
mM MgCl2, 2 mM HEPES, 1 mM EGTA, 0.2 % (w/v) fatty acid-free BSA, pH 7.2, density 1.049
g/mL) or KHS buffer (120 mM KCl, 10 mM HEPES, 325 mM sucrose, density 1.044 g/mL). After
centrifugation through oil the mitochondria from each condition were pooled and resuspended in STE
for protein quantification, before resuspension in SAB buffer as outlined in (Section 2.5.1). OCR
traces for rat liver mitochondria isolated using SAB (A and B) or KHS buffer (C and D). A and C
contained 100 µL of supernatant and B and D contained 400 µL of supernatant. E) shows the OCR of
the time point immediately before FCCP addition and immediately after FCCP addition. Control was
rat liver mitochondria isolated via the standard method (Section 2.2.1.1) Succinate: 5mM; FCCP: 4
µM; Antimycin: 3 µM.
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Fig. 4.6 Seahorse analysis of respiration in mouse liver. A mouse liver was homogenised in 5 mL
of 200 mM sucrose STE + 100 µg/mL digitonin. 1 mL aliquots were centrifuged at 1,000 x g for
1 min. 100 µL of supernatant was mixed with 600 µL of spin buffer (150 mM sucrose STE + 25
mM AB) and layered on 300 µL of 60:40 DSMPS:DOP above 100 µL of HSAB (300 mM sucrose,
220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1 mM EGTA, 0.2 % (w/v) fatty
acid-free BSA, pH 7.2). This was centrifuged at 9,727 x g for 1 min. The top and oil layers were
removed and the mitochondrial pellet was gently resuspended in the HSAB. The protein content
was assessed as 9.7 mg/mL for the control (mitochondria isolated from a whole mouse liver by the
standard method on the same day as the rapid method) and 3.8 mg/mL for the rapid sample. The
control and rapid mitochondria were then diluted in SAB and run on the Seahorse as described in
Section 2.5.1. A) Respiratory trace (OCR) of control and rapidly isolated liver mitochondria. B) Ratio
of OCR immediately after:before addition of FCCP. Succinate: 5mM; FCCP: 4 µM; Antimycin: 3
µM.
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4.4.2 Oroboros analysis of mouse heart and liver mitochondrial respi-
ration
Mouse heart mitochondria were analysed by Oroboros respirometry, which overcame the
issues encountered when attempting to measure mouse heart mitochondrial respiration using
the Seahorse. The Seahorse relies on the mitochondria sticking to the bottom of the wells
because the oxygen probes are lowered to within ∼200 nm of the bottom of the well and
only measure the O2 concentration in that area. Therefore, any mitochondria that are above
the probes will not contribute to the O2 measurement. In contrast, the Oroboros measures
the O2 content of the whole chamber in which the mitochondria are kept in suspension, and
therefore does not require the mitochondria to adhere and gives more consistent readings.
The OCR responded to the addition of succinate, and increased ∼2-fold on addition of FCCP
(Figure 4.7B and C). Rat liver mitochondria were also analysed by the Oroboros (Figure
4.7A) and also showed good response to FCCP (Figure 4.7C). The above experiments
demonstrate that both mouse heart and liver mitochondria isolated by the rapid method have
intact membranes and are capable of coupled respiration. This indicates that the mitochondria
have retained their metabolites during their movement through the oil into the lower layer.
4.4.3 Adenine nucleotide retention by rapidly isolated mitochondria
The ATP and ADP levels were assayed in rapidly isolated mitochondria. In tissue, the assay
is often used to calculate the ATP/ADP ratio. This is an accurate readout of mitochondrial
energy status and function. A high ATP/ADP ratio (typically 5-10 in tissue and up to 20 in
cultured cells) is required for cells to perform essential energy-requiring processes (Hardie,
Hawley, 2001). Therefore, if cells perform more work than they can sustain they will deplete
their ATP/ADP ratio. However, rather than looking at energy metabolism, the ATP/ADP
assay was used on rapidly isolated mitochondria and cytosolic fractions to identify whether
the isolation was performed such that nucleotide exchange was limited. The total pools of
ATP and ADP were measured, as this gives an indication of the ability of the mitochondria to
retain metabolites.
The assays were performed in collaboration with Anja Gruszczyk at the MRC MBU. The ATP
and ADP assay had to be adapted and optimised for use with liquid samples (mitochondrial
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Fig. 4.7 Oroboros analysis of respiration. Mouse liver (A) and heart (B) mitochondria were isolated
via the rapid method as described in 2.2.2, except they were centrifuged into 100 µL HSAB before
dilution to 0.5 mg/mL mitochondrial protein in SAB and placed in the Oroboros chamber with 4
µg/mL rotenone before the addition of 1 mM succinate and 1 µM FCCP. The control liver trace is
from a whole mouse liver isolated by the standard method on the same day as the rapid method. C)
Oxygen consumption rate (OCR) before and after addition of FCCP. D) Fold increase of OCR after
addition of FCCP.
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pellet in FA), as it had previously only been used on solid tissue samples. For optimisation
experiments, rat heart mitochondria were rapidly isolated, spun into 4.2% PCA and made up
to 400 µL with Tris-acetate (TA) buffer (100 mM Tris, 2 mM Na2EDTA, 50 mM MgCl2, pH
7.75; Section 2.4.3). Homogenate, supernatant and cytosolic fractions were diluted 2:1 (2%
PCA final concentration) in TA buffer and ATP and ADP was assayed. Other concentrations
of PCA were also trialled for these fractions but 2% was shown to be optimal. Figure 4.8
shows the total pool of adenine nucleotides and the proportion of ATP and ADP in the pools.
The lower ATP/ADP ratio in the cytosol compared to the supernatant could reflect some
adenine nucleotide degradation during the isolation procedure, as the cytosolic fraction is
obtained after the supernatant fraction.
After establishing that the assay works on liquid samples in rat tissue, the retention of adenine
nucleotides was tested in rapidly isolated mouse heart mitochondria and cytosol (Figure
4.9). As expected, the cytosolic adenine nucleotide pool was larger than the mitochondrial
pool and had a high level of ADP, possibly suggesting that some breakdown has occurred.
The mitochondrial pool has a high proportion of ADP (approximately 2:1 ADP:ATP), which
is expected as this drives ATP synthase to make more ATP. On average, ∼1 mg of protein
is obtained in per rapid mitochondrial isolation. Therefore, approximately 3 nmol AMP +
ADP/mg protein was detected in the assay. This is comparable to the value of 5 nmol total
adenine nucleotides (including AMP)/mg protein reported by Geisbuhler et al. (1984). This
indicates that the rapidly isolated mitochondria are able to retain a sizeable proportion of
their adenine nucleotides.
4.5 Do damaged mitochondria pass through the oil?
After confirming that functional mitochondria pass through the oil, the next step was to
identify to what level (if at all) damaged mitochondria pass through the oil phase into the
lower layer along with healthy mitochondria. Damaged mitochondria lose their membrane
potential, rendering them unable to maintain their ion gradients and osmolarity. This can lead
to swelling and changes in density, preventing them passing through the oil. If the damage is
extensive then the mitochondria may burst, generating fragments of mitochondrial membrane.
As membranes are protein-dense, these fragments may be able to pass through the oil into the
lower layer. This has implications for the LC-MS analysis and the method of normalisation
of metabolite levels. Ideally, to normalise to protein the metabolites should be normalised
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Fig. 4.8 ATP and ADP analysis in rapidly isolated rat heart mitochondria and other fractions.
Absolute amounts of ATP and ADP in rat heart supernatant, cytosolic fraction and mitochondria.
Supernatant and cytosolic fractions were prepared by adding 133 µL to 267 µL of TA buffer (2:1) to
give a final concentration of 2% PCA. Mitochondrial fractions were prepared by centrifuging through
38:62 DSMPS:DOP oil into 4.2% PCA. ATP and ADP levels were assayed by the ATP and ADP
assay. Data is mean ±SEM, n=3 biological replicates.
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Fig. 4.9 ATP and ADP pools in rapidly isolated mouse heart cytosolic and mitochondrial
fractions. Mitochondria were rapidly isolated from mouse heart by centrifuging through 38:62
DSMPS:DOP oil into 4.2% PCA. Cytosolic fraction was prepared by adding 133 µL to 267 µL
of TA buffer. ATP and ADP levels were measured and extrapolated to calculate the total nmol of
adenine nucleotides in the original cytosolic (layered on oil) and mitochondrial fractions (in 100 µL
of mitochondria obtained after centrifugation). Data is mean ±SEM, n=3.
only to the amount of intact mitochondrial protein. However, if damaged mitochondria pass
through the oil the ratio of mitochondrial metabolites to mitochondrial protein would be
artificially decreased by the presence of mitochondrial membrane fragments. Figure 4.10
depicts the possible fates of damaged mitochondria in rapid isolations.
4.5.1 GSH quantification in rapidly isolated mitochondria
GSH was measured in rapidly isolated mitochondria to investigate whether they are able
to retain their metabolites during the rapid isolation procedure. It was decided to measure
GSH because it is an abundant metabolite with slow transport mechanisms (Booty et al.,
2015), with a robust, quantitative assay. GSH was detected at ∼2 mM in both mouse heart
and liver mitochondria (Figure 4.11). Although this is within the range of 1-5 mM reported
in the literature (Booty et al., 2015; Scarlett et al., 1996; Smith et al., 1996), it is towards
the lower end of the range and liver mitochondria are thought to have more GSH than heart
mitochondria. Unpublished work from this lab has reported GSH concentrations of 12 mM
in fed mouse liver tissue, which dropped to 5 mM in starved mouse liver tissue. Mouse heart
tissue GSH was calculated as 2 mM. These concentrations are higher than those obtained
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Fig. 4.10 Schematic of the possible fates of damaged mitochondria in rapid mitochondrial iso-
lations. A) Rapidly isolating intact mitochondria generates a mitochondrial pellet containing mito-
chondrial metabolites (Section 4.4). B) Damage to mitochondria can result in swollen mitochondria,
mitochondria with holes in their membrane (signified by red shapes) either losing some of their
metabolites or cause the mitochondria to burst, losing all their metabolites and forming mitochondrial
membrane fragments. It was not known how these damaged mitochondria would behave upon rapid
isolation or whether mitochondrial metabolites would be brought through the oil. To investigate,
mitochondrial damage was simulated by treatment with alamethicin. m: mitochondrial metabolite.
in Figure 4.11, suggesting that damaged mitochondrial protein (with no GSH) is able to
pass through the oil, along with the intact mitochondria which have retained their GSH. The
damaged mitochondrial protein then artificially decreases the calculated GSH concentration
due to the protein component of the volume correction (∼0.6 µL/mg mitochondrial protein
(Ross et al., 2006)).
4.5.2 Use of alamethicin to damage mitochondria
To investigate further, mitochondria were damaged by the addition of increasing amounts of
alamethicin (AlaM), a pore-forming antibiotic that permeabilises mitochondrial membranes
(Gostimskaya et al., 2003). After adding AlaM to the supernatant of the mouse liver ho-
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Fig. 4.11 Detection of GSH in mitochondrial pellets. Mouse heart and liver mitochondria were
isolated via the rapid method as described in Section 2.2.2. After resuspension in glycerol, 40 µL
of isolated mitochondria was added to 40 µL of 10% SSA, and GSH concentration was assessed by
the GSH recycling assay, as described in Section 2.4.2. A) GSH concentration displayed relative to
amount of protein in assay; B) GSH concentration displayed as mM. This was calculated based on the
approximate value of 0.6 µL/mg mitochondrial protein (Ross et al., 2006). n=3, data is mean ±SEM.
mogenate (see legend to Figure 4.12), the suspension was layered above 60:40 DSMPS:DOP
and centrifuged into 23% glycerol. Portions of the cytosolic fraction and mitochondrial
fraction were retained for GSH and protein quantification as described in the legend of
Figure 4.12. Figure 4.12 shows that within individual biological experiments there is poor
correlation between protein and GSH levels in the mitochondrial pellet. Figure 4.13 shows
that plotting µmol GSH against µg protein exhibits some correlation, but the correlation is
offset: even when there is no GSH detected (at 40 µg/mL AlaM, red dots in Figure 4.13)
there is protein in the pellet. This indicates that damaged mitochondria, which have lost their
metabolites, are able to pass through the oil. Therefore, normalising metabolites, such as
GSH, to protein concentration is not appropriate as there is no fixed ratio between metabolite
and protein levels.
The increase in both protein and GSH concentrations between 0 and 5-10 µg/mL AlaM was
unexpected. It may be that at low concentrations of AlaM the pores formed facilitate the
release of GSH for analysis, similar to the action of digitonin. The concentrations of protein
and GSH may then decline at higher AlaM concentrations as it becomes more damaging: by
forming more pores more GSH is released in the layer above the oil before centrifugation.
Similarly, the mitochondrial protein concentration decreases at higher AlaM concentrations
as more mitochondria are severely damaged and are not able to pass through the oil.
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Freeze-thaw was also trialled as a method to damage the mitochondria by placing the
supernatant of homogenate into a dry ice and ethanol bath followed by thawing in a 37◦C
heat block for up to 5 cycles. However, no differences were seen, which could have been due
to the sucrose in the buffer acting as a cryopreservant.
Fig. 4.12 Correlation of protein and GSH in mouse liver isolations. A mouse liver was ho-
mogenised as described in Section 2.2.2. After the first centrifugation step, 200 µL aliquots of the
supernatant were added to 500 µL of buffer with alamethicin to a final concentration of 0, 2, 5, 10, 20
or 40 µg/mL, with a total volume of 700 µL. Each concentration of alamethicin was run in duplicate.
The 700 µL was layered on 300 µL of 60:40 DSMPS:DOP and centrifuged into 100 µL of 23%
glycerol. 10 µL of the cytosolic fraction was removed and added to 90 µL of 5% SSA for analysis of
GSH concentration, 500 µL was retained for protein quantification, and the rest was removed, along
with the oil:DOP layer. The mitochondrial pellet was resuspended in the glycerol and 40 µL was
added to 40 µL of 10% SSA for analysis of GSH concentration, and the rest was retained for protein
quantification. The protein and GSH concentrations of the cytosolic and mitochondrial fractions was
assessed. Protein and GSH absolute amounts at increasing alamethicin concentrations for each mouse.
AlaM: alamethicin.
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Fig. 4.13 Correlation of protein and GSH in mouse liver isolations. A mouse liver was ho-
mogenised as described in Section 2.2.2. After the first centrifugation step, 200 µL aliquots of the
supernatant were added to 500 µL of buffer with alamethicin to a final concentration of 0, 2, 5, 10, 20
or 40 µg/mL, with a total volume of 700 µL. Each concentration of alamethicin was run in duplicate.
The 700 µL was layered on 300 µL of 60:40 DSMPS:DOP and centrifuged into 100 µL of 23%
glycerol. 10 µL of the cytosolic fraction was removed and added to 90 µL of 5% SSA for analysis of
GSH concentration, 500 µL was retained for protein quantification, and the rest was removed, along
with the oil:DOP layer. The mitochondrial pellet was resuspended in the glycerol and 40 µL was
added to 40 µL of 10% SSA for analysis of GSH concentration, and the rest was retained for protein
quantification. The protein and GSH concentrations of the cytosolic and mitochondrial fractions was
assessed. Correlation between GSH and protein levels in the mitochondrial pellet, colour coded by
alamethicin concentration. AlaM: alamethicin.
4.6 Discussion
The WBs in Section 4.2 show that the mitochondria are well separated from the cytosol
and that there is a comparable level of organelle contaminants to a standard mitochondrial
prep. The preliminary LC-MS graphs in Figure 4.3 show that the procedure is capable of
distinguishing mitochondrial and cytosolic pools, and excludes cytosolic metabolites such as
the glycolytic intermediate fructose-6-phosphate from the mitochondrial metabolite pools.
Thus, the mitochondria are successfully separated from the cytosol by the procedure.
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The purity of the mitochondrial pellet was further examined using the enrichment of CS
activity in the mitochondrial pellet. Table 4.1 shows that CS activity is enriched by∼8.8-fold
and ∼1.2-fold in liver and heart mitochondria respectively. The recovery of mitochondria
from this procedure is 86.0% from liver and 47.2% from heart. For metabolomic analysis
speed is paramount, so to reduce the processing time not all of the tissue homogenate is
used. For example, 5 mL of tissue homogenate is produced during a liver mitochondria
isolation: 1 mL of this centrifuged slowly and of this, only 200 µL of supernatant (liver)
and 650 µL (heart) per isolation is centrifuged through the oil (with 4 isolations performed
per mouse for LC-MS samples). This is to reduce the time of the isolation procedure as it
would take more time to layer the supernatant on the oil for more than 4 separate isolations
and to pool all of the mitochondrial pellets after the final centrifugation. Using all of the
tissue homogenate would easily increase the absolute amount of mitochondria obtained,
and the overall yield from the tissue, but would require the assistance of another person
and additional centrifuges to maintain the speed required for the isolation. If the isolated
mitochondria are to be used for an application that is not dependent on the speed of the
isolation then the amount of mitochondria obtained could be increased easily. Alternatively,
the procedure could be modified to be performed in a larger tube, so that more supernatant
could be centrifuged through the oil at once, but this would require a longer centrifugation
time and possibly further optimisation.
The mitochondrial respiration assays demonstrate that the mitochondrial membranes remain
intact during the isolation process. This means that any matrix metabolites will be brought
through the oil into the lower layer, and can therefore be analysed by LC-MS. The preliminary
LC-MS data displayed in Figure 3.6 also confirmed that a range of metabolites can be
detected in the isolated mitochondria.
The experiments with alamethicin to damage the mitochondria strongly indicate that mi-
tochondrial protein can be detected in the lower layer even when no metabolites can be
detected. This demonstrates that damaged mitochondria are able to pass through the oil,
either as semi-intact mitochondria with many holes that have lost all matrix metabolites, or
as fragments of mitochondrial protein, formed when extensively damaged mitochondria have
burst or been sheared. Regardless of the form in which the mitochondrial protein passes into
the lower layer, these experiments show that there is no correlation between mitochondrial
metabolites and mitochondrial protein. Therefore, the metabolites cannot be quantified by
normalisation to protein. A caveat to consider here is that the use of alamethicin is inducing
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artificial damage and may not truly mimic the damage that may occur during the isolation
process.
Overall, the above experiments highlight that a proportion of the mitochondria remain
intact during the rapid isolation procedure and are suitable for their intended application of
metabolomic analysis by LC-MS. They also indicate that the method is adaptable and the
mitochondria can be used in different applications.
Chapter 5
Optimisation of LC-MS analysis of
rapidly isolated mitochondria
5.1 Introduction
Chapter 4 described the testing and confirmation of the rapid mitochondrial isolation proce-
dure, which is to be coupled with an LC-MS analysis. In this chapter, the development and
optimisation of the LC-MS protocol and analysis is described. Below I outline important
factors that I considered when designing the metabolomic approach and cover the main
aspects involved: the extraction method, LC columns used, the normalisation technique and
the caveats to consider. I then present results of the optimisation of these factors. Next, I
investigate whether the use of transport and respiratory inhibitors are necessary to quench
metabolism, or whether performing the isolation procedure quickly and at low temperature is
sufficient.
5.1.1 Metabolite analysis by LC-MS
To analyse metabolites, this project used LC-MS for a range of reasons: it has very high
sensitivity (limit of detection of 0.5 nM compared to 0.5 µM for GC-MS); requires only small
sample volumes (10 - 100 µL); can detect a wide range of organic molecules (Lu et al., 2017)
and can analyse complex mixtures (Mackay et al., 2015). Compared to NMR, separation on
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the LC column provides an extra parameter for distinguishing metabolites: metabolites are
retained on the column for different amounts of time (based on their chemical characteristics,
such as hydrophobicity and charge), meaning they enter the MS at different times. However,
using LC has limitations, as it cannot detect all metabolites and is not ideal for the detection
of lipids. Therefore, it was decided to focus on the detection of polar metabolites such as
TCA cycle intermediates, amino acids and nucleotide breakdown products, as previous work
from this lab (Chouchani et al., 2014; Martin et al., 2019) has suggested that these are the
most important and relevant for studying mitochondrial metabolism during IRI. Furthermore,
the use of positive/negative polarity switching allows the detection of a range of metabolite
classes to be analysed in a single run (Mackay et al., 2015).
This project employed hydrophilic interaction liquid chromatography (HILIC). In this chro-
matographic method, only water-miscible solvents are used and small polar metabolites are
separated on polar stationary phases and eluted using a gradient of increasing water content
(Buszewski, Noga, 2012; Lu et al., 2017). In HILIC, water is the strongest solvent, which
eliminates the issue of low aqueous solubility and increases MS sensitivity (Guo, Gaiki,
2005). The zwitterionic ZIC-HILIC and ZIC-pHILIC columns were used, which are both
packed with a stationary phase with a zwitterionic sulfobetaine group. This sulfobetaine
group is covalently bonded to porous silica in the ZIC-HILIC column, and to porous polymer
beads in the ZIC-pHILIC column (Lu et al., 2017; Mackay et al., 2015). The permanent
zwitterion enhances the retention of polar metabolites to the column. Due to the nature of
the polymeric beads, the ZIC-pHILIC column is used at a high pH (pH 9.2, maximum pH
10), whereas the ZIC-HILIC column is used at a much lower pH (pH 2.8, maximum pH 8).
The mobile phase used for the ZIC-pHILIC column was A) (aqueous) 20 mM ammonium
carbonate and 0.05% ammonium hydroxide and B) (organic) 100% acetonitrile and for
the ZIC-HILIC column was A) 0.01% formic acid in H2O and B) 0.01% formic acid in
acetonitrile. The gradients used for separation are shown in Figure 5.1. The LC-MS
metabolomic analysis conditions chosen for this project have been used in many projects
(Chouchani et al., 2014; Mills et al., 2016; Tannahill et al., 2013).
The ZIC-pHILIC column has the broadest coverage of metabolites, and performs better in
terms of least variability in retention time and peak areas, as well as peak shape (Zhang,
2012). In particular, amino acids, nucleosides, phosphates, organic acids and sugars perform
better on the ZIC-pHILIC column. This is because organic acids and phosphates ionise better
in negative ion mode on the MS and as the high pH of the ZIC-pHILIC column is above
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Fig. 5.1 Mobile phase gradients for HILIC columns. A) Mobile phase gradient for ZIC-pHILIC
column. B (green): 20 mM ammonium carbonate and 0.05% ammonium hydroxide; C (blue):
Acetonitrile. B) Mobile phase gradient for ZIC-HILIC column. A (yellow): 0.01% formic acid in
water; B (green): 0.01% formic acid in acetonitrile.
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Fig. 5.2 Succinate LC-MS analysis using the ZIC-HILIC column. A) Chromatogram of peaks
with mass:charge ratios (m/z) of 117.01874-117.01992 (m/z of succinate). A peak is seen at retention
time (RT) 6.67 min, which is the retention time of succinate on the ZIC-HILIC column. B) Mass
spectra of peaks with RT of 6.67 min. The main ion for succinate is at m/z 117.02 (circled in red).
The chromatogram and mass spectra are from a 200 µM succinate standard.
the pKa of these acids and phosphates, negative ions are more easily generated. More basic
amino acids and amines perform better on the lower pH of the ZIC-HILIC column (Zhang,
2012). The ZIC-HILIC column is also better for cysteine, cystine, GSH and succinate.
Cysteine and GSH are less reactive at the lower pH of the ZIC-HILIC column due to their
free thiol groups (Mackay et al., 2015). Fumarate is a difficult metabolite to quantify, as
although the peak shape is better on the ZIC-pHILIC column, the high pH of the mobile
phase can cause ∼10% of malate to be converted to fumarate (Zhang, 2012), artificially
elevating the fumarate signal and depressing the malate signal. To ensure that conversion
from malate is not artificially elevating the fumarate signal, the normalised ion intensities
for fumarate from both columns are presented to check that they show the same trend. The
chromatogram and mass spectrum from a succinate standard are shown in Figure 5.2.
This project used the Thermo Q Exactive mass spectrometer with Orbitrap technology, which
is a high-resolution mass analyser (>100,000) with accurate mass analysis (<2 ppm) (Mackay
et al., 2015). The mass spectrometer was operated in full MS and polarity switching mode, to
improve the overall ionisation response for the full range of metabolites to be analysed: amino
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acids have a better response in positive ion mode, whereas organic acids and phosphates
ionise better in negative ion mode (Mackay et al., 2015). The following sections describe the
relevant factors to consider when designing an LC-MS metabolomics experiment.
5.1.2 Metabolite quenching and extraction
Quenching of further metabolism is an important step in any metabolomic study and aims to
generate a stable sample that contains an accurate representation of the metabolites in the
cell or tissue that is being studied (Dettmer et al., 2007; Jang et al., 2018). Quenching is
one of the most crucial steps of a metabolomic analysis to perform correctly, as inefficient
quenching can lead to artefactual levels of metabolites and incorrect conclusions. The main
challenges are to not perturb metabolite levels and to terminate enzyme activity fast. This can
be very difficult in practice as enzymes that have ATP and glucose-6-phosphate as substrates
can have extremely high turnover numbers (Lu et al., 2017; Matuszczyk et al., 2015). To
successfully quench enzymatic activity, organic solvent, cold, heat, acid or base can be used,
alone or in combination (Lu et al., 2017; Zhou et al., 2012). When measuring whole tissue,
the tissue sample is rapidly frozen using Wollenberger clamps pre-cooled in liquid nitrogen
to increase heat transfer. When working with cells, organic solvent is added directly to
the tissue culture plate. Boiling ethanol is another approach and denatures enzymes, but
is problematic due to the increased risk of thermal degradation of metabolites. The use of
an acidic solvent, such as formic acid or PCA, is a common extraction method to stabilise
metabolites and to precipitate protein (Lu et al., 2017).
Once the metabolic activity has been quenched, the metabolites are extracted. The extraction
step aims to generate a sample with the representative amounts of metabolites as well as
releasing metabolites bound to protein, such as NADP+(Dettmer et al., 2007). Degradation
products can be formed if the extraction is performed slowly or not at low enough temper-
atures, such as adenosine formation from AMP breakdown. Organic solvent mixtures are
commonly used as extractants, such as 40:40:20 acetonitrile:methanol:water with 0.1 M
formic acid (Lu et al., 2017). The solvent mixture used must often be adapted for the specific
metabolites of interest, as no single solvent is efficient at extracting all metabolites. For tissue
experiments the frozen tissue can be ground to a powder before addition of the extractant, or
can be lysed directly in the extractant.
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For extractions using acid, the sample is often neutralised after extraction because some
metabolites are prone to acid-catalysed degradation. However, this is not the case for all
metabolites and many metabolites are more stable in acidic conditions than basic or neutral
conditions, due to the base lability of esters and thioesters. Therefore, to achieve stability for
the majority of metabolites, this project used formic acid for quenching and extraction. The
volatile formic acid was then evaporated and the dried metabolites were resuspended in water
before storage at -80◦C (Section 5.3.2). After removing the formic acid, the samples retained
an acidic pH and were not neutralised as the acidic matrix was thought to be beneficial for
stabilising the metabolites during storage. Water-soluble and insoluble metabolites require
different solvents for optimal extraction. Therefore, water-insoluble metabolites, such as
lipids, will be under-represented in this project due to the single extraction approach. A
further consideration for extraction is that redox-active metabolites, such as NADPH and
GSH, can be oxidised during the drying step (discussed in Section 5.3.2).
5.1.3 Missing value imputation
In large metabolomic datasets, there are often missing values. These can occur for a number
of reasons, such as the metabolite is present but at a concentration less than the limit of
detection of the method, or because the data processing software did not detect and report
the metabolite (Di Guida et al., 2016). It is important to understand the reason behind the
missing values, which can be grouped into 3 categories: missing completely at random
(MCAR); missing at random (MAR); and missing not at random (MNAR). MCAR occurs
when the missing value is not related to any variable or response, MAR is related to one or
more variables and MNAR refers to when the missing value is related to the response itself
(Di Guida et al., 2016). As such, missing values can be due to biological or technical causes.
In order to correct for these values, missing value imputation (MVI) is often applied. This
aims to logically replace the missing values with a non-zero value, which will maintain the
data structure and allows statistical analyses to be performed (Di Guida et al., 2016). There
are several MVI methods, including small value replacement (SV), mean replacement (MN)
and median replacement (MD). This project used the SV method, and assigned the smallest
detected value of 0.0002% of taurine signal to the missing values.
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5.1.4 Normalisation
Ion intensities alone are not sufficient to quantify metabolites, because different metabolites
ionise with different efficiencies. This means that the same ion intensity for two different
metabolites could represent millimolar and nanomolar concentrations. Furthermore, there is
significant variation between different MS runs and detector responses, even on the same
machine. Therefore, to quantify metabolites either quantified standards must be added
(enabling absolute quantification) or the ion intensities must be normalised to an independent
factor, such as protein or another metabolite (termed relative quantification). Absolute values
for metabolites can be acquired by comparing the MS signals to internal standards, such as
13C-labelled or deuterated standards, which are added externally to the sample. This must
be done before the extraction step to account for losses during the extraction and matrix
effects, which occur when the matrix (e.g. the tissue) that is co-extracted with the metabolites
interfere with the signal response (Cappiello et al., 2008). Internal standards are not available
for all metabolites. As this project aimed to study a very wide range of metabolites and
to explore differences between cytosolic and mitochondrial pools, a relative quantification
strategy was chosen.
5.2 Aims and Strategy
The first aim of this section was to identify the LC-MS conditions that would yield accurate
metabolomic data, such that comparisons and deductions could be drawn on mitochondrial
and cytosolic metabolism in tissues. The second aim was to identify if the procedure
is performed sufficiently quickly or whether transport inhibitors are required to prevent
metabolite distribution. The strategy employed to optimise the sample preparation, LC-
MS analysis protocol and the normalisation method was to focus on a selected group of
specific metabolites to assess how well the procedure was working. These metabolites were
taurine, GSH and succinate. All of these metabolites are abundant and are either relevant for
normalisation purposes (taurine), susceptible to oxidation and are thus an insightful readout on
the speed of the method (GSH and succinate) or relevant to the goal of studying mitochondrial
metabolism (succinate). Other metabolites were also studied further, depending on the
preliminary experimental aim. To address the second aim, the metabolite transport inhibitors
pyridoxal phosphate (PRP), N-ethylmaleimide (NEM), butylmalonate (BTM) and respiratory
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inhibitors oligomycin and carboxyatractyloside (CATR) were added to the homogenisation
buffer of mouse heart and liver and the metabolites were measured by LC-MS, or via the
ATP and ADP assay for oligomycin and CATR.
5.3 Metabolomic analysis
5.3.1 Sample analysis & data normalisation
Often, in metabolomic LC-MS analysis, either a standard curve of metabolites is run to
enable metabolite quantification or the data is normalised to protein concentration. Using the
rapid isolation procedure means it is not possible to normalise to protein because the amount
of mitochondria that pass through the oil is variable, and damaged mitochondria (which may
have lost their metabolites) also pass through the oil (described in Section 4.5). Therefore,
the metabolites must be normalised to a parameter that will behave in the same way to
them, i.e. another metabolite. This metabolite should be relatively metabolically inactive;
abundant for ease of LC-MS measurement; have similar concentrations in the mitochondria
and the cytosol and/or have a slow transport system between these compartments. Metabolite
candidates that fit this description include GSH and taurine. These metabolites should also
remain stable during conditions such as ischaemia, thus enabling changes in other metabolites
to be attributed to ischaemia alone.
GSH is an important antioxidant in mitochondria, but is synthesised in the cytosol, leading to
both mitochondrial and cytosolic pools of GSH. Therefore, to enter the mitochondria there
must be a transport system. The OGC and DIC were thought to transport GSH, but this
has been disproved and the identity of the GSH transporter remains unknown (Booty et al.,
2015). Previous work in this lab has calculated the mitochondrial GSH concentration is in
the range of 1-5 mM (Booty et al., 2019), which is abundant enough to be easily measured
by LC-MS under most conditions. 95-99% of the glutathione pool is in the reduced GSH
form (Booty et al., 2015), with the rest as glutathione disulphide (GSSG). The cytosolic GSH
concentration is thought to be similar to the mitochondrial concentration, between 1-10 mM
(Mari et al., 2009; Ribas et al., 2014; Smith et al., 1996). However, normalising to GSH gave
inconsistent results, possibly due to oxidation to GSSG and therefore it was not used here.
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Fig. 5.3 The structure of taurine. Taurine is a sulphur-containing amino acid.
Taurine is an appealing candidate for normalisation, even though the metabolic role of
taurine is not well established. Taurine is a sulphur-containing amino acid (Figure 5.3)
which is known to be present in mammalian cells at high concentrations, up to 20-50 mM
in leukocytes (Schuller-Levis, Park, 2003) and in heart tissue it has been reported at levels
of 6.5 mmol/kg wet weight in human and 33.9 mmol/kg wet weight in mouse (Chapman
et al., 1993). Its zwitterionic nature prevents it crossing lipid membranes and necessitates its
specific transporter (TauT) to cross the PM (Lambert, 2004; Ripps, Shen, 2012; Warskulat
et al., 2004). Taurine is known to be present at high concentrations inside the mitochondria,
despite the fact that the mitochondrial taurine transporter has not been identified yet (Hansen
et al., 2010). It is an important osmolyte (Lambert, 2004) and antioxidant (Jong et al., 2012),
with a role in oxidative tissues (Hansen et al., 2010).
Succinate is known to be distributed across the cell in both the mitochondria and the cytosol,
and to be transported out of the mitochondria via the DIC (Murphy, O’Neill, 2018), (Section
1.5.2.4). It is thought to act as an electron sink during ischaemia (Chouchani et al., 2014).
It is known to have a role in the HIF-1α pathway by inhibiting PHD activity, stabilising
and activating HIF-1α (Tannahill et al., 2013). It has also been implicated in inflammation
(Mills, O’Neill, 2014). Studies into the behaviour of succinate would aid understanding of
its involvement in these areas.
Figure 5.4 displays the raw ion intensities of taurine in the heart and liver, from both column
analyses. It shows that in the heart, the taurine signal is significantly lower in the normoxic
and ischaemic mitochondrial fractions than the other fractions. As taurine is relatively
stable, this implies that there was less sample loaded onto the MS for these samples, further
emphasising the need for normalisation. In the liver, this difference is less pronounced.
To ensure that any trends that were inferred from this normalisation were not merely due to
changes in the taurine pool, the raw ion intensities of the metabolites were also analysed. As
an example, the raw and normalised signals of succinate (ZIC-HILIC column) and malate
(ZIC-pHILIC column) from the heart and liver are displayed in Figures 5.5 and 5.6. In
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Fig. 5.4 Ion intensities of taurine from both column analyses in heart and liver. The ion intensi-
ties of taurine from heart (top) and liver (bottom) datasets in all fractions. For heart, data is average
of 6 biological replicates, displayed as mean ±SEM and for liver, data is average of 3 biological
replicates, displayed as mean ±SEM. The statistical differences between the fractions were analysed
by a two-way ANOVA. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction; WI: Warm ischaemia.
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Fig. 5.5 Comparison of raw and taurine-normalised ion intensities in heart. The raw and taurine-
normalised ion intensity of a metabolite from each column was compared to ensure normalisation
to taurine does not alter the trend. Data is average of 6 biological replicates, presented as mean
±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction; WI: Warm
ischaemia.
applying these analytical approaches, I had to be very cautious about interpretation because
if a metabolite has a higher ion intensity than taurine or another metabolite, it does not
necessarily mean that it is present at a higher concentration, but may merely indicate that it
ionises or is detected by the MS more efficiently than the other metabolite. Taurine levels
may be different between the heart and the liver. This means that to make comparisons
between these tissues only the trends, and not the percentage of the taurine signal, can be
compared.
Both the ZIC-HILIC and ZIC-pHILIC columns were used to increase the range of metabolite
classes that could be analysed (discussed in Section 5.1.1). Initial work was performed by
normalising metabolites from either the ZIC-pHILIC or ZIC-HILIC column to taurine on
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Fig. 5.6 Comparison of raw and taurine-normalised ion intensities in liver. The raw and taurine-
normalised ion intensity of a metabolite from each column was compared to ensure normalisation
to taurine does not alter the trend. Data is average of 3 biological replicates, presented as mean
±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction; WI: Warm
ischaemia.
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one column only. To investigate if this was appropriate, the raw ion intensities from the ZIC-
HILIC column were plotted against the raw ion intensities from the ZIC-pHILIC column for
GSH, taurine, succinate, glutamate and lactate. Glutamate was included in the select group
of metabolites due to its abundance and involvement in mitochondrial metabolism (Frigerio
et al., 2008). Lactate was informative as it accumulates during hypoxia and ischaemia and
so was an indicator of the speed of the extraction, and should not accumulate to high levels
inside the mitochondria (Chen et al., 2016a). However, Figure 5.7 shows there is limited
correlation between ion intensities between the ZIC-pHILIC and ZIC-HILIC columns. Some
metabolites exhibited a strong correlation between the columns, e.g. lactate had an r2 value
of 0.9542 and the r2 value for succinate was 0.9126. However, other metabolites showed very
poor correlation, such as GSH (r2 = 0.1854). This poor correlation means normalising across
the columns is not appropriate. Instead, metabolites should be normalised to a metabolite
from the same column. The ZIC-pHILIC column demonstrated the most consistent data and
covers a broad range of metabolites, so the majority of metabolites were analysed using data
from the ZIC-pHILIC column only. There are two main differences between the columns:
the mobile phase pH and the internal diameter of the column. The mobile phase for the
ZIC-pHILIC column was pH 9.5, whereas the ZIC-HILIC column mobile phase was only
pH 2.6. It may be that some precipitation occurs at the extreme pH level of the ZIC-HILIC
which interferes with the detection of certain metabolites. The internal diameter of the
ZIC-HILIC is 4.6 mm, whereas the ZIC-pHILIC is 2.1 mm. The larger diameter results in
more sample dispersion which is not good for low abundance compounds, which could be
why the ZIC-pHILIC produced better signals overall. Therefore, the majority of metabolites
were analysed from the ZIC-pHILIC column, with the exception of individual metabolites of
importance that performed better on the ZIC-HILIC column, such as succinate.
5.3.2 Optimisation of LC-MS sample preparation
LC-MS experiments were performed in collaboration with Ana S. H. Costa and Efterpi
Nikitopolou (MRC Cancer Unit, University of Cambridge). Preliminary mitochondrial
samples for LC-MS were prepared by centrifuging the mitochondria through oil into formic
acid (23% for liver and 15% for heart), removing the oil and briefly centrifuging the resulting
formic acid extract (1 min, 10,000 x g, 4◦C) to remove particulates. Similarly, homogenate,
supernatant and cytosolic samples were prepared by placing 10 µL of each fraction into 100
µL of formic acid (23% for liver and 15% for heart) and centrifuging. These samples had
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Fig. 5.7 Correlation of ion intensities between ZIC-pHILIC and ZIC-HILIC columns. Raw ion
intensities (AU) for GSH, taurine, glutamate, lactate and succinate across all 4 fractions of 6 mouse
liver mitochondria isolations from the ZIC-HILIC column were plotted against raw ion intensities for
the ZIC-pHILIC column. Lines of 95% confidence intervals are shown, n= 6 biological replicates.
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different retention times to the standards run in parallel, as well as variable and low MS
signals for many metabolites. This made analysis and quantification difficult and produced
variable results. It was hypothesised that the different retention times could have been due to
differences in pH, caused by the formic acid in the samples. The experiment was repeated
and the formic acid was evaporated from the samples under vacuum (4 hours, ∼40◦C) before
resuspension in 75 µL ultrapure H2O to increase the pH. This resolved the retention times of
the metabolites to match the standards, but low metabolite yields and MS signals remained
an issue.
It was hypothesised that using a different extraction approach may increase metabolite yields
and MS signals. To investigate, a rapid mouse liver isolation was performed, with 4 isolation
experiments run per mouse. Of these 4 isolations, 2 of them had their mitochondrial fractions
pooled prior to the drying step, and after evaporation of the formic acid they were resuspended
in 75 µL ultrapure H2O. The remaining 2 isolations were not pooled, and after evaporation
of the formic acid 1 was resuspended in 75 µL ultrapure H2O and the other was resuspended
in 75 µL MS extraction solution (50 % methanol, 30 % acetonitrile, 20 % ultrapure H2O, 100
ng/mL HEPES). This is a commonly used extraction solution, in which HEPES is added
as an internal standard and was used by this lab in Chouchani et al. (2014). Figure 5.8
shows unexpectedly that using the MS extraction solution does not seem beneficial and for
some metabolites it reduces the signal, particularly in mitochondrial samples. Therefore, all
subsequent samples were resuspended in water after evaporation of the formic acid. Although
this experiment was performed on only 1 biological replicate, pooling the mitochondrial
samples increased the signal for taurine and glutamate (Figure 5.8) and other metabolites,
so subsequently 4 mitochondrial isolations per mouse were run in parallel and pooled to
increase the signal for mitochondrial metabolites. 4 isolations was chosen because it was
the maximum amount of isolations that could be run in parallel without impacting too much
on the speed of the procedure. Accordingly, the amount of homogenate and supernatant
signal was increased by adding 40 µL of homogenate or supernatant to 400 µL of formic acid,
before vortexing and drying, then resuspending in 75 µL of H2O. The samples were kept in
agitation for 10 min at 4◦C to aid metabolite resuspension, before a 1 min centrifugation at
17,000 x g to remove any remaining particulates. The supernatants were transferred to MS
vials and stored at -80◦C until analysis by LC-MS.
When evaporating the formic acid, a balance must be obtained between time and temper-
ature, especially considering that the vacuum concentrator is not a perfect vacuum and so
some oxygen is present. A higher temperature means the sample will dry quicker and be
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Fig. 5.8 Use of MS extraction solution to resuspend dried metabolites. Mitochondria were rapidly
isolated from mouse liver. 10 µL of homogenate and homogenate supernatant were placed in 100 µL of
25 % formic acid. All fractions were centrifuged at maximum speed for 10 min before the supernatant
was removed and dried under vacuum. For the pooled mitochondrial sample 2 mitochondrial samples
were pooled before the drying step. Dried samples were either resuspended in 75 µL of H2O or 75 µL
of MS extraction solution (50% methanol, 30% acetonitrile, 20% ultrapure water, 100 ng/mL HEPES)
and sent for MS analysis. Samples extracted with MS extraction solution were centrifuged for 10
min at full speed before incubation at -20◦C for 1 hour. The pooled mitochondria were resuspended
in 75 µL H2O. All samples were kept in agitation for 15 min at 4◦C then centrifuged for 10 min to
remove debris. The supernatants were transferred to MS vials and analysed by LC-MS. n=1 biological
replicate.
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exposed to oxygen for a shorter period but the higher temperature makes it more likely for
reactions to occur within the sample, especially as they become more concentrated. Using a
lower temperature would reduce the rate of reaction but would increase the time it takes to
evaporate and therefore time exposed to oxygen. Drying the metabolites for 4 hours, with
the temperature capped at 40◦C, was found to dry the metabolites completely without excess
metabolic activity (confirmed by the lack of adenine nucleotide breakdown products such as
xanthine and hypoxanthine).
5.3.3 Optimised sample preparation and analysis protocol
Based on the above experiments the isolation procedure was adapted so that 4 isolation
experiments were run in parallel per mouse. The optimised protocol for LC-MS sample
preparation is shown in Figure 5.9. Mitochondria were centrifuged into 100 µL of 25%
(liver) or 15% (heart) formic acid, to quench and extract the metabolites. To match the
mitochondrial volume, 40 µL of homogenate, supernatant and cytosolic fractions were added
to 400 µL of 25% (liver) or 15% (heart) formic acid. All fractions were centrifuged for
10 min at 17,000 x g at 4◦C to remove any particulates that may block the LC column.
The supernatants from the homogenate, supernatant and cytosolic fractions were removed
into fresh Eppendorf tubes, and the supernatants from the 4 mitochondrial samples were
pooled into the same tube. After drying under vacuum for 4 hours at ∼40◦C, the metabolites
were resuspended in 75 µL of H2O. The samples were kept in agitation for 10 min at 4◦C,
centrifuged for 1 min at 17,000 x g, 4◦C and the supernatants were transferred to MS vials.
The raw ion intensities for metabolites were normalised to both taurine and GSH ion intensi-
ties from the same column (i.e. the ion intensity for succinate from the ZIC-HILIC column
was normalised to the taurine and GSH ion intensity from the ZIC-HILIC column, and the ion
intensity for succinate from the ZIC-pHILIC column was normalised to the taurine and GSH
ion intensity from the ZIC-pHILIC column). In general, most metabolites were analysed
using data from the ZIC-pHILIC column. However, for some metabolites, such as succinate
and fumarate, the ZIC-HILIC column data was also used as this column is preferable for
some metabolites (discussed in Section 5.3.1).
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Fig. 5.9 LC-MS sample preparation protocol. 4 isolation experiments per animal were run in
parallel. 40 µL of homogenate, supernatant and cytosolic fraction was added to 400 µL of 25% (liver)
or 15% (heart) to extract the metabolites. All 4 mitochondrial samples as well as the homogenate,
supernatant and cytosolic extracted samples were centrifuged for 10 min at 17,000 x g, 4◦C. The
supernatants from the mitochondrial samples were pooled into the same fresh 1.5 mL Eppendorf
tube, and the supernatants from the other fractions were removed into fresh tubes. The FA was
evaporated under vacuum (4 hr, 40◦C) and the dried metabolites were resuspended in 75 µL of
H2O under agitation for 10 min at 4◦C. After a 1 min centrifuge at 17,000 x g, 4◦C the supernatants
were transferred to LC-MS vials and stored at -80◦C until LC-MS analysis. FA: formic acid; M:
mitochondria; H: homogenate; S: supernatant; C: cytosol.
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5.4 Effect of transport and respiratory inhibitors on metabo-
lite retention
Attempts were made to carry out the mitochondrial isolation from tissue as quickly as possible
with rapid cooling in order to quench metabolism. The heart is placed in ice-cold buffer
within 25 sec and the liver within 30 sec of culling the animal, and both are fully homogenised
in ice-cold buffer within 1.5 min of culling. However, it could be that this is not sufficient
to quench metabolism or limit metabolite distribution. To identify whether metabolism
is indeed quenched by rapid cooling, a range of respiratory and transport inhibitors were
added to the homogenisation buffer prior to homogenisation to see if they further affected
metabolite distribution in addition to cooling. The results were assessed by LC-MS with
a focus on succinate. This is a metabolite of interest because it is known to be distributed
between the mitochondria and the cytosol and is elevated during ischaemia. The hypothesis
was that if the procedure is successfully quenching metabolism and limiting the exchange of
metabolites across the MIM, then there should be no difference between the relative amounts
of metabolites between samples that contained inhibitors and control samples (Figure 5.10).
5.4.1 Time dependence of extraction
To determine the extent of the time dependence of the isolation procedure, homogenised
mouse liver was left for 10 min on ice before continuing with the rapid mitochondrial
isolation procedure. The results are shown in Figure 5.11 and show that in general, after 10
min left on ice the level of metabolites are very similar to those processed immediately, or
are only slightly lower. Therefore, the most time-sensitive step of the procedure is to get
the tissue homogenised because this speeds up the cooling of the whole organ, similar to
freeze-clamping the organ with Wollenberger clamps.
The cooling that occurs during homogenisation slows metabolism and helps prevent metabo-
lite distribution by reducing the activity of metabolite transporters. Homogenising also
prevents metabolite distribution by limiting the exchange of metabolites across the MIM be-
cause the concentration of metabolites outside the mitochondria is diluted in the large volume
of buffer, reducing the driving force of these exchangers. Thus, mitochondrial metabolites
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Fig. 5.10 Schematic of transport inhibitors used. Butylmalonate (BTM) inhibits the dicarboxylate
carrier (DIC), which transports succinate and malate in exchange for Pi. Pyridoxal 5’-phosphate
(PRP) inhibits transporters containing lysine residues, such as the oxoglutarate carrier (OGC). Car-
boxyatractyloside (CATR) inhibits the ATP/ADP carrier (AAC). Oligomycin inhibits ATP-synthase.
N-ethylmaleimide (NEM) is a general transport inhibitor and will affect many transporters, either
through direct inhibition or indirectly affecting ion transporters which influence their activity. If
the rapid isolation procedure is not quenching metabolism then adding the inhibitors should have
the following effects in the mitochondria - BTM: elevated succinate and malate; PRP: reduced α-
ketoglutarate (αKG) and increased malate; CATR and oligomycin: increased adenine nucleotide
pools.
should remain trapped inside the matrix. To investigate the activity of these transporters
further, various transport and respiratory inhibitors were added to the homogenisation buffer.
5.4.2 Butylmalonate
Butylmalonate (BTM) is an inhibitor of the DIC. It was added to the homogenisation buffer to
determine whether dicarboxylates (i.e. succinate and malate) are lost during the mitochondrial
isolation procedure. It was hypothesised that if the DIC is exchanging dicarboxylates across
the MIM during the procedure, leading to loss of some metabolites, then adding BTM
should increase the amount seen in the mitochondrial fraction. By blocking mitochondrial
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Fig. 5.11 LC-MS analysis of TCA cycle intermediates and nucleotide breakdown products after
10 min on ice. Mouse liver mitochondria were rapidly isolated from 2 mice, except one was processed
immediately and for the other the homogenate was left on ice for 10 min before isolating the
mitochondria. The metabolites were analysed by LC-MS and normalised to taurine. A) TCA cycle
intermediates normalised to taurine; B) Nucleotide breakdown products normalised to taurine; C) raw
ion intensities of TCA cycle intermediates; D) Raw ion intensities of nucleotide breakdown products.
Unless otherwise specified data is from the ZIC-HILIC column. n=1.
dicarboxylate transport, the exchange of some metabolites between the mitochondria and the
cytosol is slowed down.
As a mouse heart weighs ∼200 mg (Wettmarshausen, Perocchi, 2017) it was estimated there
are 40 nmol of succinate in a mouse heart. This was based on the approximate value of 1 mg
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tissue equating to ∼1 µL volume and the published value of 200 µmol/L succinate in whole
tissue (Martin et al., 2019). As a whole heart is placed in 3 mL of homogenisation buffer the
succinate concentration in the homogenate is estimated as 13.3 nmol/mL succinate (13 µM).
500 µM butylmalonate was added (a 50 X excess over succinate). This concentration was
chosen as the IC50 of BTM is 0.99 mM at 1 mM succinate (in rat liver mitochondria) (Hiran
Prag, unpublished work), therefore 500 µM BTM should be sufficient to block the DIC.
As a mouse liver weighs ∼1 g (Wettmarshausen, Perocchi, 2017) it was estimated there are
200 nmol of succinate in a mouse liver. This calculation was based on the same values as
used for the heart calculations: 200 µmol/L succinate in whole tissue, 1 mL volume in mouse
liver = 200 nmol. As a whole liver is placed in 5 mL of homogenisation buffer there was an
estimated 40 nmol/mL succinate (40 µM) in the whole liver homogenate. 500 µM of BTM
(∼10 X excess over succinate) was hypothesised to be a large enough excess to inhibit the
carrier.
Figure 5.12 demonstrates that the addition of BTM does not significantly increase the amount
of succinate inside the mitochondria, indicating there is minimal dicarboxylate loss during
the extraction process. This is probably due to the temperature being suitably low and the
lack of substrates available for exchange on the other side of the membrane (phosphate,
sulphate and thiosulphate, Table 1.2). Across other metabolites there is no effect from the
addition of BTM.
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Fig. 5.12 Effect of butylmalonate inhibition on metabolite levels. Left: Mouse heart metabolites.
Right: Mouse liver metabolites. Mouse heart and liver mitochondria were isolated in the presence
of 500 µM butylmalonate. Control: n=2, BTM: n=3 biological replicates. Data is range for control
samples and mean ±SEM for BTM samples. BTM: Butylmalonate; H: Homogenate; S: Supernatant;
C: Cytosol; M: Mitochondria.
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5.4.3 NEM and PRP
N-ethylmaleimide (NEM) modifies cysteine residues in proteins and is reactive to thiols.
It is known to be a potent inhibitor of many transporters that have an exposed cysteine
residue, such as the carnitine/acylcarnitine carrier (CAC) (Tonazzi et al., 2017). Pyridoxal
5’-phosphate (PRP) is a lysine reagent (Lundblad, 1991) and has been shown to inhibit
transporters containing a lysine residue in the binding site, such as the oxoglutarate carrier
(Natuzzi et al., 1999), the tricarboxylate carrier (Gremse et al., 1995), the yeast citrate carrier
(Remani et al., 2008) and the yeast dicarboxylate carrier (Kakhniashvili et al., 1997).
A caveat to using these inhibitors is that any metabolite with a thiol, e.g. GSH, will be
labelled by NEM and any metabolites with lysines will be labelled by PRP, which generates
problems for normalisation. These labelled metabolites will still be present in the sample,
but the analysis methods must be changed as the metabolites will be labelled with one or two
NEM molecules, and therefore will have a higher mass.
To investigate the effect of these inhibitors, 3 mouse livers were isolated with 200 µM PRP or
500 µM NEM added to the homogenisation buffer. The taurine ion intensities and a selection
of metabolites from the LC-MS analysis are shown in Figure 5.13. Neither homocysteine
or cysteine were detected in the samples with inhibitor added, which suggests that their
thiol groups were labelled and their detection was prevented. Many of the samples with
NEM and PRP had particulates present, which affected the detection method and blocked
the MS columns. These particulates may have been caused by NEM and PRP altering
the hydrophobicity of the metabolites and causing aggregation. The particulates may also
have been due to trace remnants of the oil, DOP or hexane. Hexane must be completely
removed, as although most metabolites shouldn’t enter hexane due to its negative charge,
some metabolites may move into it, such as acyl carnitines. This could be why there is a
low amount of palmitoylcarnitine and oleylcarnitine, and fatty acids such as linoleic acid
and oleic acid seen in the samples, although the analysis conditions are not optimal for these
metabolites anyway. In general, the presence of NEM or PRP led to a reduction in the amount
of metabolites detected, possibly for reasons explained above.
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Fig. 5.13 LC-MS analysis of metabolites in the presence of the inhibitors PRP and NEM in
mouse liver fractions. A) Ion intensities of taurine. B) Metabolite levels normalised to taurine. n=3
biological replicates, data is mean ±SEM. Data was analysed by 2-way ANOVA as not significant. H:
Homogenate; S: Supernatant; C: Cytosol; M: Mitochondria.
5.4.4 Oligomycin and CATR
The inhibitors carboxyatractyloside (CATR) and oligomycin were added to the homogenisa-
tion buffer to investigate whether the isolation is performed sufficiently quickly such that
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mitochondrial adenine nucleotides are maintained. CATR is a selective inhibitor of the AAC
and stabilising a specific conformation of the carrier. Oligomycin inhibits ATP synthase,
blocking oxidative phosphorylation and the ETC. The results are displayed in Figure 5.14.
Fig. 5.14 ATP/ADP analysis in rapidly isolated mouse heart mitochondria. Mitochondria were
rapidly isolated from mouse hearts with either no inhibitor, 20 µM CATR or 5 µM oligomycin
in the homogenisation buffer. ATP and ADP levels were measured and extrapolated to calculate
the total nmol of adenine nucleotides in the original cytosolic (650 µL layered on oil) and final
mitochondrial fractions (100 µL of mitochondria obtained after centrifugation). A) Mitochondrial
nucleotide concentrations; B) Cytosolic nucleotide concentrations; C) Total mitochondrial nucleotide
pools; D) Total cytosolic nucleotide pools. Differences in ATP and ADP between control and CATR
and oligomycin in A and B were analysed by 2-way ANOVA as not significant. Data is mean ±SEM,
n=3. CATR: carboxyatractyloside.
Figure 5.14 shows that the cytosolic pools of adenine nucleotides were only mildly affected
by the addition of either inhibitor, with a slight increase in the level of ATP. In contrast, the
total mitochondrial adenine nucleotide pool was reduced by both inhibitors, although neither
inhibitor caused a statistically significant change. CATR caused a large reduction in the level
of ADP, with a smaller reduction in ATP. CATR inhibits the AAC, preventing the import of
ADP into the mitochondria in exchange for ATP. Conversely, oligomycin caused a larger
reduction in ATP levels than ADP levels. This could be due to oligomycin inhibiting ATP
synthase and preventing ATP production.
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5.5 Discussion
5.5.1 LC-MS analysis technique
The optimised LC-MS sample preparation was to quench and extract the metabolites in
either 15% (heart) or 23% (liver) formic acid. It was found that pooling 4 mitochondrial
isolations increased the LC-MS signal. The acidic extracts were dried under vacuum and
resuspended in water to increase the pH, as a low pH was found to alter retention times.
Taurine was chosen as the best metabolite for normalisation of metabolite ion intensities.
Although normalisation has some caveats, it is the best approach for this technique as it
enables a wide range of metabolites to be quantified. To achieve absolute quantification of
metabolites, multiple metabolite isotopes would have to be added as standards.
HILIC was chosen as the chromatographic method for this project. The 2 columns (ZIC-
pHILIC and ZIC-HILIC) are optimised for polar metabolites, such as TCA cycle intermedi-
ates. The relative quantification of polar metabolites is of potential interest to this lab in the
context of IRI. Other metabolites, such as positively charged fatty acids and carnitines, will
not be ionised as efficiently and will therefore not be detected as accurately. Therefore, only
tentative conclusions can be drawn on the behaviour of these non-polar metabolites using
HILIC.
5.5.2 Transport inhibitors
Neither BTM, PRP or NEM resulted in any statistically significant change in the levels of
metabolites detected in any fraction. This supports the view that the use of these inhibitors
is not necessary because the procedure is performed quickly and with rapid cooling such
that metabolism and distribution is quenched successfully. It could also be that the time
frame for the inhibitors to have an effect is longer than the time they are exposed to the
mitochondria (i.e. the time from the homogenisation of the tissue to the time the mitochondria
pass through the oil into the acid), although this is unlikely as they are very fast-acting. The
cold temperature could also inhibit their efficacy. If any of these reasons is correct then the
use of inhibitors is limited. Alternatively, it is possible that the concentration of inhibitor
used was not optimal, or that the metabolites are switching to transport through other carriers.
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In this case, adding a targeted cocktail of different inhibitors may be beneficial. However,
the exchange of metabolites across the MIM will be limited during homogenisation due to
dilution of external metabolites in the large volume of homogenisation buffer, so the activity
of most carriers will be reduced after homogenisation.
The addition of oligomycin and CATR did not generate any statistically significant changes
in the cytosolic or mitochondrial total adenine nucleotide pools. Again, this indicates that the
extraction is performed quickly enough that metabolite degradation does not occur, or that it
is performed quicker than the inhibitors can have an effect.
The use of inhibitors may be suitable for a more targeted approach, such as looking at a
particular metabolite like succinate, but does not seem necessary or helpful for looking at
a range of metabolites. Using a combination of different inhibitors, targeted to specific
transporters, may aid understanding of mitochondrial metabolite pools. Nevertheless, the use
of pharmacological inhibition is challenging, because the inhibitors may well have effects on
other transporters, causing complex downstream effects on multiple metabolite pools.
Chapter 6
Metabolic characteristics of normoxic
and ischaemic mitochondria and cytosol
6.1 Introduction
Chapters 3 to 5 developed and optimised the rapid mitochondrial isolation procedure from
tissues. This section describes the results of the application of this method to study the
metabolism of control and ischaemic mouse heart and liver. This builds upon previous
studies which looked at whole cell metabolomics in mouse heart subjected to cold and warm
ischaemia (Chouchani et al., 2014; Martin et al., 2019).
It was hoped that measuring metabolites in rapidly isolated cytosolic and mitochondrial
fractions would expose any metabolic changes that may have been masked by whole cell
analyses. Control, normoxic tissue was measured first to get an understanding of how
normoxic metabolite pools in the cytosol and mitochondria behave and therefore provide a
baseline to help understand more about those changes that occur during ischaemia.
Although the distribution and transport of some metabolites is well known, the behaviour
of others in both normoxia and ischaemia is less well-established. For example, TCA cycle
intermediates are known to be present in the mitochondria, but some are also thought to be
distributed throughout the cell by transporters on the MIM. Therefore, it was of potential
interest to determine how the distribution of these metabolites was altered during ischaemia.
It was also of interest to establish those metabolite pools that did not change during ischaemia.
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6.2 Aims
Chapter 4 described the development of the rapid mitochondrial isolation procedure and
Chapter 5 described the optimisation of the procedure for metabolite analysis by LC-MS. In
this Chapter, the second aim of the project was addressed: to use the method to elucidate
and understand the differences between cytosolic and mitochondrial metabolite pools in
mouse heart and liver, during normoxia and ischaemia. The optimised rapid mitochondrial
isolation procedure generates homogenate, supernatant, cytosolic and mitochondrial fractions
sequentially. The LC-MS analysis aimed to examine how the metabolic profile of each of
these fractions differs.
6.3 Strategy
The strategy was to generate a control data set for the cytosol and mitochondria of mouse
heart and liver. After this, an ischaemic data set was generated for both organs by subjecting
them to 30 min warm ischaemia (WI), which is a duration we routinely use in mouse studies
of IRI before reperfusion, hence these changes are pathologically relevant. As 30 min is
late-stage ischaemia, a more detailed viewpoint of relative changes to metabolite pools was
also obtained by performing a time course of WI at earlier time points. To quantify the
metabolites, the ion intensities were normalised to taurine, as described in Section 5.1.4.
The data was displayed as bar graphs showing the taurine-normalised ion intensity in each
fraction. To help understand differences between the mitochondrial and cytosolic pools, the
ratio of mitochondrial:cytosolic normalised ion intensities in normoxia and ischaemia was
displayed as heat maps.
To facilitate analysis, the metabolites were divided into metabolic pathways and metabolite
types. This gave information on how particular pathways were behaving during normoxic and
ischaemic conditions in both compartments. As the cellular localisation of some metabolites
is well known, this grouping also served as a marker for how well the isolation procedure had
worked in separating the mitochondria and cytosol. For example, phosphorylated glycolytic
intermediates, such as 3-phosphoglycerate and fructose-6-phosphate, are not able to enter
the mitochondria and, therefore, should only be detected at low levels (or not at all) in
the mitochondrial fraction. Similarly, the nucleotide breakdown products xanthine and
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hypoxanthine are established markers of ischaemia, so the presence of these metabolites
were good indicators of the success of the ischaemic protocol.
6.4 Data analysis
The metabolites were generally normalised to taurine. The rationale for normalisation to
taurine is discussed in detail in Section 5.3.1. The normoxic datasets for heart and liver
are displayed as bar graphs of taurine-normalised ion intensities. To elucidate how the
distribution of these metabolites differs between the mitochondria and the cytosol, this
data was also presented as heat maps of mitochondrial:cytosolic taurine-normalised ion
intensities. These heat maps clearly show which metabolites are compartmentalised to the
mitochondria or the cytosol (at the extreme ends of the heat maps) and which metabolites are
distributed throughout the cell. Heat maps were also made to explore how these distributions
changed following 30 min WI by comparing the normoxic mitochondria:normoxic cytosol
and ischaemic mitochondria:ischaemic cytosol ratios.
As is often the case with LC-MS analyses, there were some missing values in the datasets.
For metabolites that were present in only one fraction, MVI was applied and they were
assigned an "adjusted zero" value of 0.0002% of taurine (the smallest detected value), so
that a virtual ratio could be calculated for comparison with the other data (see Section 5.1.3).
These metabolites are included on the heat maps, but are separated from the other metabolites
as the ratio will be artificially increased (for metabolites not detected in the cytosol) or
decreased (for metabolites not detected in the mitochondria) by the adjusted zero value.
Metabolites that were expected, but nevertheless not detected in either fraction, either due to
column suitability, or for unknown reasons, were excluded.
Although data for all 4 fractions (homogenate, supernatant, cytosol and mitochondria)
was collected, the differences between the cytosolic and mitochondrial fractions were of
particular interest for this project and so were the focus of this section. Figure 6.1 shows
two examples of metabolites, fumarate and glutamate, showing that the signal for the
homogenate, supernatant and cytosolic fractions are broadly similar. The signals for all
fractions are displayed in Appendix C. Most analyses and interpretations were based on
taurine-normalised ion intensities, unless otherwise indicated.
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Fig. 6.1 The normalised ion intensities for the homogenate, supernatant and cytosolic fractions
are broadly similar. The taurine-normalised ion intensities from the heart (top) and liver (bottom)
datasets are displayed to demonstrate that the signals from the homogenate, supernatant and cytosolic
fractions are similar. Data is average of 6 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction; WI: Warm ischaemia.
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The majority of metabolites for this project were analysed using the ZIC-pHILIC column
because it detects the broadest range of metabolites (Section 5.1.1). Some metabolites are
detected better under the conditions of the ZIC-HILIC column, and so were analysed on both
columns, where this was possible. These metabolites were: arginine, cysteine, cystine, GSH,
histidine, lysine and succinate. In addition, the ZIC-HILIC column was used to supplement
any gaps in the data set from metabolites that were not detected by the ZIC-pHILIC column,
which are listed in the relevant sections.
6.5 Normoxic metabolism
First, the distribution of metabolites of control mice under normoxia was studied. The control
data set was compiled from 6 WT C57/BL6 mouse hearts and 3 WT C57/BL6 mouse livers
which were kept under normoxic conditions. The control distribution of metabolites was
studied by an initial screen of raw ion intensities (displayed in Appendix A). Next, the data
was analysed by normalisation to taurine (values displayed in Appendix B) and displayed in
bar graphs. In the following section, the bar graphs for TCA cycle intermediates, glycolytic
intermediates and nucleotides and breakdown products are displayed. The bar graphs for
amino acids and peptides, fatty acids and carnitines and any ungrouped metabolites are
displayed in Appendix C.1 and C.2 alongside the 30 min WI data. To aid in identifying
the relative distribution of metabolites across the cytosolic and mitochondrial compartment,
the data was then collated into heat maps of mitochondrial:cytosolic taurine-normalised ion
intensities.
6.5.1 Metabolite analysis in the control heart
The ZIC-HILIC column was used to increase metabolite coverage, as the following metabo-
lites were not detected on the ZIC-pHILIC column in the control heart dataset: allantoin,
dihydrothymine, GABA, leucine, N-acetylaspartate, nicotinamide, tyrosine, uracil, uric acid,
uridine and xanthine.
The levels of taurine-normalised TCA cycle intermediates across all fractions are shown
in Figure 6.2. Relative to taurine, aconitate, αKG and citrate are compartmentalised to
the mitochondria, whereas malate and succinate are seen to be more distributed across
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Fig. 6.2 TCA cycle intermediates in control mouse heart homogenate, supernatant, cytosol and
mitochondria. Metabolite ion intensities from the control heart data set were normalised to taurine.
Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data is average
of 6 biological replicates, presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic
fraction; M: Mitochondrial fraction. NF: Not found.
Fig. 6.3 Glycolytic intermediates in control mouse heart homogenate, supernatant, cytosol and
mitochondria. Metabolite ion intensities from the control heart data set were normalised to taurine.
Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data is average
of 6 biological replicates, presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic
fraction; M: Mitochondrial fraction. NF: Not found.
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the cellular fractions. NAD+ was only detected at very low levels in the homogenate and
supernatant fractions, and was not seen at all in the cytosolic fraction, whereas it was seen in
the mitochondrial fraction. The glycolytic intermediates 3-phosphoglycerate and fructose-6-
phosphate were not detected or were at very low levels relative to taurine in the mitochondrial
fraction, whereas lactate was distributed across the cell (Figure 6.3).
Nucleotides and their breakdown products were generally evenly distributed across the
two compartments (Figures 6.4 and 6.5), except for kynurenic acid and guanosine which
were not detected in the cytosol and were abundant in the mitochondria. Conversely, CDP,
hypotaurine, uracil, uric acid and uridine were not detected in the mitochondria.
Figures C.1 and C.2 shows that amino acids are evenly distributed across the cell, except
for asparagine and glycine which were higher in the mitochondria relative to taurine. On the
ZIC-pHILIC column GSH is shown to be evenly distributed across the all fractions, whereas
on the ZIC-HILIC column analysis, GSH is lower in the mitochondrial fraction. GSSG was
also seen distributed across all fractions.
Figure C.3 lists the fatty acids and carnitines that were detected in the control heart. Other
fatty acids and carnitines were looked for, but were excluded from this analysis due to having
less than 3 values per fraction above zero. These are listed in the legend of Figure C.3.
Acetylcarnitine, butyrylcarnitine, carnitine and propionylcarnitine were relatively evenly
distributed across the cell, with slightly lower levels in the mitochondrial fraction.
The high level of sucrose seen in both compartments (Figure C.5) is due to contamination
carried through from the sucrose-based homogenisation buffers.
Figure 6.6 shows the ratio of mitochondrial:cytosolic metabolites. The data show which
metabolites are accumulated in the mitochondria and which are depleted compared to the
cytosol, relative to taurine. TCA cycle intermediates αKG, aconitate and citrate are seen at
a higher level in the mitochondria, with phosphorylated glycolytic intermediates fructose-
6-phosphate and 3-phosphoglycerate not detected in the mitochondria. Kynurenic acid,
NAD+, guanosine, palmitic acid and oleic acid were increased relative to taurine more in the
mitochondria. However, none of these were found in the cytosol and were therefore assigned
a low virtual ratio value. Furthermore, fatty acids and their derivatives are poorly detected
in this system, which was mainly optimised for the TCA cycle, and had low ion intensities
(in the range of 105 - 106, Figure A.2). Succinate is shown to be lower in the mitochondrial
fraction compared to the cytosolic fraction, relative to taurine. Further, on the ZIC-HILIC
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Fig. 6.4 Nucleotides and breakdown products in control mouse heart homogenate, supernatant,
cytosol and mitochondria. Metabolite ion intensities from the control heart data set were normalised
to taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column.
Data is average of 6 biological replicates, presented as mean ±SEM. H: Homogenate; S: Supernatant;
C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
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Fig. 6.5 Nucleotides and breakdown products in control mouse heart homogenate, supernatant,
cytosol and mitochondria (ctd.). Metabolite ion intensities from the control heart data set were
normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC
column. Data is average of 6 biological replicates, presented as mean ±SEM. H: Homogenate; S:
Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
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column fumarate is higher than succinate, relative to taurine. Hypoxanthine was high in the
mitochondria (ZIC-pHILIC) but xanthine was low in the mitochondria on the ZIC-HILIC
column analysis.
6.5.2 Metabolite analysis in the control liver
As was the case for the control heart data set, the majority of metabolites for the control liver
data set were analysed using the ZIC-pHILIC column. The ZIC-HILIC column was used to
improve metabolite coverage, as asparagine, cytidine, dihydrothymine, GABA, homocysteine,
hypotaurine, leucine, nicotinamide, uracil, uric acid, uridine, valine and xanthine were not
detected by the ZIC-pHILIC column analysis.
Compared to control heart, TCA cycle intermediates in the control liver appear more evenly
distributed across the cell (Figure 6.7). As for the heart, glycolytic intermediates are much
lower or are not detected in the mitochondria (Figure 6.8).
Figures 6.9 and 6.10 indicate that there are more nucleotide breakdown products detected
in the mitochondria relative to the cytosol. In particular, hypoxanthine, inosine and xanthine
were not detected or were very low in the cytosol but were relatively high in the mitochondria.
In general, amino acids were distributed across the compartments (Figures C.6 and C.7),
except for citrulline which was much higher in the mitochondrial fraction. Similarly to the
control heart data, GSH was seen to be slightly lower in the mitochondria on the ZIC-HILIC
column analysis.
The fatty acids and carnitines that were detected are displayed in Figure C.8, and the
excluded metabolites are listed in the legend. Acetylcarnitine, butyrylcarnitine, carnitine and
propionylcarnitine are evenly distributed, whereas all other fatty acids and acylcarnitines that
were detected are compartmentalised, mostly in the cytosol.
Figure C.11 indicates the liver also has some sucrose contamination from the homogenisation
buffers in both compartments.
Figure 6.11 shows that, relative to taurine, succinate is evenly distributed between the
mitochondria and the cytosol, whereas in the control heart it was lower in the mitochondrial
fraction. The accumulation of hypoxanthine in the mitochondria suggests that there was ATP
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Fig. 6.6 Metabolite enrichment in control mouse heart mitochondria. Metabolites from the
control heart data set were normalised to taurine and presented as a ratio of mitochondrial:cytosolic
relative amounts (log2 of the values), arranged in order of accumulation in the mitochondria. A)
Metabolites analysed on the ZIC-pHILIC column; B) metabolites analysed on the ZIC-HILIC column.
Data is average of 6 biological replicates. Metabolites which were assigned an adjusted zero value,
due to no detection in the cytosolic or mitochondrial fraction, are placed above (cytosolic adjusted
zero) or below (mitochondrial adjusted zero) the gaps in the heat map.
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Fig. 6.7 TCA cycle intermediates in control mouse liver homogenate, supernatant, cytosol and
mitochondria. Metabolite ion intensities from the control liver data set were normalised to taurine.
Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data is average
of 3 biological replicates, presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic
fraction; M: Mitochondrial fraction. NF: Not found.
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Fig. 6.8 Glycolytic intermediates in control mouse liver homogenate, supernatant, cytosol and
mitochondria. Metabolite ion intensities from the control liver data set were normalised to taurine.
Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data is average
of 3 biological replicates, presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic
fraction; M: Mitochondrial fraction. NF: Not found.
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Fig. 6.9 Nucleotides and breakdown products in control mouse liver homogenate, supernatant,
cytosol and mitochondria. Metabolite ion intensities from the control liver data set were normalised
to taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column.
Data is average of 3 biological replicates, presented as mean ±SEM. H: Homogenate; S: Supernatant;
C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
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Fig. 6.10 Nucleotides and breakdown products in control mouse liver homogenate, supernatant,
cytosol and mitochondria (ctd.). Metabolite ion intensities from the control liver data set were
normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC
column. Data is average of 3 biological replicates, presented as mean ±SEM. H: Homogenate; S:
Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
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breakdown, but there was none in the cytosol where ATP breakdown occurs. As was found
in the heart, the TCA cycle intermediates aconitate, αKG and citrate were accumulated in
the mitochondria relative to the cytosol. Phosphorylated glycolytic intermediates (fructose-
6-phosphate, glucose-6-phosphate and glyceraldehyde-3-phosphate) were depleted in the
mitochondria. Unlike in the heart, succinate was found to be more accumulated in the
mitochondria than fumarate.
6.6 Ischaemic metabolism
6.6.1 Glycolysis and energy storage during ischaemia
During ischaemia, the lack of oxygen causes the cessation of oxidative phosphorylation, and
the lack of blood flow means that glucose is no longer delivered to tissue from the blood.
This forces the cell to switch to glycogen-fuelled glycolysis to maintain the ATP/ADP ratio in
order to supply the energetic demands of the cell and also supplies many of the precursors for
ischaemic metabolites. To investigate how energy stores change during both cold and warm
ischaemia, glycogen was measured in various tissues that had been subjected to ischaemia by
the model described in Section 2.4.1.2, using the assay described in Section 2.4.1. Glycogen
was measured via this assay instead of LC-MS because it is a large, heterogeneous molecule.
Where possible, human heart samples were also analysed, but supply was limited. Pig heart
was also used as this is very similar in terms of size, blood-flow and metabolism to human
heart. The limited amount of human heart samples available meant that only WI experiments
were performed in human. Glycogen was found to deplete rapidly in mouse and pig heart
during WI (Figure 6.12A and B) and plateaued after approximately 1 hour, despite 20-25%
of the glycogen remaining. When subjected to CI, glycogen stores in mouse and pig heart
decreased in a slower, more steady manner and did not reach a plateau after 1 hour but
continued to decrease for up to 120 min. Glycogen stores in human heart subjected to WI
also plateaued after approximately 1 hour (Figure 6.12C), but did not decrease as rapidly
during early WI compared to mouse and pig. However, due to the nature of the collection
procedure of the human heart tissue, the tissue is not frozen as rapidly as the mouse tissues.
Therefore, it is possible that previous episodes of WI during acquisition may have depleted
some of the glycogen prior to the freezing of the tissue, meaning that the control value has
artificially low glycogen values.
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Fig. 6.11 Metabolite enrichment in control mouse liver mitochondria. Metabolites from the
control liver data set were normalised to taurine and presented as a ratio of mitochondrial:cytosolic
relative amounts (log2 of the values), arranged in order of accumulation in the mitochondria. A)
Metabolites analysed on the ZIC-pHILIC column; B) metabolites analysed on the ZIC-HILIC column.
Data is average of 6 biological replicates. Metabolites which were assigned an adjusted zero value,
due to no detection in the cytosolic or mitochondrial fraction, are placed above (cytosolic adjusted
zero) or below (mitochondrial adjusted zero) the gaps in the heat map.
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Fig. 6.12 Glycogen in mouse, pig and human heart during warm and cold ischaemia. A) Glyco-
gen in ischaemic mouse heart. n=5 for time points 0 to 30 min and n=4 for time points 45 to 120 min.
B) Glycogen in ischaemic pig heart. n=3. C) Glycogen in warm ischaemic human heart. n=3 for time
points 0 to 30 min and n=2 for 60 min. Data is mean ±SEM, and range for 60 min values, for all
graphs.
The ischaemic metabolism of the kidney was of interest to this lab, as it can also be subjected
to both WI and CI during surgery. To investigate this in parallel, the glycogen stores of WI
mouse kidney were measured. The kidney displayed a similar trend to mouse heart in that
the glycogen stores of WI tissue were depleted rapidly and plateaued after approximately 45
min, whereas in CI tissue glycogen levels were reduced more slowly (Figure 6.13).
6.6.2 Metabolite analysis of rapidly isolated ischaemic mitochondria
and cytosol
The above experiments shed light on glycolysis, which is an important metabolic pathway
during ischaemia that helps to maintain the energy requirements of the cell. The glycogen
assay was used to investigate the behaviour of glycolysis during ischaemia. To investigate
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Fig. 6.13 Glycogen in mouse kidney during warm and cold ischaemia. Glycogen in ischaemic
mouse kidney. n=4. Data is mean ±SEM.
how other glycolytic intermediates, and other metabolites, behave during ischaemia, the
mitochondrial and cytosolic fractions from ischaemic mouse heart and liver were rapidly
isolated, their metabolites measured by LC-MS and the relative enrichment of metabolites
in the cytosol and mitochondria were calculated. To do this, whole mouse hearts and livers
were rapidly removed and placed in a heat block at 37◦C for 30 min before homogenisation
and mitochondrial isolation (described in further detail in Section 2.2.2.1). These data were
collected in parallel to the control heart and liver data sets. To understand how the distribution
of metabolites in the cytosolic and mitochondrial pools change due to warm ischaemia, the
ion intensities were normalised to taurine and presented as bar graphs. To improve the
strength of any conclusions, two-way ANOVAs were performed, comparing the normoxic
cytosol to ischaemic cytosol, normoxic cytosol to normoxic mitochondria, ischaemic cytosol
to ischaemic mitochondria and normoxic mitochondria to ischaemic mitochondria. The
data was also presented in heat maps comparing the mitochondrial:cytosolic ratio of taurine-
normalised ion intensities in normoxia and after 30 min WI.
6.6.2.1 Metabolite analysis in the ischaemic heart
To identify ischaemic trends in metabolic groups, the metabolic intermediates of the TCA
cycle and glycolysis and nucleotides and their breakdown products are displayed below. To
simplify statistical analysis, only the cytosolic and mitochondrial fractions are displayed.
Amino acids and peptides, fatty acids and carnitines and all other metabolites are displayed
in Appendix C.1.
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Fig. 6.14 TCA cycle intermediates in control and 30 min WI mouse heart homogenate, super-
natant, cytosol and mitochondria. Metabolite ion intensities from the control and 30 min WI heart
data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated as
from ZIC-HILIC column. Data is average of 6 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found. Statis-
tical analysis was performed by a two-way ANOVA. Means were considered statistically significant
when ****p < 0.0001; ***p < 0.0002; **p < 0.0021; *p < 0.0032.
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Fig. 6.15 Glycolytic intermediates in control and 30 min WI mouse heart homogenate, super-
natant, cytosol and mitochondria. Metabolite ion intensities from the control and 30 min WI heart
data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated as
from ZIC-HILIC column. Data is average of 6 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found. Statis-
tical analysis was performed by a two-way ANOVA. Means were considered statistically significant
when ****p < 0.0001; ***p < 0.0002; **p < 0.0021; *p < 0.0032.
Succinate was seen to increase significantly in the cytosolic fraction following WI (Figure
6.14). A slight increase was seen in the mitochondrial fraction but this change was not
statistically significant. Fumarate decreased in the mitochondrial fraction on both column
analyses following ischaemia (although not significantly). In the ZIC-pHILIC column
analysis, fumarate increased in the cytosolic fraction after ischaemia but this change was not
significant. Fumarate was barely detected in the cytosol on the ZIC-HILIC analysis.
The phosphorylated glycolytic intermediates 3-phosphoglycerate and fructose-6-phosphate
decreased in the cytosol following ischaemia (Figure 6.15). 3-phosphoglycerate was not
detected in normoxic or ischaemic mitochondria, and fructose-6-phosphate was only seen at
very low levels. Lactate was seen to accumulate in both fractions following ischaemia.
As expected, there was a general decrease in nucleotides and an increase in nucleotide break-
down products in both compartments following ischaemia (Figures 6.16 and 6.17). There
were some discrepancies seen between the two compartments, with adenine and adenosine
increasing in the cytosol and remaining stable in the mitochondria and the accumulation of
kynurenic acid exclusively in the mitochondria. Conversely, ADP, CMP and hypotaurine
decreased in the cytosol following ischaemia but remained stable, or were not detected in
the case of hypotaurine, in the mitochondrial fraction. Interestingly, GMP decreased in the
cytosolic fraction following ischaemia but increased in the mitochondrial fraction.
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Fig. 6.16 Nucleotides and breakdown products in control and 30 min WI mouse heart ho-
mogenate, supernatant, cytosol and mitochondria. Metabolite ion intensities from the control
and 30 min WI heart data sets were normalised to taurine. Data is from ZIC-pHILIC column unless
otherwise stated as from ZIC-HILIC column. Data is average of 6 biological replicates, presented
as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction.
NF: Not found. Statistical analysis was performed by a two-way ANOVA. Means were considered
statistically significant when ****p < 0.0001; ***p < 0.0002; **p < 0.0021; *p < 0.0032.
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Fig. 6.17 Nucleotides and breakdown products in control and 30 min WI mouse heart ho-
mogenate, supernatant, cytosol and mitochondria (ctd.). Metabolite ion intensities from the
control and 30 min WI heart data sets were normalised to taurine. Data is from ZIC-pHILIC column
unless otherwise stated as from ZIC-HILIC column. Data is average of 6 biological replicates, pre-
sented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found. Statistical analysis was performed by a two-way ANOVA. Means were
considered statistically significant when ****p < 0.0001; ***p < 0.0002; **p < 0.0021; *p < 0.0032.
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There is little change in most amino acids between normoxia and ischaemia in the heart
(Figures C.1 and C.2), with some exceptions. Namely, aspartate was seen to decrease in all
fractions, and asparagine and citrulline (both higher in the mitochondrial fraction relative to
taurine), decreased in the mitochondrial fraction after ischaemia but remained stable in all
other fractions. Interestingly, on the ZIC-HILIC analysis, cysteine was seen to increase after
ischaemia in all compartments, except the mitochondrial fraction. On both column analyses,
GSH remained stable across all fractions. Some increase in GSSG levels were seen after
ischaemia.
Of the carnitines that were detected, the trends following ischaemia were the same across the
compartments for carnitine and propionylcarnitine (both increased following ischaemia) and
butyrylcarnitine (decreased following ischaemia) (Figure C.3). In contrast, acetylcarnitine
decreased in the cytosolic fraction but increased in the mitochondrial fraction after ischaemia.
Figure 6.18 uncovers metabolites whose cellular distribution is altered by 30 min WI,
by comparing the mitochondrial:cytosolic ratio of taurine-normalised ion intensities in
normoxia and after 30 min WI. Adenine, hypoxanthine, adenosine and methionine were more
accumulated in the mitochondria relative to taurine under normoxic conditions, but were
higher in the cytosol relative to taurine after ischaemia. In contrast, ADP, acetylcarnitine and
GMP were lower in the mitochondria under normoxia but higher after ischaemia. The ZIC-
HILIC column data shows that fumarate accumulates in the mitochondria after ischaemia,
whereas the mitochondria:cytosol ratio for succinate decreases after ischaemia, suggesting
that succinate leaves the mitochondria.
After looking at late stage-ischaemic metabolism, the metabolic changes of ischaemia were
investigated in more detail by measuring metabolites at the earlier time points of 6 and 12
min WI. Mouse hearts were removed and either processed immediately (0 min WI control) or
incubated at 37◦C in a heat block for 6 or 12 min before homogenisation and rapid isolation
of mitochondria. These data are displayed in bar graphs in Appendix C.3.
These data show that for the majority of metabolites, any increase or decrease has already
occurred after 6 min of WI. Some metabolites, such as glycolytic intermediates (Figure
C.13) and nucleotide breakdown products (Figure C.14 and C.15) continue to accumulate
or deplete to 12 min, suggesting that glycolysis and nucleotide breakdown are continuing
over this time frame. Fatty acids and carnitines and amino acids do not exhibit much change
during the time course (Figure C.18).
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Fig. 6.18 Metabolite enrichment in normoxic and ischaemic mouse heart mitochondria. Metabo-
lites from the control and ischaemic heart data sets were normalised to taurine and are presented as
a ratio of mitochondrial:cytosolic relative amounts (log2 of the values), arranged in order of accu-
mulation in the mitochondria. A) Metabolites analysed on the ZIC-pHILIC column; B) metabolites
analysed on the ZIC-HILIC column. * - Metabolites that were not detected in the cytosolic (red) or
mitochondrial (blue) fraction and were assigned an adjusted zero value. Crosses: blank values in both
ischaemia and normoxia. Data are average of 6 biological replicates.
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6.6.2.2 Metabolite analysis in the ischaemic liver
The ischaemic metabolism of liver was then investigated. As was done for the heart, the
metabolic intermediates of the TCA cycle, glycolysis and nucleotides and their breakdown
products are displayed below. Again, only the cytosolic and mitochondrial fractions are
displayed. Amino acids and peptides, fatty acids and carnitines and all other metabolites are
displayed in Appendix C.2.
Figure 6.19 shows the TCA cycle intermediates in control and ischaemic liver. Although it
is hard to draw strong conclusions from these data due to the lack of statistical significance,
succinate and 2-HG, a derivative of αKG, are seen to increase in both fractions following
ischaemia, whereas aconitate, αKG, citrate and fumarate decrease. Malate was seen to
decrease in the cytosolic fraction but increase in the mitochondrial fraction after ischaemia.
Figure 6.20 shows that the glycolytic intermediates 3-PG, glyceraldehyde-3-phosphate and
PEP all decrease in ischaemic cytosol, with fructose-6-phosphate and glucose-6-phosphate
remaining stable. The end products of glycolysis lactate and pyruvate are seen to increase in
both the cytosolic and mitochondrial fractions following ischaemia.
In general, nucleotides, such as ADP and CTP decreased in both fractions during ischaemia
and breakdown products, such as hypoxanthine and xanthine increased (Figure 6.21 and
6.22).
As for the heart, the majority of amino acids show the same trend across all fractions
in the liver during ischaemia (Figure C.6 and C.7). Many amino acids remain stable
during ischaemia but some, such as asparagine, cysteine, phenylalanine, proline and tyrosine
increased following ischaemia. Others, such as serine decreased after ischaemia. Aspartate
was seen to decrease in all fractions after ischaemia, except in the mitochondria where it
remained stable.
The normoxic and ischaemic levels of fatty acids and carnitines detected are displayed in
Figure C.8. Carnitine and propionylcarnitine increased in all fractions following ischaemia.
Acetylcarnitine decreased in all fractions except the mitochondria, where it increased slightly.
Similarly, butyrylcarnitine decreased in all fractions except the mitochondria, where it
remained stable.
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Fig. 6.19 TCA cycle intermediates in control and 30 min WI mouse liver homogenate, super-
natant, cytosol and mitochondria. Metabolite ion intensities from the control and 30 min WI liver
data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated as
from ZIC-HILIC column. Data is average of 3 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction; WI: Warm ischaemia.
NF: Not found. Statistical analysis was performed by a two-way ANOVA. Means were considered
statistically significant when ****p < 0.0001; ***p < 0.0002; **p < 0.0021; *p < 0.0032.
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Fig. 6.20 Glycolytic intermediates in control and 30 min WI mouse liver homogenate, super-
natant, cytosol and mitochondria. Metabolite ion intensities from the control and 30 min WI liver
data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated as
from ZIC-HILIC column. Data is average of 3 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction; WI: Warm ischaemia.
NF: Not found. Statistical analysis was performed by a two-way ANOVA. Means were considered
statistically significant when ****p < 0.0001; ***p < 0.0002; **p < 0.0021; *p < 0.0032.
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Fig. 6.21 Nucleotides & breakdown products in control and 30 min WI mouse liver homogenate,
supernatant, cytosol and mitochondria. Metabolite ion intensities from the control and 30 min WI
liver data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated
as from ZIC-HILIC column. Data is average of 3 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction; WI: Warm ischaemia.
NF: Not found. Statistical analysis was performed by a two-way ANOVA. Means were considered
statistically significant when ****p < 0.0001; ***p < 0.0002; **p < 0.0021; *p < 0.0032.
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Fig. 6.22 Nucleotides & breakdown products in control and 30 min WI mouse liver homogenate,
supernatant, cytosol and mitochondria (ctd.). Metabolite ion intensities from the control and 30
min WI liver data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise
stated as from ZIC-HILIC column. Data is average of 3 biological replicates, presented as mean
±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction; WI: Warm
ischaemia. NF: Not found. Statistical analysis was performed by a two-way ANOVA. Means were
considered statistically significant when ****p < 0.0001; ***p < 0.0002; **p < 0.0021; *p < 0.0032.
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Figure 6.23 examines how ischaemia alters the cellular distribution of metabolites, as
was presented in Figure 6.18 for the heart. It shows that succinic glutathione, ATP and
acetylcarnitine are more accumulated in the mitochondria after ischaemia. The ZIC-HILIC
column analysis (right) shows that succinate is consistently lower in the mitochondria than
the cytosol (relative to taurine) in normoxia and ischaemia, as was fumarate. Cytidine was
seen to become higher in the mitochondria than the cytosol after ischaemia.
As was done for the heart, a more detailed exploration of ischaemic changes in liver
metabolism was performed by measuring metabolites at 0, 6, 12 and 30 min WI (Appendix
C.4). Similar to the situation in the heart, a lot of ischaemic metabolism appears to have
already occurred by 6 min WI in the liver. However, one difference from the heart was
that αKG decreases over the time course of WI in liver but increases in the heart (Figure
C.21). Amino acids and peptides generally remained stable across all fractions (Figure C.25
and C.26). Nucleotides decreased over the time course of ischaemia and their breakdown
products increased (Figure C.23 and C.24).
6.7 Summary & Discussion
6.7.1 Data analysis
The data displayed here were analysed by a two-way ANOVA to investigate the statistical
relationships between all fractions. However, this may not be the most appropriate method
of analysis. Going forward, the data may be reanalysed using a different statistical analysis,
such as a one-way ANOVA. Importantly, this may alter the statistical significance of the
changes between the normoxic and ischaemic fractions and allow us to draw more confident
conclusions from the data.
6.7.2 Normoxic metabolism
Analysis of the control heart showed that TCA cycle intermediates and associated metabolites
aconitate, αKG and citrate were compartmentalised to the mitochondria, and the other TCA
intermediates that were detected were distributed across the cell, including succinate. NAD+
was detected in the mitochondria but not the cytosol. This is consistent with the finding that
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Fig. 6.23 Metabolite enrichment in normoxic and ischaemic mouse liver mitochondria. Metabo-
lites from the control and ischaemic liver data sets were normalised to taurine and are presented as
a ratio of mitochondrial:cytosolic relative amounts (log2 of the values), arranged in order of accu-
mulation in the mitochondria. A) Metabolites analysed on the ZIC-pHILIC column; B) metabolites
analysed on the ZIC-HILIC column. * - Metabolites that were not detected in the cytosolic (red) or
mitochondrial (blue) fraction and were assigned an adjusted zero value. Crosses: blank values in both
ischaemia and normoxia. Data is average of 3 biological replicates.
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up to 70% of cellular NAD+ is in the mitochondria (VanLinden et al., 2015). However, why
NAD+ was not detected in the cytosol is unclear. In comparison, the control liver TCA cycle
intermediates were all more evenly distributed throughout the cell. Phosphorylated glycolytic
intermediates were either not detected or were only seen at low levels relative to taurine in
both heart and liver mitochondria, which was anticipated because these metabolites do not
have carriers on the MIM. These results indicate that the method is capable of showing the
correct locations of metabolites whose distribution is already known, suggesting that it can
be used to determine the distribution of metabolites with unknown cellular distributions.
The breakdown of nucleotides occurs when there are excess nitrogenous compounds or when
the cell is deprived of oxygen and needs an alternative energy source. Therefore, it was not
expected to see a high level of breakdown products in the control data set. Figures 6.4, 6.5,
6.9 and 6.10 show that some are seen in both control heart and liver in all fractions, and that,
overall, they are evenly distributed between the mitochondria and cytosol, although there
are some differences. Namely, hypotaurine was not detected in heart mitochondria and was
very low in liver mitochondria, but was high relative to taurine in the cytosol. Kynurenic
acid and guanosine were only found in heart mitochondria (they were not present in the liver
dataset). In the heart, hypoxanthine was highest in the mitochondrial fraction, with xanthine
distributed across all fractions, whereas in the liver hypoxanthine and xanthine were detected
in the mitochondrial fraction but were very low in the cytosolic fraction.
In the heart, the amino acids that were analysed were evenly distributed between the mito-
chondria and the cytosol. In comparison, in the liver, many amino acids were seen to increase
after ischaemia. In both tissues, GSSG was very low relative to taurine, indicating very little
oxidation of GSH had occurred during the isolation procedure.
The conditions of the LC-MS method are not optimal for fatty acids and carnitines, so it is
difficult to draw strong conclusions from the data obtained for these metabolites. Carnitine
was shown to increase after 30 min WI in all fractions of heart and liver, and acetylcarnitine
was shown to increase in the mitochondria of both tissues but decrease in all other fractions
after ischaemia. However, for the technical reasons given above, this needs to be assessed
further before we can draw any conclusions.
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6.7.3 Ischaemic metabolism
Glycogen is an important energy storage molecule, which releases glucose that can enter
glycolysis to generate energy under conditions such as ischaemia. The levels of glycogen
were measured over a time course of both warm and cold ischaemia in heart tissue of mouse,
pig and human (Figure 6.12). During WI, all animals showed a rapid drop in the levels of
glycogen in the early stages of WI, as the cell shifts to glycolysis to survive the ischaemic
insult. This decrease then plateaus, despite some glycogen remaining. In contrast, the
depletion of glycogen levels is much more steady during CI, and does not reach a plateau but
continues to decrease for the full time course of ischaemia measured in the experiment. This
suggests that cooling the tissue is a protective mechanism that slows down metabolism and
may enable the tissue to withstand longer periods of ischaemia and, in addition, to more fully
utilise its glycogen stores to supply energy to the tissue.
A caveat to the ischaemic experiments is that during ischaemia, and other insults, the mito-
chondria will become damaged, potentially affecting the isolation yield. The mitochondrial
density may change due to swelling and could even burst, so it may be that a greater propor-
tion of "healthy" mitochondrial metabolites is obtained in the mitochondrial pellet, because
the very "unhealthy" mitochondria will have not passed through the oil and are thus ex-
cluded from the mitochondrial pellet. In this case it may be that we see a higher level of
mitochondrial metabolites in the cytosolic fraction.
Citrate was seen to be compartmentalised to the mitochondria in heart, which confirms
the robustness of the method as the CIC has low activity in heart tissue (Palmieri, 2004).
In contrast, in the liver, which has much higher CIC activity, citrate was more distributed
throughout the cell, consistent with its role in fatty acid synthesis.
Lactate was seen to accumulate in both the cytosol and the mitochondria after ischaemia
in the heart and the liver (Figures 6.15 and 6.20). Lactate accumulates during ischaemia
when the end-product of glycolysis, pyruvate, is converted to lactate. Lactate can then
enter gluconeogenesis to regenerate glucose. Traditionally, it was assumed that lactate was
converted back to pyruvate in the cytosol, with pyruvate entering the mitochondria and the
TCA cycle via AcCoA. However, recent evidence has suggested that lactate also enters
the mitochondria and is there converted to pyruvate (Chen et al., 2016b). This theory is
reinforced by the detection of lactate in rapidly isolated mitochondria.
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A summary of the normoxic and ischaemic distributions of metabolites in heart and liver are
shown in Figures 6.18 and 6.23, respectively. Due to the high number of metabolites on
these heat maps, the scale is very large and thus they should only be used as a qualitative
tool to determine which metabolites are abundant in the mitochondria and which are more
abundant in the cytosol. They show that in both the heart and the liver, succinate is more
accumulated in the cytosol during normoxia and ischaemia. Further exploration into this
area is needed, but this could reflect one of a number of possibilities. One interesting
scenario is that the succinate that accumulates during ischaemia is exported to the cytosol,
potentially via an exchange mechanism through the DIC in exchange for malate. However,
the precise mechanism of how succinate enters the cytosol during ischaemia is not known. It
is unlikely that the succinate enters the cytosol as a result of rupturing of the mitochondria,
as other metabolites are retained, hence the low amounts of succinate in the rapidly isolated
mitochondria suggest that it is selectively exported to the cytosol. Another potential reason for
the low amount of succinate in the mitochondria is that the speed of cooling and homogenising
the organ is not sufficient to prevent the oxidation of mitochondrial succinate. Taken in the
context of the behaviour of other metabolites during ischaemia, the data is consistent with
the model depicted in Figure 6.24. In this model of heart ischaemia, fumarate is decreased
in the mitochondria following WI, due to conversion to succinate by reversal of CII. The
succinate is exported to the cytosol via the DIC, in exchange for cytosolic malate. Once
in the mitochondria, malate is converted to fumarate (by fumarate hydratase), which is
itself metabolised to succinate by reversal of SDH. The export of succinate leads to the
accumulation of cytosolic succinate following ischaemia. Succinate is known to activate its
receptor SUCNR1 on the PM, and as such is expected to be present in the cytosol (Gilissen
et al., 2016; He et al., 2004; Peti-Peterdi et al., 2013). Despite these expectations, this has not
been directly demonstrated to my knowledge and thus this project is the first time succinate
has been shown to accumulate in the cytosol of an ischaemic tissue. The succinate that is
transported to the cytosol acts as a signal, relaying the ischaemic stress signal to the rest of
the cell. For example, succinate is known to be involved in the activation of the HIF-1α
pathway, by inhibiting the PHD enzyme in the cytosol (Tannahill et al., 2013).
Upon reperfusion, there are two possible fates for the succinate that accumulated during
WI (Figure 6.24). The first is that it is reoxidised to fumarate by the forward activity of
SDH. While we did not show that the succinate that was exported to the cytosol is then
imported back into the mitochondria upon reperfusion, this seems likely because the succinate
decreases back to baseline levels in tissues upon reperfusion (Chouchani et al., 2014). In
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addition, a second fate for the succinate is that it can be released from the cell. There is
mounting evidence that succinate may act as a paracrine signal to activate SUCNR1 on
neighbouring cells (Murphy, O’Neill, 2018). Thus, the discovery of succinate accumulating
in the cytosol during WI lends credence to the hypothesis of succinate efflux from the cell
during reperfusion.
Figure 6.25 displays the two fates of the succinate that accumulates during WI. The line
graph depicts the amount of succinate detected in the perfusate over 6 min of reperfusion
following 20 min of WI. The grey bar on the right shows the amount of succinate in heart
tissue at the end of the 20 min WI period and the blue bar on the left shows the amount
of succinate in heart tissue after 6 min of reperfusion (following 20 min WI). Thus, the
difference between these 2 bars (red arrow) is the amount of succinate that is oxidised during
reperfusion. It can be seen that a significant proportion of succinate is released from the cell
into the perfusate and the remainder is reoxidised. Important future experiments would be
to explore the fate of the succinate once in the cytosol. It may activate cytosolic signalling
pathways such as the HIF pathway. There is evidence for succinate efflux from the cell after
periods of ischaemia (Figure 6.25), where it may then signal to other cells via activating the
G-coupled receptor SUCNR1. This receptor is expressed in many organs (heart, liver, kidney
and retina) and different cell types, including cardiomyocytes and immune cells. (Sundström
et al., 2013).
In conclusion, I have shown by applying this technique that succinate distributes during
ischaemia, leading to discrete pools in the cytosol and the mitochondria. The project has also
elucidated the cellular distribution of a wide range of other metabolites and highlighted some
differences between heart and liver tissue. Thus, the rapid isolation procedure is capable of
studying compartmentalisation of metabolism in tissue.
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Fig. 6.24 Schematic depicting proposed model of metabolism in the cytosolic and mitochondrial
compartments of the heart during ischaemia and reperfusion. A) During ischaemia, succinate
accumulates due to the reversal of SDH. Succinate is then exported to the cytosol through the DIC, in
exchange for cytosolic malate. Once in the cytosol, succinate is known to be involved in the activation
of the HIF-1α pathway. Investigation into other signalling roles of cytosolic succinate is an interesting
area for research. B) Upon reperfusion, succinate may either be imported back into the mitochondria
for oxidation by the forward action of SDH (1), or it may be exported from the cell (2) and act as a
paracrine signal by activating the succinate receptor, SUCNR1, on neighbouring cells.
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Fig. 6.25 Succinate accumulation and efflux during ischaemia and reperfusion in the isolated
Langendorff mouse heart. Isolated Langendorff mouse hearts were subjected to 20 min WI before
reperfusion. Succinate levels were measured in the heart and in the perfusate. Experiments performed
and data provided by Dunja Aksentijevic´ and Hiran Prag.
Chapter 7
General discussion & future directions
Detailed discussions of the method development and findings have been outlined at the
end of each chapter. In this section, the limitations of the isolation procedure, the major
implications of the findings and future experiments will be discussed. The focus of this
thesis has been to develop a rapid method of isolating mitochondria from tissue, such that
information can be obtained on the differences in metabolism between the mitochondrial and
the cytosolic compartments. This was of interest to our lab because previous studies have
shown specific metabolic changes during disease states, such as ischaemia-reperfusion injury
(Chouchani et al., 2014; Ferrari, 1995; Heather et al., 2013; Martin et al., 2019), but were not
able to identify where in the cell these metabolic changes were occurring. To do so, a new
mitochondrial isolation procedure was necessary because at the start of this project there was
no mitochondrial isolation method that was compatible with LC-MS metabolomic studies.
Furthermore, the rapid redistribution of metabolites from mitochondria to the rest of the
cell was thought to be important in pathology and signalling, but the existing mitochondrial
isolation methods were not fast enough to prevent artefactual metabolite distribution and
metabolism during isolation. The best method at the time was that of Chen et al. (2016a), but
even this took 12 min and required HA-tagging of mitochondria in cultured cells prior to
isolation. As we were interested in metabolism in tissue during normoxia and ischaemia, this
method was not suitable and we required a new isolation procedure. The major stipulations
of this new method were that it should be able to be performed extremely quickly and at a low
temperature to prevent metabolite distribution and dismutation, and that it should sufficiently
separate the mitochondria from the cytosol. The most important step to prevent metabolism
is to get the organ into the cold homogenisation buffer and fully homogenised as quickly
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as possible, because low temperature is an extremely effective way of limiting metabolite
transporter and enzymatic activities.
The first sections of the thesis addressed the development of the rapid mitochondrial isolation
procedure, first in rat heart and liver and then in mouse heart and liver. The last section
used the method to analyse metabolic differences between the mitochondria and the cytosol
under normoxic conditions in both mouse heart and liver tissue and how these change under
ischaemic conditions. The rapid isolation procedure was based on a range of previous
isolation methods and adopted the use of a tripartite layering system: the tissue homogenate
is layered on a silicone oil layer mixed with DOP, above an acidic layer at the bottom of the
tube. Whilst optimising the conditions, I discovered that the technique is extremely sensitive
to the density, and thus the temperature and methods of preparation, of the three layers.
This discovery allowed me to develop the method much further and more successfully than
previous attempts by this lab and others.
After optimising the technique to rapidly isolate mitochondria from tissue, the first objective
was to characterise the function and purity of the isolated mitochondria. The experiments
described in Chapter 4 demonstrate that the mitochondria are separated from the cytosol
and other organelles to a level similar to a standard "slow" mitochondrial isolation. The
absolute amounts of mitochondria obtained using this method from heart and liver is lower
than a standard mitochondrial isolation, but for the intended application of LC-MS this is not
an issue, as only a small amount of sample material is necessary to detect metabolites using
this sensitive method. Indeed, preliminary LC-MS data indicated that the method can detect
mitochondrial metabolites and can distinguish both mitochondrial and cytosolic metabolite
pools. The mitochondria were shown to remain intact, allowing them to perform coupled
respiration and, fundamentally, to retain their metabolites. An important finding of Chapter
4 was that damaged mitochondria are able to pass through the silicone oil into the acidic
layer. This has implications for the normalisation and analysis of the metabolomic data and
dictated that the metabolite ion intensities cannot be normalised to protein.
Building on this information, the LC-MS analytical approach was developed. To improve the
MS signal, it was found that the optimum procedure was to pool 4 mitochondrial isolations
together, before evaporating the formic acid and resuspending the dried metabolites in water.
The LC-MS method that was used was designed to focus on polar metabolites, meaning that
fatty acids and other non-polar metabolites are not measured as effectively. However, by using
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a different LC-MS method, such as different extraction conditions and LC columns, these
metabolites could easily be detected more reliably from the rapidly isolated mitochondria.
For this project, a relative quantification approach was taken, to facilitate the measurement
of a broad range of metabolites (>100), as opposed to the absolute quantification of a small
selection of metabolites. However, in future work we can use this system to analyse and
quantify the absolute distribution of certain key metabolites, such as succinate, by the use of
internal standards. For relative quantification to be performed, the metabolite ion intensities
must be normalised. The experiments with alamethicin to damage the mitochondria in
Chapter 4 demonstrated that damaged mitochondrial protein is able to pass through the
silicone oil layer. This meant that the ion intensities cannot be normalised to protein and
must be normalised to another, stable metabolite, as it will behave in the same way to
themselves. The requirements of this metabolite were that it must be: relatively evenly
distributed across the cytosolic and mitochondrial compartments, with either no or slow
transport systems between them; relatively metabolically inactive during the conditions the
organ is experimentally exposed to, and abundant enough to be easily detected on the LC-MS.
Both GSH and taurine were considered, but due to the inconsistent results when normalising
to GSH, taurine was chosen. Preliminary experiments comparing taurine-normalised and
raw ion intensities showed that normalising to taurine did not skew any trends. However,
there is evidence that taurine is not as metabolically inactive as we would wish, especially
in the ischaemic myocardium (Venturini et al., 2009). Nevertheless, its metabolism is slow
so it is unlikely to be affected in the time frames of these experiments. Indeed, the raw
ion intensities of taurine in the ischaemic heart suggest it is not affected. In the future,
normalisation to other metabolites should be trialled. For more targeted analyses, it would be
possible to quantify the metabolites by adding a stable isotope but this was not suitable for
the global metabolomic analysis performed here because of the large number of metabolites
analysed simultaneously. While developing the normalisation approach, it was found that
the correlation between the ZIC-pHILIC and the ZIC-HILIC column was not as strong as
expected, which meant that the metabolites must be normalised to the taurine ion intensity
from the same column. In the future, absolute quantification techniques will be used by
others in the lab to obtain a more accurate picture of metabolism. For example, isotope
labelling, internal standard and pulse chase could be used to quantify succinate accumulation
and distribution during ischaemia and its oxidation during reperfusion.
The use of transport and respiratory inhibitors was explored to identify whether they could
limit distribution and interconversion of metabolites within the rapid time frame of the
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isolation procedure. The preliminary data obtained shows that none of the inhibitors trialled
(BTM, NEM and PRP) had a significant effect on metabolite levels and distribution. This
probably indicates that the extraction is performed quickly enough that metabolism is
quenched sufficiently by the cold temperature and acid. However, we cannot entirely
eliminate the possibility that the concentration of inhibitor added was not high enough.
Further experiments are required here to understand the implications of these results, such
as with genetic knock-out (KO) mice or by pre-infusing with inhibitors. Nevertheless, the
addition of transport and respiratory inhibitors should be carefully considered and may be
more useful when looking at a specific area of metabolism rather than a global metabolic
overview, because the downstream and off-target metabolic effects of these inhibitors is
unknown. For example, they may also inhibit other transporters and affect other metabolite
pools, leading to erroneous conclusions that certain metabolic pathways are connected or
affected in specific conditions.
Once the isolation procedure had been fully optimised, it was used to explore the important
question of what happens to the metabolite pools in the cytosolic and mitochondrial compart-
ments, in particular succinate, during ischaemia. It is of interest to determine whether the
succinate that accumulates during ischaemia remains in the mitochondria or is transported to
the cytosol, and, if so, how much succinate is transported and at what stage during ischaemia.
Understanding the behaviour of these pools would aid in the identification of therapeutic
targets to limit damage during IRI. To this end, a metabolomic analysis was performed on
ischaemic mouse heart and liver. As discussed in Section 6.7.3, the data obtained from this
analysis suggests that the succinate that accumulates during WI is exported to the cytosol.
In the ischaemic model used, some primary WI inevitably occurs between the moment of
breaking the neck and extracting the organ from the animal and placing it into cold sucrose
buffer. To avoid this, anaesthesia could be applied before opening the chest cavity and
removing the heart, reducing the time of WI to 5 sec, as in the ischaemic model used for
glycogen measurements. However, there is evidence that anaesthetic may affect cellular
metabolism (Overmyer et al., 2015). The use of inhibitors to minimise the effect of this
primary WI was explored, but again the interpretation of the results is complicated, because
it is unknown what effect blocking some of these transporters would have on downstream
metabolism, and also whether they would target other transporters.
This method has prepared the groundwork that will enable my lab and others to perform many
potentially insightful experiments in the future. An interesting avenue would be to perform a
metabolomic analysis on tissue that has been reperfused after a period of WI. For the heart,
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this should be done using the Langendorff model, in which the whole heart is removed from
the animal and retrogradely perfused ex vivo (Bell et al., 2011). The Langendorff model
of global organ ischaemia via cessation of perfusate flow would be preferable to regional
ischaemia via occlusion of the left anterior descending artery (LAD) in this case, because it
would be difficult to quickly cut out the ischaemic zone after LAD occlusion, and this delay
could lead to metabolite distribution and degradation. This would further our understanding
of how the cytosolic and mitochondrial metabolite pools behave during the full course of
IRI, and how therapeutic treatments, such as dimethyl malonate (Chouchani et al., 2014),
alter these changes. This should also be performed in other organs, such as the liver and
kidney, to aid understanding of the different metabolic responses to ischaemic insults in these
organs. The isolation procedure could also be used to examine the metabolism of animals
with genetic KO of metabolically relevant genes, offering insight into the role of particular
steps in metabolism in health and disease.
Together, this work has contributed to the field a method that can be used to obtain more
information on many aspects of mitochondrial biology. The isolation procedure is relatively
simple to perform and does not require the use of specialised equipment or reagents. The
total time from mouse to mitochondria is under 5 min, which is much shorter than other
methods currently used. Importantly, the organ is removed from the animal within 25-30
sec and immediately placed in ice-cold buffer, and fully homogenised within 1.5 min. The
method uses whole tissue not cultured cells, meaning that the metabolic information obtained
is much more physiologically relevant. The isolation procedure has been shown to generate
comparatively pure mitochondria which are capable of coupled respiration and can be used
for a wide range of applications to study mitochondria. The metabolomic study on these
rapidly isolated mitochondria has shown that succinate accumulates in the cytosol during
ischaemia, and highlights this as an interesting avenue for future study.
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248 LC-MS data tables - raw ion intensities
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252 LC-MS data tables - raw ion intensities
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Appendix B
LC-MS data tables - taurine-normalised
ion intensities
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258 LC-MS data tables - taurine-normalised ion intensities
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260 LC-MS data tables - taurine-normalised ion intensities
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262 LC-MS data tables - taurine-normalised ion intensities
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Appendix C
LC-MS bar graphs
C.1 Control & 30 min WI Heart
266 LC-MS bar graphs
Fig. C.1 Amino acids & peptides in control and 30 min WI mouse heart homogenate, super-
natant, cytosol and mitochondria. Metabolite ion intensities from the control and 30 min WI heart
data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated as
from ZIC-HILIC column. Data is average of 6 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
C.1 Control & 30 min WI Heart 267
Fig. C.2 Amino acids & peptides in control and 30 min WI mouse heart homogenate, super-
natant, cytosol and mitochondria (ctd.). Metabolite ion intensities from the control and 30 min WI
heart data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated
as from ZIC-HILIC column. Data is average of 6 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
268 LC-MS bar graphs
Fig. C.3 Carnitines in control and 30 min WI mouse heart homogenate, supernatant, cytosol
and mitochondria. Metabolite ion intensities from the control and 30 min WI heart data sets were
normalised to taurine. The fatty acids and carnitines myristic acid, oleic acid, palmitic acid, stearic
acid, stearoylcarnitine, oleoylcarnitine, palmitoylcarnitine and myristoylcarnitine were excluded from
the analysis due to 3 or more zero values in each fraction. Data is from ZIC-pHILIC column unless
otherwise stated as from ZIC-HILIC column. Data is average of 6 biological replicates, presented as
mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF:
Not found.
C.1 Control & 30 min WI Heart 269
Fig. C.4 Miscellaneous metabolites in control and 30 min WI mouse heart homogenate, super-
natant, cytosol and mitochondria. Metabolite ion intensities from the control and 30 min WI heart
data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated as
from ZIC-HILIC column. Data is average of 6 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
270 LC-MS bar graphs
Fig. C.5 Miscellaneous metabolites in control and 30 min WI mouse heart homogenate, super-
natant, cytosol and mitochondria (ctd.). Metabolite ion intensities from the control and 30 min WI
heart data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated
as from ZIC-HILIC column. Data is average of 6 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
C.2 Control & 30 min WI Liver 271
C.2 Control & 30 min WI Liver
272 LC-MS bar graphs
Fig. C.6 Amino acids & peptides in control and 30 min WI mouse liver homogenate, super-
natant, cytosol and mitochondria. Metabolite ion intensities from the control and 30 min WI liver
data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated as
from ZIC-HILIC column. Data is average of 3 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
C.2 Control & 30 min WI Liver 273
Fig. C.7 Amino acids & peptides in control and 30 min WI mouse liver homogenate, super-
natant, cytosol and mitochondria (ctd.). Metabolite ion intensities from the control and 30 min WI
liver data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated
as from ZIC-HILIC column. Data is average of 3 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
274 LC-MS bar graphs
Fig. C.8 Fatty acids & carnitines in control and 30 min WI mouse liver homogenate, super-
natant, cytosol and mitochondria. Metabolite ion intensities from the control and 30 min WI liver
data sets were normalised to taurine. Palmitoleic acid and myristoylcarnitine were excluded from
the analysis due to 3 or more zero values in each fraction. Data is from ZIC-pHILIC column unless
otherwise stated as from ZIC-HILIC column. Data is average of 3 biological replicates, presented as
mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF:
Not found.
C.2 Control & 30 min WI Liver 275
Fig. C.9 Miscellaneous metabolites in control and 30 min WI mouse liver homogenate, super-
natant, cytosol and mitochondria. Metabolite ion intensities from the control and 30 min WI liver
data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated as
from ZIC-HILIC column. Data is average of 3 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
276 LC-MS bar graphs
Fig. C.10 Miscellaneous metabolites in control and 30 min WI mouse liver homogenate, super-
natant, cytosol and mitochondria (ctd.). Metabolite ion intensities from the control and 30 min WI
liver data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated
as from ZIC-HILIC column. Data is average of 3 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
C.2 Control & 30 min WI Liver 277
Fig. C.11 Miscellaneous metabolites in control and 30 min WI mouse liver homogenate, super-
natant, cytosol and mitochondria (ctd.). Metabolite ion intensities from the control and 30 min WI
liver data sets were normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated
as from ZIC-HILIC column. Data is average of 3 biological replicates, presented as mean ±SEM. H:
Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF: Not found.
278 LC-MS bar graphs
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Fig. C.12 Changes in TCA cycle intermediates in mouse heart during a time course of WI.
Metabolite ion intensities from the control, 6 and 12 min WI heart data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
280 LC-MS bar graphs
Fig. C.13 Changes in glycolytic intermediates in mouse heart during a time course of WI.
Metabolite ion intensities from the control, 6 and 12 min WI heart data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
C.3 Heart WI time course 281
Fig. C.14 Changes in nucleotides & breakdown products in mouse heart during a time course
of WI. Metabolite ion intensities from the control, 6 and 12 min WI heart data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
282 LC-MS bar graphs
Fig. C.15 Changes in nucleotides & breakdown products in mouse heart during a time course
of WI (ctd.). Metabolite ion intensities from the control, 6 and 12 min WI heart data sets were
normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC
column. Data is average of 3 biological replicates for controls and 6 biological replicates for all other
time points, presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M:
Mitochondrial fraction. NF: Not found.
C.3 Heart WI time course 283
Fig. C.16 Changes in amino acids & peptides in mouse heart during a time course of WI.
Metabolite ion intensities from the control, 6 and 12 min WI heart data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
284 LC-MS bar graphs
Fig. C.17 Changes in amino acids & peptides in mouse heart during a time course of WI (ctd.).
Metabolite ion intensities from the control, 6 and 12 min WI heart data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
C.3 Heart WI time course 285
Fig. C.18 Changes in amino acids & peptides in mouse heart during a time course of WI (ctd.).
Metabolite ion intensities from the control, 6 and 12 min WI heart data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
286 LC-MS bar graphs
Fig. C.19 Changes in miscellaneous metabolites in mouse heart during a time course of WI.
Metabolite ion intensities from the control, 6 and 12 min WI heart data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
C.3 Heart WI time course 287
Fig. C.20 Changes in miscellaneous metabolites in mouse heart during a time course of WI
(ctd.). Metabolite ion intensities from the control, 6 and 12 min WI heart data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
288 LC-MS bar graphs
C.4 Liver WI time course
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Fig. C.21 Changes in TCA cycle intermediates in mouse liver during a time course of WI.
Metabolite ion intensities from the control, 6, 12 and 30 min WI liver data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
290 LC-MS bar graphs
Fig. C.22 Changes in glycolytic intermediates in mouse liver during a time course of WI.
Metabolite ion intensities from the control, 6, 12 and 30 min WI heart data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
C.4 Liver WI time course 291
Fig. C.23 Changes in nucleotides & breakdown products in mouse liver during a time course of
WI. Metabolite ion intensities from the control, 6, 12 and 30 min WI liver data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
292 LC-MS bar graphs
Fig. C.24 Changes in nucleotides & breakdown products in mouse liver during a time course
of WI (ctd.). Metabolite ion intensities from the control, 6, 12 and 30 min WI liver data sets were
normalised to taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC
column. Data is average of 3 biological replicates for controls and 6 biological replicates for all other
time points, presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M:
Mitochondrial fraction. NF: Not found.
C.4 Liver WI time course 293
Fig. C.25 Changes in amino acids & peptides in mouse liver during a time course of WI. Metabo-
lite ion intensities from the control, 6, 12 and 30 min WI liver data sets were normalised to taurine.
Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data is average
of 3 biological replicates for controls and 6 biological replicates for all other time points, presented as
mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial fraction. NF:
Not found.
294 LC-MS bar graphs
Fig. C.26 Changes in amino acids & peptides in mouse liver during a time course of WI (ctd.).
Metabolite ion intensities from the control, 6, 12 and 30 min WI liver data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
C.4 Liver WI time course 295
Fig. C.27 Changes in amino acids & peptides in mouse liver during a time course of WI (ctd.).
Metabolite ion intensities from the control, 6, 12 and 30 min WI liver data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
296 LC-MS bar graphs
Fig. C.28 Changes in miscellaneous metabolites in mouse liver during a time course of WI.
Metabolite ion intensities from the control, 6, 12 and 30 min WI liver data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
C.4 Liver WI time course 297
Fig. C.29 Changes in miscellaneous metabolites in mouse liver during a time course of WI (ctd.).
Metabolite ion intensities from the control, 6, 12 and 30 min WI liver data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
298 LC-MS bar graphs
Fig. C.30 Changes in miscellaneous metabolites in mouse liver during a time course of WI (ctd.).
Metabolite ion intensities from the control, 6, 12 and 30 min WI liver data sets were normalised to
taurine. Data is from ZIC-pHILIC column unless otherwise stated as from ZIC-HILIC column. Data
is average of 3 biological replicates for controls and 6 biological replicates for all other time points,
presented as mean ±SEM. H: Homogenate; S: Supernatant; C: Cytosolic fraction; M: Mitochondrial
fraction. NF: Not found.
